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Abstract 
This PhD by publication assesses strategies aimed at improving the assessment 
process of patients presenting to the Emergency Department with symptoms of 
possible acute coronary syndrome. The aim is to determine if more refined biomarker 
analysis and risk stratification processes may identify patients at low risk who may 
safely be able to be discharged from the Emergency Department. The strategies are 
focused on accelerated protocols that maintain clinical safety whist improving the 
efficiency of the assessment process. In addition to this, the thesis focuses on clinical 
implications of the differences in clinical management strategies based on different 
biomarkers and in particular troponin assays.  Troponin is the key cardiac biomarker 
detected in myocardial necrosis, and therefore is elevated in patients who have had a 
myocardial infarction; however the performance and accuracy of different troponin 
assays vary. This variation in the precision of the assay to detect low concentrations 
may impact the clinical care of patients presenting to Emergency Department with 
symptoms of possible ACS. 
 
This is a thesis by publication that compiles the research outcomes of a 
cohesive program of research. This program was conducted by an international 
consortium within which the author was a joint leader and in particular led the 
research conducted at the Royal Brisbane and Women’s hospitals and all sites in 
China, Indonesia, Korea, and Thailand involved in the ASPECT trial. She was the 
joint principal researcher in the ASPECT (Chapter 4), ADAPT (Chapter 5) and 
modified ADAPT (Chapter 6) studies.  Additionally the candidate obtained research 
funding through granting bodies including Queensland Emergency Medicine 
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Research Foundation and the Royal Brisbane and Women’s Foundation to conduct 
the research, and contracted with private companies to allow investigation of pre-
clinical assays.  
 
The objective of this program of research was to contribute the evidence base 
for improved guidelines for the management of Acute Coronary Syndrome by 
documenting the significance, safety and effectiveness of rapid use of existing 
troponin assays and use of highly sensitive assays for troponin, in addition to novel 
accelerated risk assessment processes. The outcomes of this program have been 
extensively published by the international consortium. The candidate has contributed 
to more than 50 published papers (12 as first author) in peer reviewed journals over 
the last six years in very high ranking journals including one paper published in 
Lancet. Further articles remain under consideration. Additionally she has authored 
four book chapters (two as first author) and has had over 22 conference abstracts 
published. The research reported in this thesis address the core concepts, data 
collection and analytical methods, safety and clinical effectiveness of enhanced use 
of troponin testing, accelerated diagnostic protocols and the practical application of 
rapid assessment processes in clinical care. The publications chosen for inclusion in 
this thesis are those that speak to the core principles of ACS evaluation and which 
tests the clinical effectiveness of new analytical methods. 
 
Chapter 1 provides an overview of the clinical issue and of the research 
program and introduces the aims, objectives and research questions. An overview of 
the clinical context and literature provides the ground work for the design of the 
research and the methods used. 
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Chapter 2 (Publication one) defines the current process of assessment and 
outcomes in the assessment of ED patients based on the current National Heart 
Foundation and Cardiac Society of Australia and New Zealand (NHF/CSANZ) 
Society Guidelines. This paper aims to establish a baseline by which improved 
strategies can be measured in terms of their safety, efficiency and costs. 
Chapter 3 (Publication two) provides a robust description of data elements and 
their definitions combined into a standardised dataset for use in ED-based research of 
patients with possible ACS. This provides the framework for consistent reporting in 
ED-based publications investigating patients with chest pain.  
Chapter 4 (Publication three) investigates the safety of an accelerated 
diagnostic protocol (ADP), using a multi-marker approach in a prospective, 
international multi-centred observational trial evaluation involving 3582 patients 
from nine countries.  
Chapter 5 (Publication four) assesses the safety of the ADP for the assessment 
of ED patients with chest pain, however in this project, the multi-marker approach 
was replaced with a single cardiac biomarker, troponin, measured by sensitive 
troponin assays. This study drew participants (n= 1975) from a subset of the cohort 
used in Chapter 4. It involved only patients recruited in Brisbane, Australia and 
Christchurch, New Zealand. 
Chapter 6 (Publication five) refined the ADAPT accelerated diagnostic 
pathway replacing the troponin results from sensitive troponin assays with troponin 
results from a new high sensitivity troponin I assay. At the time of this study, the 
new assay did not have TGA approval for clinical use in Australia. The results were 
obtained from the analysis of stored samples collected during the ASPECT study 
outlined in Chapter 4 and involved 1635 patients. In addition, this chapter also 
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describes the first independent validation of the Modified ADAPT ADP in a well-
described geographically distinct cohort from the Advantageous Predictors of Acute 
Coronary Syndrome Evaluation (APACE) Study led by Prof. Christian Mueller in 
Basel, Switzerland (n=909). 
Chapter 7 (Publication six) reports on the translation of research described in 
Chapter 5 into clinical practice, with the implementation of the ADAPT ADP at the 
Nambour General Hospital, Queensland, Australia.   
Chapter 8 aims to draw together the findings of the program of research and to 
express the implications and application of those findings to clinical practice. 
 
Accelerated diagnostic protocols for the assessment of patients presenting to 
the Emergency Department with symptoms of possible ACS are safe and effective at 
identifying low risk patients who can be managed in an outpatient setting. It is 
estimated that over 20% of patients presenting to the ED with chest pain could be 
safely discharged significantly reducing the health system cost.  This important 
finding will inform clinicians and health services about improvements that can be 
made at this current time in the process of care of ED patients.  
 
Key areas of investigation that still require research have been uncovered 
during this study. The true implication of the analytical differences in troponin assays 
on actual patient care and outcomes requires additional examination. Recently there 
has been much interest in point-of-care analysers, which have the benefit over lab-
based assays in that the time that results are available to clinicians is more rapid. In 
addition they do not require the infrastructure of a laboratory to run the tests, making 
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them most useful in rural and regional areas. The analytical characteristics of theses 
assays though are significantly different to most lab assays and the true implications 
of their use, including safety and patient flow issues in the setting of an ADP are 
currently unknown.   
 
 
Notes 
Permission has been granted by all co-authors for the inclusion of the papers in 
this manuscript. Additionally the publishers of the relevant Journals have all 
provided approval for the incorporation of the articles used in this thesis. 
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Preamble 
 The Royal Brisbane and Women’s hospital Emergency Department 
(ED), a tertiary teaching ED in Queensland Australia, assesses approximately 75 000 
patients per annum. Six percent of these have symptoms of possible Acute Coronary 
Syndrome (ACS). The current National Heart Foundation and Cardiac Society of 
Australia and New Zealand (NHF/CSANZ) Guidelines have been followed at our 
institution since 2003, in a format known as the Queensland Chest Pain Pathway, 
which outline the assessment process and management of such patients. Although 
there was no data reported at the time, my impression from managing many of these 
ED patients was that the majority did not have a final diagnosis of ACS.  I believed 
the rule-out process was unduly lengthy and that there may be patients who could be 
identified that did not need such a rigorous inpatient assessment process. My aim in 
my research endeavours was to comprehensively assess possible strategies for 
accelerating this assessment process, with the hope that if a safe and effective 
strategy could be identified, it could be implemented in practice, leading to a 
reduction in costs for patients and the health care system. 
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Introduction 
 
Chest pain is one of the primary symptoms leading to patients presenting 
acutely to Emergency Departments (1, 2). Many different underlying 
pathophysiological processes can cause chest pain, however the most common, 
serious cause is an Acute Coronary Syndrome (ACS). ACS incorporates the clinical 
conditions of acute myocardial infarction (AMI) and unstable angina pectoris (UAP). 
Myocardial infarction results in necrosis of myocardial tissues which results in the 
release of proteins (biomarkers) which can be measured; the presence of which may 
confirm the presence of infarction. The diagnosis (rule-in) of ACS is based on 
clinical assessment and includes electrocardiograph (ECG) and cardiac troponin 
(cTn) measurement.  
The focus for ED physicians assessing patients with chest pain is not only to 
rapidly rule-in ACS, but to also rule-out this condition and other high risk conditions 
that may lead to morbidity and mortality. The majority of patients investigated for 
ACS do not have the disease; with some studies reporting up to 90% of all patients 
investigated having normal findings (1, 3-5). The serious consequences of a missed 
diagnosis of AMI, that occur in 2-6% of ED presentations (6, 7), coupled with the 
high rate of atypical presentations for AMI (8, 9), encourages clinicians to rigorously 
investigate large numbers of ED patients with possible ACS and in most 
circumstances, to admit patients to hospital for prolonged investigation and 
monitoring. If it were possible to accurately and safely rule out patients who do not 
have myocardial infarction, then it would be possible to safely manage those patients 
in the outpatient environment. 
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The key biomarker in the detection of myocardial necrosis (cardiac cell death) 
is troponin. Troponin assays came into clinical use in the late 1990s, and have 
evolved to replace previous, less specific markers such as creatine kinase (CK), 
aspartate aminotransferase (AST) and lactate dehydrogenase (LDH). The degree of 
elevation of troponin is indicative of the amount of cell death. The diagnosis (rule-in) 
of ACS is based not only on cardiac troponin (cTn) measurement, but includes the 
clinical context and clinical assessment including electrocardiograph (ECG) 
recordings.  
International guidelines utilising troponin testing in the assessment of patients 
with possible ACS emerged in the early 2000s (10, 11). The National Heart 
Foundation and Cardiac Society of Australia and New Zealand (NHF/CSANZ) 
developed guidelines in 2000, and updated these in 2006 and 2011 (12-14). These 
guidelines risk stratify patients using clinical features, electrocardiograph findings 
and serial troponin results, and outline the process of assessment and management 
for patients with possible ACS. The recommendations include troponin testing on 
presentation and ≥ 6 hours after presentation to the ED using sensitive troponin 
assays.  They recommend further objective testing for coronary artery disease 
following negative serial troponin and ECG results. Although not formally reported 
previously, due to the delayed serial testing and ongoing investigations, the 
assessment process is lengthy.  
 
Emergency Departments (EDs) are under mounting strain, with an increasing, 
and aging population (15) and rising financial constraints. It is clear that there is an 
increase in morbidity and mortality directly associated with overcrowding in EDs 
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(16, 17), and strategies that reduced the length of assessment whilst maintaining 
safety should be explored. 
 
Literature review 
ACS is a term that encompasses the disease entities of unstable angina pectoris 
(UAP), non-ST-segment elevation myocardial infarction (NSTEMI) and ST-segment 
elevation myocardial infarction (STEMI). Chest pain is the most common symptom 
described for Emergency Department (ED) presentations of patients with possible 
ACS (18). Establishing a diagnosis of acute coronary syndrome (ACS) is vital in 
treating these patients. 
While the initial electrocardiograph is of great clinical importance in the 
diagnosis of STEMIs, cardiac biomarkers, in particular troponin, have an important 
role in the diagnosis of NSTEMI (19).  Troponin is released following myocardial 
necrosis, with a change in concentration over time being the basis for the diagnosis 
of AMI and underpinning the importance of the serial measurement of troponin. 
International guidelines, including the recommendations of the American 
College of Cardiology (ACC) and the European Society of Cardiology (ESC) 
outlined criteria to diagnose AMI in 2000 (20).  These guidelines introduced the 
concept of a typical rise or gradual fall in troponin as a component of AMI diagnosis.  
These recommendations were further refined by the American Heart Association 
(AHA) in 2003 (21).  The definition of an adequate set of biomarkers has evolved 
with assay development, and is defined as a set of samples at least 6 hours apart 
using sensitive troponin assays, and at least 3 hours apart using highly sensitive 
assays, with at least one biomarker exceeding the 99th percentile of the distribution 
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of a reference population or the lowest level at which a 10% coefficient of variation 
can be demonstrated in a laboratory test (13, 19, 22, 23). 
It is recognized that biomarkers and electrocardiographs though in isolation do 
not support the diagnosis of AMI. The most recent Universal Definition of 
Myocardial infarction published in 2012, describes the detection of elevated cardiac 
markers preferably troponin with evidence of myocardial ischaemia, and at least one 
of the following: (a) ischaemic symptoms, (b) ECG changes indicative of ischaemia, 
(c) development of pathological Q waves or (d) imaging evidence of new loss of 
viable myocardium or new regional wall abnormalities as diagnostic (22). 
The Guidelines of the Management of Acute Coronary Syndrome 2006 (12) 
published by the National Heart Foundation of Australia and the Cardiac Society of 
Australia and New Zealand, have recommendations for assessing patients with 
possible ACS that are in keeping with international standards. The guidelines include 
repeat testing for troponin and electrocardiographs at least 6 - 12 hours after 
presentation when troponin testing is performed using sensitive troponin assays. In 
patients with troponin values that are normal on initial testing and normal ECGs, 
further provocative testing such as exercise stress tests or myocardial perfusion scans 
are recommended to rule out underlying coronary artery disease and ACS. The 
recommendations aim to define the likelihood of an ACS as the cause of a patient’s 
presentation thorough this risk stratification process. The final outcome of this 
process is the classification into low, intermediate or high risk groups for ACS. Such 
risk stratification is focused mainly on the identification of diseases, and anecdotally 
is time-consuming and likely to be costly; however cost analyses have not to date 
been reported about this process. 
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In 2011 the Addendum to these guidelines were published, with alteration to 
the troponin testing interval when using a highly sensitive troponin assay. In keeping 
with other international bodies’ recommendations, the most recent Australian 
guidelines support 0 and 3 hour troponin testing, and highlight the significance of a 
change in values over time for the diagnosis of AMI (13). 
For many reasons, including the possibility of over-investigation of some 
patients and the time-consuming nature of international guidelines, much interest has 
been placed on the development of clinical decision rules aimed at identifying very 
low risk patients who may not require the recommended extensive assessment 
processes. Reports of methods to accelerate the assessment process of patients with 
possible ACS began to emerge. These include the Vancouver Chest pain rule (24) 
and Marsan’s rule (25), and other risk stratification tools such as those by Hess (26), 
Kline (27), Goldman (28) in addition to assessment of scores (such and the TIMI 
(29) risk score) that were not initially designed for use in the ED. The applicability 
and performance of these tools for use in Australian ED for patients with chest pain 
had not been reported at the start of this PhD, however subsequently we and others 
have investigated some of these rules and even newer risk stratification tools, such as 
the HEART score, that have been published over the period of time this research 
work has occurred (30-33).   
At the commencement of this PhD, strategies designed to reduce the time to 
safely assess ED patients with symptoms of possible ACS, whist maintaining 
accuracy and safety of such risk stratification were focused on three main areas. 
These included firstly the development of risk stratification tools to identify very-low 
risk groups of patients that can be discharged without prolonged ED admission (24, 
25, 27). For instance, Christenson et al (24) in 2006 reported the Vancouver Chest 
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Pain Rule for early discharge of patient less than 40 years of age, with a normal ECG 
and no previous ischaemic chest pain who are deemed very-low risk patients. This 
research was validated in our cohort and published in 2013 with sensitive troponin 
assay results and 2014 with highly sensitive troponin results (34, 35).  
Secondly, novel biomarkers and combination of biomarkers were investigated 
to improve accuracy of risk stratification (36-39). It was reported that the combined 
negative troponin and myoglobin values at 90 minutes was a valid tool to exclude 
significant ACS (40, 41) and the combination of troponin, creatinine kinase and 
myoglobin on presentation of NSTEMI patients has a high sensitivity (97%) for the 
detection of myocardial infarction (42).  
Finally, investigation of novel biomarker strategies occurred, such as the use of 
absolute values versus relative change values and study into different time points for 
assessment of biomarkers. Research demonstrated that a change in troponin levels 
over 2 hours improved identification of ACS (43, 44). Further, a delta troponin of 
20% over a time interval ≥ 3 hours or having one positive specimen ≥6 hours after 
chest pain onset had an AMI prevalence equivalent to the American Heart 
Association definition (45). Newer, more sensitive assays continued to challenge our 
understanding of the ability to identify small but significant changes in troponin 
levels (44, 46). We investigated the use of early troponin results, changes (delta) in 
troponin results and the effect of incorporation of results from improved troponin 
assays in parallel to this PhDs focus (32, 47-54).  
Such findings indicated that there were a number of options possible available 
for use in early and accurate risk stratification. However, there existed a number of 
methodological factors that limited the ability to assess which strategy would be 
most appropriate in any emergency department. These included the use of different 
 25 
testing methods in different studies such as point of care testing (POC) (55) and 
central laboratory testing, with vast difference in the analytical performance of the 
troponin assays used, the use of varying testing times across studies including 90 
minutes after presentation (40, 41), and three hours after presentation (46),  the use of 
different combinations of biomarkers with different cut-off points, small sample size 
and single site studies limiting the ability to assess diagnostic accuracy and 
generalizability, and variation in outcome data including variable reporting of cardiac 
death, AMI and ACS diagnostic rates as endpoints. 
Despite all the international efforts, establishing a diagnosis of acute coronary 
syndrome (ACS) remained challenging and resource-intensive and research to 
improve our practices of assessment was required. A reliable and rapid method of 
assessment to rule out significant myocardial ischaemia or necrosis would facilitate 
early risk stratification of patients presenting with probable ACS including 
potentially allowing safe, early discharge of very-low risk patients, without 
unnecessary, expensive and potentially hazardous investigations. 
 
Overall Aims 
In 2007 when this project commenced, there were no accelerated assessment 
processes reported for the management of ED patients with symptoms of possible 
ACS that were designed to be safe and more rapid than the NHF/CSANZ Guidelines. 
Therefore this program of research was designed to explore ways in which patients 
could be more rapidly and accurately assessed and to identify cost effective and 
evidence based management strategies that could be utilised in Australia and 
elsewhere. 
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Thus the overall aim of this thesis is to evaluate robust, safe accelerated 
strategies in the assessment of ED patients with possible ACS, that support the early 
discharge of low risk patients from the ED. This overall aim is supported by four 
subsidiary research aims. 
Research Aims 
1. To describe the current process, cost and length of assessment for 
patients presenting to the ED with symptoms of possible ACS 
2. To define a robust data set for use in ED-based research into patients 
with possible ACS. 
3. To assess accelerated diagnostic protocols in identifying low risk 
patients who can be rapidly and safely discharged from the ED. 
4. To describe the effectiveness of translation of an accelerated diagnostic 
protocol into clinical care. 
 
 Significance 
The ability to safely shorten the assessment process of the large numbers of 
patients presenting to EDs with symptom of possible ACS could result in significant 
benefits both for patients, hospitals and health services. 
 Rapid identification of patients who could be safely discharged will reduce the 
overall patient load within the ED, while rapid identification of patients who have 
high risk of acute coronary syndrome would ensure those patients have expeditious 
access to additional investigations or to therapeutic interventions such as 
thrombolysis or coronary artery stenting. 
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This research has been conducted by an international consortium comprising 
researchers from over 10 countries and over 20 sites. The candidate has led the 
research conducted at the Royal Brisbane and Women’s hospitals and sites in China, 
Indonesia, Korea, and Thailand involved in the ASPECT trial. The candidate has also 
led the focused investigation of improved troponin assays. She had obtained research 
funding through granting bodies including Queensland Emergency Medicine 
Research Foundation and the Royal Brisbane and Women’s Foundation to conduct 
the research. In addition she has sought and obtained contracts from private 
companies to allow investigation of pre-clinical assays. This research has been 
supported by competitive state grants and international granting bodies, as well as 
partial funding by private companies. 
The research outcomes include over 44 publications in peer reviewed journals 
of which the candidate was first or second author on 26 papers. She has been invited 
to present key notes lectures at international conferences. These publications have 
had a significant impact on the professional debate in this field and include very high 
ranking general medical journals including Lancet, Journal of the American College 
of Cardiologists and Medical Journal of Australia as well as specialist emergency 
medicine international and Australasian journals.  In addition there have been four 
book chapters and 22 presentations to conferences for which abstracts have been 
published.  
 
Overview 
This thesis focusses on the development and evaluation of an accelerated 
diagnostic protocol built around the use of early testing troponin with different 
generations of assays that allows the identification of patients with ACS. However, 
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the principal focus is not on the rule-in of this disease, but on the identification of 
those patients who are at extremely low risk of myocardial infarction, so that they 
may be safely managed as an outpatient thus reducing hospital costs and patient 
inconvenience. 
The publications chosen for inclusion in this thesis are those that speak to the core 
principles of ACS evaluation, and which tests the clinical effectiveness of new 
analytical methods. This thesis in built around these six publications and seeks to 
link the research outcomes achieved in these publications with the overall aims and 
objectives of the research that forms the basis of this thesis.  
Chapter 1 (This Chapter) introduces the topic and its significance. It also provides an 
overview of the clinical issues and of the research program and introduces the aims, 
objectives and research questions. An overview of the clinical context and literature 
also provides the ground work for the design of the research and the methods used. 
Chapter 2 (Publication one) describes the current process of assessment and 
outcomes in the assessment of ED patients based on the current National Heart 
Foundation and Cardiac Society of Australia and New Zealand (NHF/CSANZ) 
Society Guidelines. This paper aims to establish a baseline by which improved 
strategies can be measured in terms of their safety, efficiency and costs. 
Chapter 3 (Publication two) provides a robust description of data elements and their 
definitions combined into a standardised dataset for use in ED-based research of 
patients with possible ACS. This provides the framework for consistent reporting in 
ED-based publications investigating patients with chest pain.  
 29 
Chapter 4 (Publication three) investigates the safety of an accelerated diagnostic 
protocol (ADP), using a multi-marker approach in a prospective, international multi-
centred observational trial evaluation involving 3582 patients from nine countries.  
Chapter 5 (Publication four) assesses the safety of the ADP for the assessment of ED 
patients with chest pain, however in this project the multi-marker approach was 
replaced with a single cardiac biomarker, troponin, measured by sensitive troponin 
assays. This study drew participants (n= 1975) from a subset of the cohort used in 
Chapter 4. It involved only patients recruited in Brisbane, Australia and 
Christchurch, New Zealand. 
Chapter 6 (Publication Five) refined the ADAPT accelerated diagnostic pathway by 
replacing the troponin results from sensitive troponin assays with troponin results 
from a new high sensitivity troponin I assay. At the time of this study, the new assay 
did not have TGA approval for clinical use in Australia. The results were obtained 
from the analysis of stored samples collected during the ASPECT study outlined in 
Chapter 4 and involved 1635 patients. In addition, this chapter also describes the first 
independent validation of the Modified ADAPT ADP in a well-described 
geographically distinct cohort from the Advantageous Predictors of Acute Coronary 
Syndrome Evaluation (APACE) Study led by Prof. Christian Mueller in Basel, 
Switzerland (n=909). 
Chapter 7 (Publication six) reports on the translation of research described in Chapter 
5 into clinical practice, with the implementation of the ADAPT ADP at the Nambour 
General Hospital.   
Chapter 8 aims to draw together the findings of the program of research and to 
express the implications and application of those findings to clinical practice. 
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Chapter 2 
 
Acute Coronary Syndrome is a relatively common complaint presenting to EDs 
comprising up to 10% of all attendances. The clinical challenge it poses is to identify 
patients who may be at high risk of having suffered an acute myocardial infarction 
(AMI) so that they may admitted to allow treatment and close observed for possible 
complications and, inversely, to identify those at low risk so that they may be 
discharged from hospital and thus to reduce the cost of unnecessary admissions to the 
health system. This program of research aims at exploring the role of early sensitive 
troponin assays as a means of identifying patients at very low risk. 
Guidelines for ED evaluation of patients (including the use of biomarkers) 
were developed by the National Heart Foundation (NHF) and the Cardiac Society of 
Australia and New Zealand (CSANZ). These guidelines were first published in 2000, 
however to date no reports have been published on the consequences of 
implementation of the approach recommended.   
The publication that forms Chapter 2 of this thesis aims to detail patient 
disposition, length of stay, costs and outcomes associated with the care of patients 
presenting to a tertiary teaching hospital with symptoms of possible ACS. This is the 
first known report of its kind and is based on use of the 2006 version of the 
NHF/CSANZ guidelines.  Although these Guidelines were updated in 2011, the risk 
stratification process, and ongoing assessment process was not altered for institutions 
utilising sensitive troponin assays. This Chapter defines many current issues with the 
Guidelines, particularly highlighting the high costs and lengthy assessment process 
for the large majority of intermediate risk patients. It defines the burden of disease in 
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ED patients with chest pain, and describes the utility of the current risk assessment 
processes in accurately defining risk for patients. It provides a benchmark by which 
the performance of accelerated diagnostic protocols can be measured to quantify the 
potential changes to costs and health outcomes from their adoption. It determines that 
the current guideline-based assessment if lengthy, costly and consumes significant 
resources. It also identifies the potential for savings arising from the implementation 
of enhanced guidelines which may arise from the implementation of new evidence 
based guidelines based on sensitive troponin assays. With great interest in future 
modification of assessment processes, clinical safety, and additionally cost and 
efficiency metrics are important for assessment.  
The candidate was the lead researcher for this element of the research program. 
She conceived the project with the support of the broader research team, undertook 
the literature review, designed the research protocol, obtained the necessary 
approvals including ethics approval form the Royal Brisbane and Women’s Hospital 
Human Research Ethics Committee, developed the research team and lead the 
conduct of the research. She also led the analysis and interpretation of the data and as 
principal author was responsible for drafting and critically reviewing the paper. All 
of the authors have approved inclusion of this paper into the thesis. Copies of these 
authorisations are available on request. 
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 Abstract 
Objectives: This study sought to characterize the demographics, length of admission, 
final diagnoses, long-term outcome and costs associated with an Australian 
Emergency Department (ED) population who presented with symptoms of possible 
acute coronary syndrome (ACS). 
Design: Prospectively collected data on ED patients presenting with suspected ACS 
between November 2008 and February 2011 was utilised, including data on 
presentation and at 30 days post discharge. Information on the disposition, length of 
stay and costs incurred was extracted from hospital administration records. 
Main outcomes: Mean and median cost and length of stay were reported for the 
primary outcome; diagnosis of ACS, other-cardiovascular conditions or non-
cardiovascular conditions within 30 days of presentation.  
Results: ACS was diagnosed in 103 of the 926 (11.1%) patients recruited. 193 
patients (20.8%) were diagnosed with other cardiovascular-related conditions and 
622 patients (67.2%) had non-cardiac related chest pain. Patients with proven ACS, 
high grade atrioventricular block, pulmonary embolism and other respiratory 
conditions had the longest length of stay. The mean cost was highest in the ACS 
group ($13,509, 95%CI: $11,794-$15,223) followed by other cardiovascular 
conditions ($7, 283, 95%CI: $6,152-8,415) and non-cardiovascular conditions 
($3,331, 95%CI: $2,976-$3,685).  
Conclusions: The majority of ED patients with symptoms of possible ACS do not 
have a cardiac cause for their presentation. The current guideline-based process of 
assessment is lengthy, costly and consumes significant resources. Investigation of 
strategies to shorten this process, or reduce the need for objective cardiac testing in 
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patients at intermediate risk according to the National Heart Foundation/Cardiac 
Society of Australia and New Zealand guideline is required. 
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Introduction 
Patients presenting with chest pain represent a large group of adult Emergency 
Department (ED) presentations (1).  The most common serious underlying causes for 
this symptom are acute coronary syndromes (ACS), incorporating acute myocardial 
infarction (AMI) and unstable angina pectoris (UAP). Over 5.5 million people 
presented to EDs in the United States in 2007-2008 with a primary complaint of 
chest pain, yet only 13% of those were diagnosed with an ACS (1). The number of 
patients presenting to EDs in Australia with possible ACS is unknown. 
Many conditions cause chest pain, yet discriminating ACS from alternate and 
generally less serious aetiologies, such as gastro-esophageal reflux, is difficult. The 
2006 National Heart Foundation and Cardiac Society of Australia and New Zealand 
(NHF/CSANZ) Guidelines on the management of ACS recommend stratifying 
patients into low, intermediate and high-risk categories (2), a strategy which remains 
unchanged in more recent updates (3). The Guidelines recommend that low risk 
patients are assessed using serial cardiac biomarkers and electrocardiographs. High 
risk patients require admission to hospital and intensive management, often including 
early invasive strategies. The largest group is the intermediate risk cohort, who 
require serial testing of biomarkers, electrocardiographs and, if negative, further 
objective testing. The most commonly performed objective test in this intermediate 
risk group is an exercise stress test (EST); other more costly tests may include CT 
coronary angiography, stress echocardiography, myocardial perfusion scanning, and 
invasive angiography. 
The costs of applying such guidelines to an undifferentiated ED chest pain 
population in Australia have not been described. The final diagnoses and one-year 
outcomes of patients presenting to the ED with chest pain have also not been 
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described. This study aims to characterize the demographics, length of admission, 
final diagnoses, long-term outcome and costs associated with an Australian ED 
population who presented with symptoms of possible ACS.  
 
Methods 
Design and Participants 
This was a prospective single centre observational study conducted between 
November 2008 and February 2011. Patients were included if they presented to the 
ED with at least five minutes of chest pain suggestive of ACS (acute chest, 
epigastric, neck, jaw, or arm pain; or discomfort or pressure without an apparent non-
cardiac source). Data were collected between 0800 and 1700. We have previously 
described that patients presenting in and out of study recruitment hours did not differ 
in demographics or clinical characteristics (4).   
Patients were excluded if they had a clear non-ACS cause for their symptoms, 
were unwilling/unable to provide informed consent (e.g. dementia), were considered 
inappropriate for recruitment (e.g. terminal illness), were pregnant, were recruited to 
the study within the past 45 days, or were unable/unwilling to be contacted after 
discharge. Patients transferred to (n=12) or from another hospital were excluded 
from the study, as we did not have data on costs or management for these patients. 
Consecutive eligible cases at the site were included. The study protocol was 
approved by the institution’s Human Research and Ethics Committee (no 2008/101 
and HREC/11/QRBW/493). 
Patients were classified into risk groups according to the Queensland Chest 
Pain pathway (Appendix), based on the NHF/CSANZ Guidelines 2006 (2). At our 
institution, low and intermediate risk patients were typically managed in the ED with 
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admission to the ED short stay unit (Figure 1). High risk patients and patients unable 
to perform an EST, due to contraindication or inability, were referred to inpatient 
Cardiology and General Medical units for admission and further assessment. A small 
proportion of patients were managed in the ED (3.9%) while the remainder were 
transferred to the ED short stay unit (46.7%) or the inpatient ward (49.4%). Patients 
requiring urgent cardiac surgery were transferred to another institution following 
inpatient admission.  
 
Data collection 
Research staff collected data using a standardised patient interview as soon as ED 
clinical assessment was complete. Interviews were cross checked with patient notes. 
Blood samples taken on presentation (0hr) and ≥ 6hrs later were sent to our 
laboratory for measurement of troponin and analysed using the Beckman Coulter 2nd 
generation AccuTnI (Beckman Coulter, Chaska, Minnesota) assay. The 0 and ≥6hr 
test results were used for patient care and cardiology endpoint adjudication. We used 
the manufacturer’s 99th% cut-point to indicate a raised troponin value.  
Data on the costs associated with investigation and care of patients during the index 
admission was extracted from hospital administration records. Inpatient costs were 
derived from procedure-related Australian refined diagnosis-related reimbursement 
codes used for Activity Based Funding. These cost codes guide federal government 
payments and are designed to reflect the health care services used during each patient 
episode (5). The weighted cost combines inputs such as staff time and consumables 
used for patient care, to determine appropriate payments to hospitals.   
ED costs reflect the payments received by the hospital based on triage 
categories of urgency. Total costs include fixed costs, which make up approximately 
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80% of overhead costs, and a variable activity-based component for pathology, 
imaging, pharmacy, clinical supplies and hotel services (5). Costs from 2008-2010 
were adjusted for inflation by 3.4% per year to equate to 2011 costs (6).    The 30-
day clinical outcome was adjudicated independently by local cardiologists using 
predefined standardized reporting guidelines, with knowledge of all clinical 
information collected within a 30-day period (7). A second cardiologist conducted a 
blind review of all ACS cases and 10% of non-ACS cases. In cases of disagreement, 
endpoints were agreed by consensus. This was achieved for all endpoints.  
The 30-day clinical outcomes were grouped into three categories that 
included cardiac-ACS related, other cardiovascular and non-cardiac diagnoses (Table 
1). Cardiac-ACS related diagnoses included ST-segment Elevated Myocardial 
Infarction, Non-ST-segment elevated myocardial infarction and UAP. These were 
according to the universal definition (8). An endpoint of UAP was given for patients 
with negative serial troponin results, ischaemic symptoms and objective evidence of 
ischaemia on the EST, stress echocardiography, myocardial perfusion scanning, CT 
coronary angiography or significant findings on coronary angiography.  
Other diagnoses such as cardiac but non-ACS and non-cardiac were based on 
all available clinical data including investigations that had occurred within the 30-
day period post presentation (Table 1). A national death registry audit was performed 
in July 2014 to obtain mortality data for patients who consented to undertake longer-
term study participation.  
 
Data analysis 
Data were analysed using Stata 12 (StataCorp, 2011, College Station, TX). Baseline 
characteristics of the sample were reported by outcome category using standard 
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descriptive statistics. The baseline characteristics of patients with and without ACS 
were compared using the chi-square test for categorical data and t-test for continuous 
data.  
Data on diagnosis, length of stay (LOS) and costs were also reported by 
outcome category. The LOS and cost data were right skewed and were reported in 
several ways. First the median and interquartile range was reported to provide a good 
estimate of the LOS and cost for a typical patient. Second, for economic analysis, 
mean costs were reported. The mean is the correct estimator because decision makers 
need to understand total costs, which are predicted by the mean and the quantity of 
services used. Bias corrected and accelerated bootstrap confidence intervals (CIs) 
were calculated using 1000 replications.  
One-year mortality was reported for a subset of patients who consented to 
ongoing participation in the study.  Kaplan-Meier survival curves for time to death 
were generated by diagnostic group and log-rank tests were used to compare survival 
curves.  Patients were then stratified according to the NHF/CSANZ Guidelines 
(Figure 1). The mean and median LOS and cost per patient were reported by risk 
category. Such data were broken down by ACS and non-ACS outcomes, and 
included all patients within the diagnostic category irrespective whether objective 
testing was performed.  
 
Results 
Nine hundred and twenty six patients were included (566 [61.1%] male, mean age 
54.7yrs). No patients were lost to 30-day follow up (Figure 2) and 693 (74.8%) 
consented to one-year follow-up.  Baseline characteristics are shown in Table 2.  
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Non-cardiac chest pain was diagnosed in 622 (67.2%) of the 926 patients (Table 
1). One hundred and ninety-three patients (20.8%) were diagnosed with other 
cardiovascular conditions including pericarditis, atrial fibrillation and heart 
failure. Of those diagnosed with ACS (103 of total 926 patients; 11.1%), the most 
common condition was Non-ST-segment elevation myocardial infarction (51.5% of 
total ACS).  
Three of the 926 patients died within 30 days; two of these were during the 
index admission. Two of the deaths were cardiac-related. An additional 14 of the 693 
patients involved in long-term follow-up died within 12 months (total 17 patients 
[2.5%, 95% CI: 1.4-3.9%]) (Table 1). Kaplan Meyer curves for death within the 
diagnostic categories are shown in Figure 3.  
The outcomes and costs by NHF/CSANZ risk group are shown in Table 3. 
ACS events occurred in 0 (0%) and 11 (1.9%) of the low and intermediate risk 
groups respectively.  Ninety-two (28.0%) of the 329 high-risk patients had an ACS 
event. Ten patients were transferred for acute cardiac surgery.  
Patients with ACS, high-grade atrioventricular block, heart failure, syncope, 
pulmonary embolism and respiratory conditions had the longest LOS (Table 1). 
Patients with ACS incurred the highest average cost of $13,509 per patient; followed 
by other cardiovascular conditions of $7,283. Patients with non-cardiac disease had 
the lowest cost of $3,331 per patient.  
Three hundred and fifty of the 580 intermediate-risk patients (60.3%) had an 
EST during the index admission. These patients incurred lower mean costs ($2,316, 
95% CI: $2126-$2507) than those who did not undergo an EST ($4,806, 95% CI: 
$4,094- $5,516). 306 (87.4%) ESTs yielded a negative result. In contrast 124 
(53.9%) of the 230 patients who did not perform an EST during the index 
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presentation were admitted to an inpatient unit and incurred higher costs. Four-
hundred and sixty-six (80.3%) of the intermediate risk patients received some 
objective testing within 30 days. The total cost for intermediate risk patients was 
$1,916,100; if divided across the 11 ACS patients, this equates to $174,191 to 
identify one ACS event.  
In the high-risk group, the average LOS was five days and the average cost 
was $8,919. The cost of treating the 237 patients in this group who did not have an 
event was $7,075 per patient, while the 92 patients who had an event incurred costs 
of $13,669. The total cost of investigating high-risk patients in this study was 
$2,934,317. If this value is divided across the 92 ACS events, this equates to an 
average of $31,895 spent to identify and treat one ACS event.  
Overall, the total ED cost for investigating the 926 patients in this study was 
$904,221 while inpatient costs totaled $3,977,234. Total ED LOS was 5,575.9 hours 
making the average cost per hour in ED $162. Total LOS as an inpatient was 
59,061.9 hours making the average inpatient cost $67 per hour.  
 
Discussion 
This is the first evaluation of the characteristics, final diagnoses, outcomes and costs 
for an Australian ED cohort investigated for possible ACS based on the 
NHF/CSANZ Guidelines (2, 3). In keeping with other international reports, the final 
proportion of patients with a diagnosis of ACS was 11.1%, with 20.8% of patients 
having other cardiovascular causes diagnosed (9-12).  
Our study demonstrates that significant resources are consumed in investigating 
ACS. However in the absence of research identifying a “negligible risk” group who 
do not require objective testing, such resource utilisation is necessary. Alternative 
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strategies to reduce the LOS in a low risk cohort have been reported (10, 13-17), and 
some studies have reported on the implementation and effect of such accelerated 
protocols (18, 19).  At the time of this study, such strategies were not in use in our 
institution.  Further research efforts should be directed to identifying patients who 
could be discharged without requiring additional cardiac investigations. 
About one fifth of intermediate risk patients did not have objective cardiac testing in-
hospital or within 30 days of their presentation, against the Guideline 
recommendations (2).  We did not record the reasons why clinicians deviated from 
the NHF/CSANZ Guidelines; however it is possible that clinician gestalt, prior 
recent investigation or known coronary artery disease may have influenced care (20). 
In addition, decision-making may have been influenced by significant debate about 
the utility of objective testing such as EST for patients thought to be at minimal risk 
(21, 22).  
No previous study in the Australian setting has examined the cost of 
assessing patients presenting with chest pain. We were able to show that costs are 
substantial and varied across the risk categories. The high-risk group incurred the 
highest cost per patient, but this group had a high rate of ACS. In contrast, the 
intermediate risk group was the most resource-intensive, yet these costs were 
expended to diagnose a very small proportion (1.9%) of patients with ACS. The 
overall costs per event in the intermediate group were high ($174,191 per ACS 
event).  An ideal accelerated diagnostic protocol would exclude patients from testing 
that have no risk of ACS. The effect would be to reduce the size of the intermediate 
risk group and define them as low risk, saving resources but not adversely impacting 
health outcomes. 
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Few prior studies have reported the costs related to chest pain assessment in 
the ED. A recent report published by KP Health for Queensland Health titled “Report 
of the Evaluation of the Clinical Services Redesign Program in Queensland 
Hospitals” recorded an estimated released value of one hour of ED cubicle time to be 
$98 and an inpatient bed day to be $779 in 2013/2014 (Personal communication: 
March 2014 Sarah Bright, Queensland Health). This figure is less than that reported 
in this study of $162 per hour for an ED bed. The difference is likely due to the high 
triage category assigned to patients presenting with chest pain and the extensive 
investigations required. These data provide the basis to test accelerated diagnostic 
protocols and build full cost-effectiveness models that quantify the potential changes 
to costs and health outcomes from their widespread adoption. 
All patients were followed up at 30 days. A National Death Registry audit 
was conducted at one year for patients who consented, however overseas deaths may 
have been missed. This is unlikely to be a significant number. All endpoints were 
adjudicated by cardiologists using available information. As such, the subcategories 
within the non-cardiac endpoints may not have the same diagnostic rigor as the 
cardiac endpoints. Non-cardiac investigations occurring away from the recruitment 
hospital were not obtained for outcome adjudication.  
Patient recruitment was within midweek working hours due to the availability 
of research staff and the extent of potential selection bias cannot be quantified; 
however we have previously reported that there are no statistically significant 
differences in the demographics or outcomes of the two groups (4). A significant 
number of patients with ACS may present atypically, and or without chest pain, and 
this cohort was not included in this study.  
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The cost estimates were derived from activity based funding cost codes. 
While our cost estimates do not include microcounts and values for each resource 
used, they are likely to reflect the resources engendered for care of chest pain 
patients. We did not include the surgical costs associated with patients transferred for 
acute surgical management of ACS.  
In conclusion, the majority of ED patients with symptoms of possible ACS do 
not have a cardiac cause for their presentation. The current Guideline-based process 
of assessment of this cohort is lengthy and requires significant resources. 
Investigation of strategies to shorten this process, or safely reduce the need for 
objective cardiac testing in patients at intermediate risk according to the 
NHF/CSANZ Guidelines is required. 
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Table 1: Hospital length of stay, mortality, median and mean costs by diagnostic 
group. 
 
Diagnosis Number 
of 
patients 
(% of 
diagnosti
c group) 
Median 
Hospital 
Length 
of stay in 
hours  
 
(25th -
75th 
percentil
e) 
Mean 
Hospital 
Length of 
Stay in hours 
(95% CI) 
No. of 
patients 
deceased 
at 1 
year/No. 
of 
patients 
within 
category*  
Median 
costs for 
Diagnostic 
groups and 
ACS 
diagnoses 
 (25th -75th 
percentile) 
 
Mean costs for 
Diagnostic 
groups and 
ACS 
diagnoses 
 (95% CI) 
ACS 103 
(100.0%) 
97.6 
(70.7-
188.8) 
187.0 
(125.3-
248.8) 
 $12,002 
(7,861-
16,517) 
$13,509 
 ($11,794-
$15,223) 
STEMI 22 
(21.4%) 
91.9 
(74.1-
142.9) 
151.5 
(95.7-207.2) 
0/17  $14,643 
($12,002-
$17,323) 
$18,297 
($13,487-
$23,107) 
NSTEMI 53 
(51.5%) 
101.3 
(70.4-
173.0) 
215.5 
(105.0-
325.9) 
5/35  $11,705 
($8198-
$15,196) 
$12,829 
($11,028-
$14,629) 
UAP 28 
(27.2%) 
96.8 
(44.2-
191.2) 
161.1 
(68.0-254.3) 
0/23  $8,311 
($4,728-
$17,860) 
$11,033 
 ($8,000-
$14,067) 
Other 
Cardio-
vascular   
193 
(100.0%) 
52.1 
(23.3-
123.8) 
92.2 
(75.5-108.8) 
 $4,826 
($2,020-
$9,297) 
$7,283 
($6,152-
$8,415) 
Coronary 
Vaso-spasm 
2 
(1.0%) 
- - 0/2    
Stable 
CAD 
50 
(25.9%) 
47.2 
(22.0-
97.1) 
81.4 
(51.5-111.2) 
2/39   
Peri-
carditis 
27 
(14%) 
28.2 
(10.8-
65.9) 
46.5 
(29.6-63.4) 
0/20   
Atrial 
Fibrillation 
33 
(17.1%) 
53.7 
(30.5-
116.5) 
86.0 
(53.7-118.2) 
2/30   
High level 
Atrio-
ventricular 
block 
4 
(2.1%) 
198.0 
(138.2-
281.4) 
209.8 
(135.6-
284.0) 
0/2   
Other Ar-
rhythmias 
16 
(8.3%) 
38.9 
(10.5-
155.8) 
86.5 
(48.3-124.7) 
0/12   
Heart 
Failure 
15 
(7.8%) 
196.3 
(142.4-
338.7) 
278.6 
(161.3-
395.9) 
1/9    
Cardio-
myopathy 
3 
(1.6%) 
- - 0/1    
Valve 
Disease 
7 
(3.6%) 
30.8 
(7.9-
76.6) 
48.5 
(16.4-80.6) 
0/4    
Hyper-
tension 
8 
(4.2%) 
41.4 
(17.5-
77.8) 
53.5 
(22.4-84.6) 
0/6    
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Syncope/ 
Pre-
syncope 
10 
(5.2%) 
76.1 
(9.3-
122.4) 
75.0 
(36.9-113.2) 
0/8    
Pulmonary 
embolism 
6 
(3.1%) 
112.7 
(101.0-
172.8) 
140.0 
(65.9-214.0) 
0/5    
Other 
cardiac 
problems 
12 
(6.2%) 
32.0 
(10.8-
57.9) 
39.7 
(21.3-58.1) 
0/9    
Non-
cardiac 
622 
(100.0%) 
24.8 
(10.0-
34.4) 
44.2 
(36.8-51.6) 
 $1,917 
($1,392-
$3,479) 
$3,331 
($2,976-
$3,685) 
No 
disease/ 
chest pain 
not 
otherwise 
specified 
444 
(71.4%) 
23.7 
(9.8-
30.6) 
37.7 
(29.1-46.3) 
2/339    
Gastro-
intestinal 
      
GOR/ 
Dyspepsia 
35 
(5.6%) 
25.2 
(10.2-
48.8) 
38.3 
(25.9-50.7) 
0/24    
Other GI 12 
(1.9%) 
33.0 
(11.2-
157.9) 
85.7 
(33.1-138.3) 
0/8    
Liver 
Disease 
2 
(0.3%) 
- - 0/1    
Respi-
ratory 
      
Asthma/ 
COAD 
5 
(0.8%) 
30.7 
(24.4-
193.2) 
100.3 
(11.8-188.9) 
0/2    
Respiratory 
Infection 
22 
(3.5%) 
25.0 
(8.8-
51.8) 
72.6 
(27.8-117.4) 
1/16    
Other 
Respiratory 
5 
(0.8%) 
105.9 
(32.1-
143.9) 
87.0 
(35.8-138.3) 
1/3    
Musculo-
skeletal 
      
Non 
specified 
musculo-
skeletal 
pain 
64 
(10.3%) 
22.7 
(9.4-
31.0) 
35.1 
(23.3-47.0) 
0/49    
Infection  
(Non-
respiratory) 
8 
(1.4%) 
74.9 
(39.3-
133.5) 
127.8 
(25.1-230.5) 
0/8    
Neuro-
vascular 
      
Stroke 2 
(0.3%) 
- - 0/0    
Neuro-
pathic pain 
8 
(1.3%) 
43.9 
(16.7-
126.6) 
78.5 
(21.03-
136.0) 
0/7   
Cancers 3 
(0.5%) 
- - 2/2    
Other 6 41.5 58.8 1/5    
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non-
cardiac 
(1.0%) (10.5-
58.0) 
(7.9-109.8) 
Anxiety/ 
Depression 
6 
(1.0%) 
20.4 
(8.6-
49.7) 
36.2 
(5.5-66.8) 
0/4    
Left 
against 
medical 
advice 
8 
(100.0%) 
14.1 
(6.0-
24.0) 
15.0 
(8.5-21.5) 
0/3 $1,366 
($1,007-
$2,027) 
$1,585 
($1,128-
$2,042) 
 
* % Mortality data represents only that from the 693 patients who consented for 1 
year follow up. 
ACS – Acute Coronary Syndromes, STEMI – ST-segment Elevated Myocardial 
Infarction, NSTEMI – non- ST-segment Elevated Myocardial Infarction, UAP – 
Unstable Angina Pectoris, CAD – Coronary Artery Disease, GOR – Gastro-
oesophageal Reflux, GI – Gastrointestinal, COAD – Chronic Obstructive Airways 
Disease. 
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Table 2: Baseline demographics of patients according to their final diagnosis 
category.  
 
Baseline 
characteristics 
Non Cardiac 
Other 
Cardiac 
ACS 
No diagnosis 
(LWBS) 
 (n=622) (n=193) (n=103) (n=8) 
Age, Mean (Range) 51.6 (19-93) 
59.32 (23-
97) 
64.50 (33-
96) 
55.13 (37-
66) 
Female 258 (41.5%) 71 (36.8%) 30 (29.1%) 1 (12.5%) 
Caucasian 542 (87.1%) 166 (86.0%) 97 (94.2%) 7 (87.5%) 
Risk Factors     
Dyslipidaemia 280 (45.0%) 113 (58.6%) 65 (63.1%) 1 (12.5%) 
Diabetes 68 (10.9%) 36 (18.7%) 24 (23.3%) 1 (12.5%) 
Hypertension 269 (43.3%) 119 (61.7%) 64 (62.1%) 2 (25.0%) 
Obesity (>30 BMI) 221 (36.4%) 63 (33.2%) 26 (27.1%) 2 (28.6%) 
Smoking 188 (30.2%) 52 (26.9%) 33 (32.0%) 6 (75.0%) 
Medical History     
Angina 111 (17.9%) 78 (40.4%) 40 (38.8%) 2 (25.0%) 
Coronary artery 
disease 
93 (15.0%) 81 (42.0%) 43 (41.8%) 1 (12.5%) 
AMI 79 (12.7%) 55 (28.5%) 29 (28.2%) 1 (12.5%) 
Arrhythmia 38 (6.1%) 49 (25.4%) 15 (14.7%) 0 (0.0%) 
Congestive Heart 
Failure 
21 (3.4%) 29 (15.0%) 11 (10. 8%) 0 (0.0%) 
CABG 24 (3.9%) 21 (10.9%) 14 (13.6%) 1 (12.5%) 
Prior Angioplasty 51 (8.2%) 37 (19.2%) 19 (18.5%) 0 (0.0%) 
Stroke 47 (7.6%) 30 (15.5%) 10 (9.7%) 2 (25.0%) 
Presentation with 
chest pain in the past 
year  
139 (22.4%) 79 (40.9%) 26 (25.5%) 1 (12.5%) 
 
Data are n(%) unless otherwise specified. 
AMI - Acute Myocardial infarction, CABG - Coronary Artery Bypass Graft, BMI - 
Body Mass Index, ACS - Acute Coronary Syndromes, LWBS - Left Without Being 
Seen  
 55 
Table 3: Median and mean cost and length of stay for ACS events and non-events 
amongst ED presentations with chest pain stratified by NHF/CSANZ risk group. 
 
 Number 
of 
patients 
N=926 
(%) 
Median cost  
(25-75th 
percentile) 
Mean cost per 
patient 
(95% CI) 
Median 
Length of 
Stay in hours 
(25-75th 
percentile) 
Mean Length 
of Stay in 
hours 
(95% CI) 
All 
categories 
926 
(100.0%) 
$2,443 
($1,458-$6,778) 
$5,272 
($4,835-$5,708) 
27.8 
(10.5-75.0) 
69.8 
(59.9-79.7) 
ACS 
events 
103 
(11.1%) 
$12,003 
($7861-$16,517) 
$13,509 
 ($11,794-
$15,223) 
97.6 
(70.7-188.8) 
187.0 
(125.3-248.8) 
Non-
events 
823 
(88.9%) 
$2,127 
($1,406-$5,027) 
$4,241 
($3,843-$4,638) 
26.4 
(10.2-52.5) 
55.13  
(48.0-62.3) 
Low risk 9 (1.0%) $1,530 
($1,298-$3050) 
$2,040 
 ($1,306-$2,774) 
11.5 
(11.3-29.6) 
20.4 
(11.2-29.7) 
ACS 
events 
 
0 (0.0%) 
 
$0 ($0) 
 
$0 ($0) 0.0 (0.0) 
 
0.0 (0.0) 
Non-
events 
9 (1.0%) $1,530 
($1,298-$3,050) 
$2,040 
($1,306-$2,774) 
11.5 
(11.3-29.6) 
20.4 
(11.2-29.7) 
Intermedi
ate risk 
580 
(62.6%) 
$1,849 
($1,376-$3,570) 
$3304 
($2,963-$3,644) 
24.5 
(9.9-34.6) 
42.4 
(34.6-50.2) 
ACS 
events 
11 (1.9%) $8,082 
($7174-$18,554) 
$12,169 
($6,803-$17,536) 
99.1 
(51.5-222.0) 
148.4 
(66.1-230.8.8) 
Non-
events 
569 
(61.4%) 
$1,831 
($1,372.13-
$3,338) 
$3,132 
($2,844-$3,420) 
23.9 
(9.9-32.8) 
40.3 
(33.2-47.5) 
High risk 329 
(35.5%) 
$6,452 
($2,650-$11,829) 
$8,919 
 ($7,971-$9,867) 
72.3 
(27.5-142.4) 
120.8 
(97.8-142.9) 
ACS 
events 
92 (9.9%) $12,357 
($8216-16,353) 
$13,669 
($11,857-
$15,481) 
97.2 
(71.0-180.9) 
191.6 
(116.7-266.6) 
Non-
events 
237 
(25.6%) 
$4380 
($2151-$8812) 
$7,075 
($6,013-$8,137) 
50.4 
(22.9-125.0) 
93.3 
(77.7-108.9) 
*Left 
against 
med. 
advice 
8 (0.9%) $1,366 
($1007-$2,027) 
$1585 
($1,128-$2,042) 
14.1 
(6.0-24.0) 
15.0 
(8.5-21.5) 
ACS 
events 
0 (0.0%) $0 ($0) $0 ($0) 0.0 (0.0) 0 (0.0) 
Non-
events 
8 (0.9%) $1,366 
($1007-$2027) 
$1585 
($1,128-$2,042) 
14.1 
(6.0-24.0) 
15.0 
(8.5-21.5) 
 
* This group was added to the original NHF risk groups for completion 
ACS – Acute Coronary Syndromes 
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Figure 1: Process of care for patients with possible Acute Coronary Syndrome. 
 
 
 
 
Legend: ED = Emergency Department; SSU = short stay unit. Risk classifications 
according to the NHF/CSANZ guidelines (Appendix) 
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Figure 2: STARD diagram. 
 
Legend: STARD = STAndards for the Reporting of Diagnostic accuracy studies, 
ACS = Acute Coronary Syndromes 
 
 
Patients meeting 
inclusion criteria 
(n=1500) 
Enrolled patients 
(n=926) 
Excluded 
Declined/unable/inappropriate to consent 
(n=382) 
Identified>2hrs after presentation (n=77) 
Inter-hospital transfer (n=42) 
Pregnant (n=16) 
Transferred to a private facility (n=12) 
Did not have matching cost data (n=45) 
 
ACS 
(n=103) 
Other 
Cardiovascular 
(n=193) 
Non Cardiac 
(n=622) 
Left against 
medical advice 
(n=8) 
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Figure 3: Kaplan Meyer survivor curves. 
 
 
 
Legend: ACS=Acute Coronary Syndromes, LWBS = Left Without Being Seen. The 
omnibus log-rank test provided some support for differences in the survival function 
across diagnostic groups (p=0.05). The rate of death was slightly higher for ACS 
compared to non-cardiac patients (p=0.01) but did not differ in the ACS versus other 
cardiac (p=0.31) or non-cardiac versus other cardiac groups (p=0.14).  
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Chapter 3 
 
The previous chapter defined the current process of care, costs and outcomes 
associated with the assessment of ED patients with chest pain, highlighting concerns 
about the efficiency of the current situation. 
Before rigorous research could be conducted into new assessment strategies, 
key data elements and definitions needed to be described to support study in this 
area, and allow future comparisons amongst similar ED studies. Existing national 
datasets were focused on key information of relevance to patients with ACS, rather 
than for an ED-based population in whom the diagnosis was not yet made. In 
addition, international datasets were found to be incomplete for the assessment of 
ADPs. 
With the plan for a large international trial it was apparent that this could not 
progress until a comprehensive standardised data set was developed. As such we 
involved experts in emergency, cardiology, and chemical pathology from around the 
world. This data set was utilised for the Asia Pacific Evaluation of Chest pain Trial 
(ASPECT) (Chapter 4). We hoped this publication would provide an unambiguous 
data definition set both for the body of research in this thesis and additionally support 
future ED-based research. 
The publication both described the current issues around the assessment of ED 
patients with chest pain, the limitations of existing datasets from our perspective as 
well as over 100 individual data elements with corresponding definitions. 
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Abstract 
Patients with chest discomfort or other symptoms suggestive of acute coronary 
syndrome (ACS) are one of the most common categories seen in many Emergency 
Departments (EDs). While the recognition of patients at high-risk of ACS has 
improved steadily, identifying the majority of chest pain presentations who fall into 
the low-risk group remains a challenge.  
Research in this area needs to be transparent, robust, applicable to all 
hospitals from large tertiary centres to rural and remote sites, and to allow direct 
comparison between different studies with minimum patient spectrum bias. A 
standardised approach to the research framework using a common language for data 
definitions must be adopted to achieve this.   
The aim was to create a common framework for a standardised data 
definitions set that would allow maximum value when extrapolating research 
findings both within Australasian ED practice, and across similar populations 
worldwide. 
Therefore a comprehensive set of data definitions for the investigation of 
non-traumatic chest pain patients with possible ACS was developed, specifically for 
use in the ED setting. This standardised data definitions set will facilitate ‘knowledge 
translation’ by allowing extrapolation of useful findings into the real-life practice of 
emergency medicine. 
 
Introduction 
Patients with chest discomfort or other symptoms suggestive of acute coronary 
syndrome (ACS) are one of the most common presenting categories seen in many 
Emergency Departments (EDs). These patients account for an estimated 5 - 10% of 
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presentations to Australasian EDs per year, yet between 75 and 85% of the patients 
assessed ultimately do not have a final diagnosis of ACS (3-6, 13).  
Although the recognition of patients at high-risk of ACS has improved 
steadily, identifying the majority of chest pain presentations who fall into the low-
risk group remains a challenge (5, 14). The process of assessing patients in the ED 
with possible ACS remains time-consuming, and is not without controversy. Many 
key questions remain unanswered, such as the role of accelerated biomarker risk 
stratification as early as two hours following ED presentation; the added value of 
multiple biomarker assays including change in their absolute levels (delta values); 
and the clinical utility of early (within 72 hours) provocation testing such as an 
exercise ECG, particularly in patients under 40 years of age without risk factors who 
present with normal serial ECGs and biomarkers (see Discussion).   
A recent report in 2009 by Access Economics on the impact and economic 
burden of acute coronary syndrome in Australia found that the cost of acute 
myocardial infarction (AMI) and unstable angina pectoris (UAP) was Aus $17.9 
billion (15). This included the direct health care system costs such as hospital and 
medical bills, indirect costs such as loss of productivity, and loss in the value of 
health such as through disability and early death. However, the cost associated with 
those 85% of patients found not to have an ACS-related diagnosis remains 
unquantified at this time. 
A valid, safe and efficient process is required to assess potential ACS patients 
in currently already overstretched Emergency Departments. Research in this area 
must be transparent, robust, applicable to all hospital from large tertiary centres to 
rural and remote sites, and allow direct comparisons to be made between different 
studies. Also, investigators must be cautious to avoid patient heterogeneity giving 
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rise to spectrum bias, as this is the biggest source of error in determining the 
performance of the diagnostic tests used (16). 
A standardised approach to the research framework using a common 
language set for data definitions must be adopted to achieve this. This standardised 
data definitions set will facilitate ‘knowledge translation’ by allowing extrapolation 
of useful findings into the real life practice of emergency medicine. Therefore a 
comprehensive data definitions set for the investigation of non-traumatic chest pain 
patients with possible ACS was developed, specifically for use in the ED setting. 
 
Development of the Data Set 
A modified Delphi process was performed by an expert panel of emergency 
physicians and cardiologists. The data elements included were chosen following an 
extensive review of the literature and by circular input from the authors. Key 
published documents containing existing data definitions relating to acute coronary 
syndrome were identified, and formed the initial content data set.   
Those documents used in the data analysis process included amongst others 
the Emergency Medicine Cardiac Research and Education Group – International 
(EMCREG-I) guidelines for the conduct and reporting of research into the field (17) 
endorsed by the Society for Academic Emergency Medicine (SAEM), the American 
College of Emergency Physicians (ACEP), the American Heart Association (AHA) 
and the American College of Cardiology (ACC). Also included was the American 
College of Cardiology Key Data Elements document (18), which complements the 
EMCREG-I guidelines, as well as the AHA and the National Academy of Clinical 
Biochemistry (NACB) additional case definitions that defined parameters around 
cardiac biomarkers (19, 20). Finally, the ACS Dataset that forms part of the National 
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Health Data Dictionary (21) which facilitates the collection of data within 
Australasia relating to ACS research was included, in a form to suit the local context. 
Key elements were sourced from these documents, and additional variables were 
identified from the literature including those by Hess et al (22), and by consensus 
opinion of the authors. 
Most individual data points required no re-definition, given the robust, 
explicit justification of data elements already contained within these key 
publications. However some elements, for instance recommended by Hess et al (22), 
were not clearly defined. Therefore, the authors agreed on changes to these existing 
data definitions, which were indicated by * alongside the definition (see Appendix 
A). These changes included the addition of modern drugs; amalgamation of 
elements; changes of units to SI, and formatting changes.  
In addition, new data points relevant to ED practice were introduced by 
consensus opinion of the authors to expand the data definitions set, where they did 
not previously exist. Thus for example ‘Pulmonary Embolism’ was included in both 
the Clinical History and Outcome Event sections as this condition is an important 
confounder when assessing the undifferentiated patient with chest pain. Another key 
addition is the ‘Reported’ and ‘Adjudicated’ elements in the patient’s history. ED 
physicians often have to rely on the patient’s self-reporting of the clinical history due 
to lack of immediate access to supporting documentation.  
All data elements were then amalgamated into a single, comprehensive 
standardised data definitions set deemed by the authors to be most appropriate for 
use in ED-based research into ACS chest pain within, but not confined to, local 
practice in Australasia (see Appendix A).  
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Discussion 
There is currently no universally accepted definition of what is meant by a 
‘low-risk’ patient for ACS. This is a critical issue because, as according to Bayes 
Theorem, accurate interpretation of post-test probability following any given test 
result depends upon a clear recognition of the pre-test odds.  Pre- and post-test odds 
are most intuitive when converted into pre- and post-test probabilities (percentages).  
An accurate and widely accepted method to determine true risk grouping, that is 
prevalence, for pre-test purposes using an agreed definition is an essential 
requirement for test interpretation. 
Assessment of the pre-test odds is also vital when deciding whether a test is 
required at all. Diagnostic equipoise or the ‘test threshold’ represents the level of pre-
test probability at which the risk of proceeding with an investigation (from the 
investigation itself, and from any action ensuing from a false positive result) is 
balanced by the risk and cost of doing no investigation at all. Thus the test 
‘threshold’ represents the pre-test probability that should be exceeded in order to 
justify doing a diagnostic test for the disease in question (23).  Kline et al using 
attribute matching of standard historical risk, physical examination, 
electrocardiographic and laboratory data have calculated that a patient with a pre-test 
probability of ACS as low as  <2% will not benefit from further diagnostic testing 
(24).   
One of the reasons there is a lack of clarity over the definition of ‘risk’ is that 
some research studies of diagnostic accuracy report the risk of an ACS-related 
diagnosis (24, 25), while other studies of prognosis report outcome related risks, such 
as adverse events including death, AMI or need for urgent revascularisation (26-29). 
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Whilst these concepts may overlap, the different research endpoint intentions must 
be clearly and explicitly stated.  
The terms  ‘low-’, ‘intermediate- ‘and ‘high-risk’ groups for ACS are used 
inconsistently, as regards their absolute risk of an adverse outcome within 30 days 
(30, 31). Accurate determination of risk is still the key to evaluating patients with 
possible ACS (32). Definitions will depend on whether the intention is to ‘rule-out’ 
ACS in a patient and therefore allow that patient to safely go home from the 
emergency department; or whether the intention is to ‘rule-in’ ACS in a patient who 
thus will be in need of an acute cardiology service. Thus, one suggestion for the 
definition of a patient being ‘low-risk’ for suspected ACS by outcome events is any 
patient with a <1% risk of a 30-day adverse event (33, 34). This definition is 
therefore suitable for risk stratification to ‘rule out’ ACS in the Emergency 
Department patient, who may then be allowed home. Yet it should be emphasised 
that this represents a ‘low-risk’ for short term outcomes only. The longer term 
adverse outcome rate at one 1 year may still be significant, and consequently such 
patients may still require further planned investigations and follow-up. Conversely, 
the Acute Coronary Insufficiency-Time Insensitive Predictive Instrument (ACI-TIPI) 
defines ‘low-risk’ as a less than 10% chance of an AMI or unstable angina (35). This 
is useful for ‘rule in’ decision making to determine the likely need for cardiac 
monitoring, or an acute interventional cardiology service care, but clearly this 
definition does not allow a ‘rule out’ ACS decision, signalling that the patient can be 
safely discharged from the emergency department, as that level of risk (potentially up 
to 10%) is unacceptable. 
The National Heart Foundation of Australia  (NHFA) and the Cardiac Society 
of Australia and New Zealand (CSANZ) last produced in 2006  guidelines for the 
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initial evaluation of patients with non-traumatic chest pain, which defined the 
likelihood of ACS, and determined short-term risk for adverse outcomes(31). These 
recommendations outlined an assessment process that included elements in the 
history and examination, initial ECG and cardiac markers to give a risk assignment 
into a low-, intermediate- or a high-risk category for nonST-segment acute coronary 
syndrome (NSTEACS). Patients with suspected NSTEACS were defined as ’low-
risk’ if the presentation was with clinical features of acute coronary syndrome 
without intermediate- or high-risk features. This ‘low-risk’ group included patients 
with the onset of anginal symptoms within the last month, or worsening in severity or 
frequency of angina, or lowering of anginal threshold. These ‘low-risk’ patients 
could be discharged on upgraded medical therapy with urgent cardiac follow up (23). 
The majority of patients presenting to emergency departments are classified as 
‘intermediate-risk’ according to these guidelines (23). That is, they present with 
features on history, examination, ECG and investigative findings that are consistent 
with ACS, but they do not meet the criteria for ‘high-risk’ NSTEACS. These 
‘intermediate-risk’ patients require further observation and risk stratification that 
moves them into either ‘high-risk’ (see later) or ‘low-risk’, to be allowed home (23). 
‘High-risk’ NSTEACS patients need immediate admission for aggressive medical 
management and coronary angiography and revascularistion (23). Research shows 
that clinical findings (36, 37) and traditional risk factors (38) are not as 
discriminatory in risk analysis as was they were once considered.  
The existence of a ‘very-low risk’ group of patients in whom the likelihood of 
ACS is so small that little or no assessment is required at all has also been suggested 
(33, 34). Marsan et al (33) identified a cohort of patients who were at particularly 
low risk (0.14%) for ACS at 30 days by using a modified clinical decision rule. 
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Similarly the Vancouver Chest Pain rule (34)  also defined a group of patients who 
could be safely discharged after brief ED evaluation including clinical assessment, 
ECG +/- CK-MB at, or before, 2 hours from presentation. These findings are to yet 
be prospectively validated in other centres.  
These examples given exemplify the importance of standardising the 
definition, recognition and evaluation of specific risk groups within the spectrum of 
suspected acute coronary syndrome. Several methods that permit rapid identification 
of patients in need of more prolonged investigation or hospital admission to rule out 
ACS have now been described (39-42).  Combinations of biomarkers, and or newer 
biomarkers may lead to even more rapid risk stratification for patients with possible 
ACS and hence facilitate early discharge.  Straface et al have identified a multi-
marker approach that was superior to TnI alone for the triage of patients with chest 
pain(43). Ultrasensitive troponin assays will increase the sensitivity for the detection 
of ACS compared with standard assays (44).  
Addition of novel cardiac biomarkers may also provide information on 
prognosis for AMI and/or death, ranging from 30 day outcome  to 1 year event rates, 
but are unable to identify those at risk of the full spectrum of ACS-related 
diagnoses(45).  A panel-type approach that includes additional biomarkers such as 
natriuretic peptides, myeloperoxidase, C-reactive protein and monocyte chemo-
attractant protein-1 may increase the sensitivity for the detection of short-term ACS-
like events. This is likely to be at the  cost of decreased test specificity (46). Again 
such methods may identify those at short term risk, but individuals with a detectable 
troponin level even if below the nominal cut-off level, should still be considered for 
further investigation and follow-up (47). 
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At present there is insufficient published evidence to support the safety of 
very short (2 hour) assessment pathways. Australasian-based trials such as the ASia 
Pacific Evaluation of Chest pain Trial (ASPECT) and Multiple Infarct Markers In 
Chest pain (MIMIC) are investigator-lead, industry-sponsored studies aimed at 
answering some of the questions that remain about multi-marker approaches to chest 
pain evaluation. ASPECT will prospectively validate an investigative pathway in 
patients presenting to hospital with symptoms suggestive of possible ACS, which 
involves using risk stratification (using ECG and/or risk stratification tools) and 
serial cardiac biomarkers over a 2 hour time period from presentation, to allow 
identification of patients at very low risk of a serious adverse cardiac event at 30 
days after initial presentation.  
Currently the ECG and cardiac biomarkers are first used to identify patients 
with ST elevation myocardial infarction (STEMI) or non-ST elevation myocardial 
infarctions (NSTEMIs). The next step in ruling out ACS, when serial ECG and 
cardiac biomarkers are negative, requires provocative testing to exclude inducible 
ischaemia or angina. This includes those patients deemed at significant risk for an 
adverse event within 30 days. Questions remain in this group about the most 
appropriate investigation to exclude significant coronary artery disease. The utility of 
exercise stress ECG testing (EST) has been challenged(48). EST has a sensitivity and 
specificity of 68% and 77% respectively, and a positive predicative accuracy of 
about 70% for the diagnosis of coronary artery disease (49-52). It is not clear 
whether EST does indeed currently identify that population at risk. Concerns remain 
about false positive results leading to further unnecessary investigations such as 
coronary angiography, with its attendant additional risks and costs. Thus the 
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incremental value of EST remains unclear. If EST is deemed necessary then evidence 
suggests that this can occur at an earlier timeframe (53) 
Meanwhile, the emerging role of coronary CT angiography (CCTA) shows 
promise (54-57) with a reported high negative predictive value in patients presenting 
to the ED with possible ischaemic chest pain. Although radiation dose is an issue, the 
CCTA may allow the definitive rule-out of coronary disease in the low- and 
intermediate-risk group (54, 55, 57-59). However normal findings on CCTA do not 
exclude all significant diagnoses, for example myocarditis. 
Finally the appropriate timing of objective testing is unclear. Inpatient 
assessment does at least mean that the risk assessment test is actually completed.  
Alternatively it may be safe and more practical to perform investigations such as 
exercise stress testing on an early outpatient-basis. The responsibility for test 
attendance and follow up of the result is then transferred to the community local 
medical practitioner, but he or she may be unaware of the details of the acute 
attendance at the ED.  Likewise outpatient service follow up has the same duty of 
care risk with patients who fail to present for further testing.   
A coordinated, health system approach to the diagnosis and management of 
ACS is clearly required, with current gaps in ACS management in Australasia having 
recently been identified by a national forum, and explicit recommendations made for 
strategies for closing these gaps (52). 
 
Conclusion 
This paper aims to disseminate a comprehensive standardised data definitions 
set for use in research in Australasia, and across other sites wishing to replicate local 
research methodology in investigating patients presenting to the emergency 
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department with possible ACS. These definitions will be essential for consistency in 
terminology, as well as in avoiding the danger of spectrum bias from inadvertent 
heterogeneity in the patients studied.  
The comprehensive standardised data definitions set combined components 
from existing guidelines of the EMCREG-I, the AHA, the ACC and the National 
Health Data Dictionary, with new elements suitable for ED-based research conducted 
within Australasia.  
The process used ensured that a common framework was developed for a 
standardised data definitions set that will allow maximum value when extrapolating 
research findings both within Australasian ED practice, and across similar 
populations worldwide. 
 
Disclaimer: The comprehensive standardised data definitions set in Appendix A at 
present represents the consensus views of the authors alone. 
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Appendix A - A comprehensive standardised data definitions set for acute coronary 
syndrome research in emergency departments in Australasia  
 
General Information 
Subject Details 
 
Hospital 
Identifier 
 
The reference number the local hospital uses to identify this 
patient in their computer systems and registries. 
 
Date of Birth 
 
Provide date in the DD/MM/YYYY format. 
 
Ethnicity/ 
Race 
 
The patients reported ethnicity or race. 
Trial Eligibility 
 
Inclusion 
Criteria 
 
In accordance with AHA guidelines, symptoms consistent with 
possible ACS include: 
Presence of acute chest, epigastric, neck, jaw or arm pain or 
discomfort or pressure without apparent non-cardiac source. (1) 
More general/atypical symptoms, such as fatigue, nausea, 
vomiting, diaphoresis, faintness and back pain, may be used as 
inclusion criteria if specified. Data collection must allow for sub 
analysis of the included groups. 
 
Exclusion 
Criteria 
 
Exclusion criteria from the study must be clearly documented. 
PRESENTATION DATES 
 
Acute 
Coronary 
Syndrome 
(ACS) 
Symptom 
Onset: date 
and time (2) 
 
Date and time of the onset of symptoms that prompted the patient 
to seek medical attention.  
Provide date in the DD/MM/YYYY format and time in 24 hour 
format. 
In the event of stuttering symptoms, ACS symptom onset is the 
time at which symptoms became constant in quality or intensity. 
 
Date of ED 
Presentation : 
date and time 
 
Date and time the patient first presented to the hospital. Provide 
date in the DD/MM/YYYY format and time in 24 hour format. 
 
Date of 
Recruitment: 
date and time 
 
Date and time the patient recruited into the trial. Provide date in 
the DD/MM/YYYY format and time in 24 hour format. 
History 
Symptoms at presentation  
 
Chest Pain 
 
If the patient complained of chest pain/discomfort that was 
existing on presentation to hospital. If symptoms resolved 
prior to arrival at hospital report as ‘no’. 
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(Atypical symptoms are defined below). 
 
Cardiac Arrest at 
Admission 
 
If the patient is presenting to the ED in cardiac arrest. 
 
Repeat 
Presentation 
 
Identify if the patient has previously presented to hospital 
with possible cardiac ischemia and define the time period 
(e.g. within the last year). 
 
Pain Location 
 
The location of the pain/discomfort can be described as 
follows: 
  Left Chest: The pain/discomfort is on the left side of the 
sternum  
  Right Chest: The pain/discomfort is on the right side of the 
sternum 
Sternal/parasternal: The pain/discomfort is over, 
underneath or around     the sternum 
  Arms (L or R): The pain/discomfort is located in the left or 
right arm 
 Throat/jaw: The pain/discomfort is located above the 
clavicle in anterior neck or lower face 
Back (upper): The pain/discomfort is located in the patient’s 
back, over the thorax/ribcage 
Epigastric: The pain/discomfort is located in the central 
upper abdomen, and below the ribs 
 
Character  
(How does the 
patient describe 
the 
pain/discomfort?) 
 
The character of the predominant pain/discomfort can be 
described as follows: 
   Dull: The pain/discomfort is steady  or sustained, not 
intense or acute 
   Sharp: The pain/discomfort peaks in a highly specific area, 
or is described as “knife-like” 
   Burning: The pain/discomfort can be described as feeling 
hot, or like the pain of a burn 
   Heavy: The patient feels as though there is a heavy weight 
on the affected region 
   Indigestion: The pain/discomfort feels similar to reflux, or 
heartburn 
   Crushing: The pain/discomfort is similar to heavy, 
squeezing from one or all sides 
   Stabbing: The pain/discomfort feels like having pointed 
object pressed against body, and may be episodic 
   Other (specify): Any descriptions which are not better 
described above 
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Exacerbating 
Factors 
 
The pain/discomfort is either reproduced or worsens in one or 
more of the following situations. 
On Inspiration: The pain/discomfort is worsened by 
inspiration 
On Exertion: The pain/discomfort is worsened by increased 
exercise 
On Palpation: Pressing on the patient's chest reproduces the 
pain/discomfort of the same character as the pain they  
originally experienced 
On Movement: The pain/discomfort is worsened by 
particular movements 
On Position: The pain/discomfort is worsened when the 
patient’s body is in a particular position, such as when they 
are standing, or sitting, or lying down. 
 
Radiation 
 
The extension of the pain/discomfort to another site whilst the 
initial pain/discomfort persists – identify the location(s): 
L chest: The pain/discomfort is on the left side of the sternum 
R chest: The pain/discomfort is on the right side of the 
sternum 
Sternal/parasternal: The pain/discomfort is underneath or 
around the sternum 
Arms (L or R): The pain/discomfort is located in the left or 
right arm 
Throat/jaw: The pain/discomfort is located above the 
clavicle 
Back (upper): The pain/discomfort is located in the patient’s 
back, over the thorax/ribcage 
Epigastric: The pain/discomfort is located centrally, and 
immediately below the ribs 
 
Associated 
Factors 
 
The patient developed one of the following symptoms in 
conjunction with their pain/discomfort: 
Nausea: the sensation of need to, or likelihood of, vomiting 
Vomiting: The patient has expelled the contents of their 
stomach 
Diaphoresis/sweating/clamminess: The patient is sweating 
more than usual 
Syncope/blackout/unexplained LOC: The patient has lost 
consciousness at some stage since the pain/discomfort started, 
which cannot otherwise be explained 
SOB/breathlessness: The patient is finding breathing 
difficult or uncomfortable 
 
Reported Patient 
HISTORY 
 
These are to be self-reported (as determined during the ED 
interaction between the clinician / health researcher and the 
patient), without access to medical records. 
 
Previous 
 
Reported – For example-“Have you ever suffered a heart 
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Myocardial 
Infarction (MI) 
attack?” 
 
Prior Angina 
 
Reported – For example-“Have you ever suffered from 
angina, or chest pains related to the heart?” 
 
Ventricular 
Tachycardia 
 
Reported – For example - “Have you ever suffered from a 
heart irregularity called Ventricular Tachycardia?” 
 
Prior CAD 
 
Reported – For example-“Have you ever suffered from 
narrowing of the heart vessels or Coronary Artery Disease?” 
 
Atrial 
Arrhythmia 
 
Reported – For example-“Have you ever suffered from 
Atrial Fibrillation?” or “Do you take digoxin?” 
 
Prior Congestive 
Heart Failure 
(CHF) 
 
Reported – For example-“Have you ever suffered from 
(Congestive) Heart Failure?” 
 
History of Stroke 
or Transient 
Ischaemic Attack 
(TIA) 
 
Reported – For example-“Have you ever suffered from a 
Stroke, or Transient Ischaemic Attack?” 
 
Peripheral 
Arterial Disease 
 
Reported – For example-“Have you ever suffered from 
Peripheral Arterial Disease?” 
 
Previous CABG 
 
Reported – For example-“Have you ever had Coronary 
Bypass surgery?” 
 
Previous 
Percutaneous 
Coronary 
Intervention  
 
Reported – For example-“Have you ever had an 
Angioplasty or a Stent?” 
 
Rheumatoid 
Arthritis 
 
Reported – For example-“Have you ever had Rheumatoid 
arthritis?”  If type of ‘arthritis’ is not known by the patient 
report as NO. 
 
Pulmonary 
Embolism 
 
Reported – For example – “Have you ever had a pulmonary 
embolism or a ‘clot’ in your lung?” 
 
Other: specify 
 
Any other Reported Cardiac history not otherwise specified. 
 
Reported Risk 
Factors 
 
These are to be self-reported (as determined during the ED 
interaction between the clinician / health researcher and the 
patient), without access to medical records. 
 
Hypertension 
 
Reported – For example-“Have you ever suffered from high 
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blood pressure?” 
 
Diabetes 
 
Reported – For example-“Have you ever suffered from 
diabetes?” 
 
Dyslipidaemia 
 
Reported – For example-“Have you ever suffered from high 
cholesterol?” 
 
Family History of 
CAD 
 
Reported – For example-“Has anyone in your family ever 
suffered from heart disease?” 
 
Smoking 
 
Reported – For example-“Have you ever smoked?” 
Classify as follows (2):  
1. Current: Smoking cigarettes within 1 month of this 
admission  
2. Recent: Stopped smoking cigarettes between 1 month and 
1 year before this admission  
3. Former: Stopped smoking cigarettes greater than 1 year 
before this admission  
4. Never: Never smoked 
 
Cocaine Use or 
Amphetamine 
Use  
 
Reported – For example – “Have you ever used cocaine?” 
Classify as follows (3): 
1. Current (past week) 
2. Recent  <1 year 
3. Former >1year 
4. Never 
Adjudicated CardiovascuLAR History  
These are to be adjudicated (i.e. as recorded from the notes).  
The Adjudicated field is based on all available information of the patient’s history, 
including patient notes. If the patient’s report contradicts evidence in the notes, the 
notes take precedence. Provided below is the concise requirements for completing 
each adjudicated cardiovascular history field.  
Note: The person performing the final review of the case must be clearly identified 
(e.g. cardiologist, emergency physician) and blinding to the results of the test 
article and other adjudicators explicitly stated. 
 
Previous 
Myocardial 
Infarction 
(MI) (2) 
 
Adjudicated – The patient has at least 1 documented previous 
MI before admission. (For a complete definition, please refer to 
"MI" in the "Endpoints" section.) Date should be noted. 
 
Prior Angina 
(2) 
 
Adjudicated – History of angina before the current admission. 
"Angina" refers to evidence or knowledge of symptoms described 
as chest pain or pressure, jaw pain, arm pain, or other equivalent 
discomfort suggestive of cardiac ischemia. Indicate if angina 
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existed more than 2 weeks before admission and/or within 2 
weeks before admission. 
 
Prior 
Ventricular 
Arrhythmia 
(2) 
 
Adjudicated – Ventricular tachycardia or ventricular fibrillation 
requiring cardioversion and/or intravenous antiarrhythmics. 
 
Prior PCI 
and/or CABG 
(2) 
 
Adjudicated – Previous percutaneous coronary intervention 
(PCI), coronary artery bypass graft (CABG), or prior 
catheterization with stenosis greater than or equal to 50%. 
 
Prior Atrial 
Arrhythmia 
(2)* 
Adjudicated – An episode of atrial arrhythmia documented by 1 
of the following:  
1. Atrial fibrillation/flutter  
2. Supraventricular tachycardia requiring treatment 
(supraventricular tachycardia that requires cardioversion or 
drug therapy) or is sustained for greater than 1 minute. (2) 
 
 
Prior 
Congestive 
Heart Failure 
(CHF) (2) 
 
Adjudicated – History of CHF. "CHF" refers to evidence or 
knowledge of symptoms before this acute event described as 
dyspnea, fluid retention, or low cardiac output secondary to 
cardiac dysfunction, or the description of rales, jugular venous 
distension, or pulmonary oedema before the current admission. 
 
History of 
Stroke or 
Transient 
Ischaemic 
Attack (TIA) 
(2)* 
 
Adjudicated – Documented history of stroke or cerebrovascular 
accident (CVA) or TIA. Typically there was loss of neurological 
function caused by an ischemic event with residual symptoms at 
least 24 hours after onset, or a focal neurological deficit that 
resolves spontaneously without evidence of residual symptoms at 
24 hours. 
 
Peripheral 
Arterial 
Disease (2) 
 
Adjudicated – Peripheral arterial disease can include the 
following: 1. Claudication, either with exertion or at rest 2. 
Amputation for arterial vascular insufficiency 3. Vascular 
reconstruction, bypass surgery, or percutaneous intervention to 
the extremities 4. Documented aortic aneurysm 5. Positive non-
invasive test (e.g., ankle brachial index less than 0.8). 
 
Previous 
CABG (2)* 
 
Adjudicated – Evidence that the patient had coronary artery 
bypass grafting. 
 
Previous 
Percutaneous 
Coronary 
Intervention 
(PCI) (2) 
 
Adjudicated – Previous PCI of any type (balloon angioplasty, 
atherectomy, stent, or other) done before the current admission. 
Date should be noted. 
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Rheumatoid 
Arthritis 
 
Adjudicated – Documented history of rheumatoid arthritis or 
history of ‘arthritis’ and treatment with glucocorticoids, disease-
modifying antirheumatic drugs (e.g. methotrexate, sulfasalazine, 
hydroxychloroquine, penicillamine), TNF inhibitors, or 
immunosuppressive agents (e.g. cyclosporine).  
 
Pulmonary 
Embolism 
 
Adjudicated – Documented history of pulmonary embolism.  
 
Other: Specify 
 
Please note if it is Reported or Adjudicated. 
adjudicated Risk 
These are to be adjudicated (i.e. as recorded from the notes). 
The Adjudicated field is based on all available information on the patient’s history, 
including patient notes. If the patient’s report contradicts evidence in the notes, the 
notes take precedence. Provided below is the concise requirements for completing 
each adjudicated risk factors field. 
Note: The person performing the final review of the case must be clearly identified 
(e.g. cardiologist, emergency physician) and blinding to the results of the test 
article and other adjudicators explicitly stated. 
 
Hypertension 
(2) 
 
Adjudicated – Hypertension as documented by: 1. History of 
hypertension diagnosed and treated with medication, diet, and/or 
exercise 2. Blood pressure greater than 140 mmHg systolic or 90 
mmHg diastolic on at least 2 occasions 3. Current use of 
antihypertensive pharmacological therapy. 
 
Diabetes (2) 
 
Adjudicated – History of diabetes, regardless of duration of 
disease, need for antidiabetic agents, or a fasting blood sugar 
greater than 7 mmol/l or 126 mg/dl. If yes, the type of diabetic 
control should be noted (check all that apply): 1. None 2. Diet: 
Diet treatment 3. Oral: Oral agent treatment 4. Insulin: Insulin 
treatment (includes any combination of insulin) 
 
Dyslipidaemia 
(2)* 
 
Adjudicated – History of dyslipidaemia diagnosed and/or treated 
by a physician. 
 
Family 
History of 
CAD (2) 
 
Adjudicated – Any direct blood relatives (parents, siblings, 
children) who have had any of the following at age less than 55 
years: 1. Angina 2. MI 3. Sudden cardiac death without obvious 
cause. 
 
Smoking (2) 
 
Adjudicated – History confirming cigarette smoking in the past.  
Choose from the following categories:  
1. Current: Smoking cigarettes within 1 month of this admission  
2. Recent: Stopped smoking cigarettes between 1 month and 1 
year before this admission  
3. Former: Stopped smoking cigarettes greater than 1 year before 
this admission  
4. Never: Never smoked cigarettes 
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Cocaine Use 
or 
Amphetamine 
Use 
 
Adjudicated – History confirming cocaine use. This may include 
results of toxicology testing. 
Classify as follows(3): 
1. Current (past week) 
2. Recent  (<1 year) 
3. Former (>1year) 
4. Never 
 
Medications 
For all the medications listed below, their use should be noted if used before 
hospital admission. 
 
Nitrates (oral 
or topical) (2) 
 
Oral or topical nitroglycerin was administered. Commonly 
prescribed agents include isosorbide dinitrate, isosorbide 
mononitrate, Nitro-Dur transdermal infusion system, or 
nitroglycerin paste. (Sublingual nitroglycerin or nitroglycerin 
spray used on an as-needed basis only should not be noted in this 
category). 
 
Aspirin 
 
Aspirin administered within 7 days. 
 
Clopidogrel 
 
Clopidogrel administered. 
 
Other 
Antiplatelet 
Agents 
 
Another antiplatelet agent not listed above that is administered 
(e.g., dipyridamole, ticlopidine, prasugrel). 
 
Warfarin (2) 
 
Warfarin (or coumarol, coumarin) administered. 
 
Oral Beta-
blockers (2)* 
 
Oral beta-blockers administered. Some generic forms of oral 
beta-blockers include atenolol, metoprolol, nadolol, pindolol, 
propranolol, timolol, acebutolol, bucindolol, bisoprolol, labetalol, 
and carvedilol. 
 
Calcium 
Channel 
Blockers (2) 
 
Calcium channel blockers administered. Some generic forms of 
calcium channel blockers include verapamil, nifedipine, 
diltiazem, nicardipine, nimodipine, nisoldipine, felodipine, and 
amlodipine. 
 
ACE 
Inhibitors (2) 
 
ACE inhibitors administered. Some generic forms include 
captopril, enalapril, lisinopril, and ramipril. 
 
Diuretics (2) 
 
Diuretics administered. Some commonly prescribed agents are 
furosemide, ethacrynic acid, hydrochlorothiazide, spironolactone, 
metolazone, and bumetanide. 
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Other 
Antihypertens
ive Agent 
 
Specify agent used. 
 
Statin (HMG 
Co-A 
reductase 
inhibitors) 
(2)* 
 
Examples include: atorvastatin, simvastatin, pravastatin, 
fluvastatin, lovastatin. 
 
Other Lipid-
lowering 
agents (2)* 
 
Fibrates, nicotinic acid, resin drugs (e.g. cholestyramine, 
colestipol, probucol, and gemfibrozil). 
Physical Examination 
Physical Measures 
The time of measurements recorded needs to be specified in the DD/MM/YYYY 
format. 
 
Height (2)* 
 
Patient’s height in centimetres. Specify ‘self reported’ or 
‘measured’. 
 
Weight (2)* 
 
Patient’s weight in kilograms. Specify ‘self reported’ or 
‘measured’. 
 
Temperature 
 
Patient’s body temperature on arrival in centigrade. 
 
Heart Rate (2) 
 
Heart rate (beats per minute) should be the recording that was 
done closest to the time of presentation to the healthcare 
facility.  
 
Blood 
Pressure 
 
Supine systolic and diastolic blood pressure (mmHg) should be 
the recording that was done closest to the time of presentation 
to the healthcare facility. 
 
Respiration 
Rate 
 
Respiratory rate should be recorded closest to the time of 
presentation. 
 
Lung 
Auscultation 
(2)* 
 
Findings should be reported as: 
1. Absence of rales 
2. Rales over 50% or less of the lung fields 
3. Rales over more than 50% of the lung fields 
4. Not done 
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Killip Class 
(2) 
Class 1: Absence of rales over the lung fields and absence of S3  
Class 2: Rales over 50% or less of the lung fields or the presence 
of an S3 
Class 3: Rales over more than 50% of the lung fields 
Class 4: Shock 
 
Pitting 
Oedema 
 
Presence or absence of an indentation of the skin over the mid-
tibia after palpation for 2 seconds should be recorded. 
Treatments 
 
TREATMENT IN HOSPITAL 
 
Heparin 
 
Indicate if heparin (unfractionated) was given to the patient 
during the Index admission. The duration of treatment must be 
stated (e.g. single dose, <24 hours or >24hours). 
 
Low 
Molecular 
Weight 
Heparin 
 
Indicate if LMWH was given to the patient during the Index 
admission. The duration of treatment must be stated (e.g. single 
dose, <24 hours or >24hours). 
Available drugs include: ardeparin, certoparin, enoxaparin, 
dalteparin, nadroparin, parnaparin, reviparin. 
 
GP IIb/IIIa 
Inhibitors (2)* 
 
Indicate if GP IIb/IIIa blockers administered at any time during 
INDEX admission. 
Available drugs include: abciximab, eptifibatide, tirofiban. 
 
Clopidogrel 
 
Indicate if clopidogrel (oral anti-platelet medication) was given to 
the patient during the Index admission. The duration of treatment 
must be stated (e.g. single dose, <24 hours or >24hours). 
 
Other 
Antiplatelet 
Medication 
 
Indicate if another antiplatelet agent was administered at any time 
during the INDEX admission. Agents include: dipyridamole, 
ticlopidine, prasugrel, ticagrelor.  
Investigations 
 
 Electrocardiogram 
(ECG) 
Note: The specialty of the person performing the review of the investigations must 
be clearly identified (e.g. cardiologist, emergency physician). 
 
Date & Time 
 
Date and time of the ECG. Provide date in the DD/MM/YYYY 
format and time in 24 hour format. 
 
Normal  (2) 
 
No possible evidence for ischaemia. 
 
Nonspecific 
ST-T wave 
Changes (2) 
 
Accepted deviation from the norm, with the lowest likelihood of 
ischemia (eg, inverted T wave axis in III or V1). 
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Abnormal but 
not Diagnostic 
of Ischaemia 
(2) 
 
Prolonged PR, QRS, QTc intervals, bundle branch blocks, left 
ventricluar hypertrophy with strain.  
 
Ischaemia or 
Previous 
Infarction 
Known to be 
Old 
 
ST-segment depression of at least 0.5 mm (0.05 mV) in 2 or more 
contiguous leads (includes reciprocal changes), T-wave inversion 
of at least 1 mm (0.1 mV) including inverted T waves that are not 
indicative of acute MI, or Q waves ≥30ms in duration with 
evidence that this is pre-existing on previous ECGs 
 
Ischaemia or 
Previous 
Infarction 
NOT Known 
to be Old  
 
ST-segment depression of at least 0.5 mm (0.05 mV) in 2 or more 
contiguous leads (includes reciprocal changes), T-wave inversion 
of at least 1 mm (0.1 mV) including inverted T waves that are not 
indicative of acute MI, or Q waves ≥30ms in duration with 
evidence that this is not pre-existing on previous ECGs 
 
Consistent 
with AMI 
 
New or presumed new ST-segment elevation at the J point in 2 or 
more contiguous leads with the cut-off points greater than or 
equal to 0.2 mV in leads V1, V2, or V3, or greater than or equal 
to 0.1 mV in other leads or new LBBB STE or LBBB. 
ADDITIONAL ECG INTERPRETATION 
In addition to the interpretation, additional ECG findings may be reported. These 
include: 
ST-Elevation  In men: New ST elevation at the J-point in two contiguous leads 
with the cut-off points: >=0.2 mV in leads V2-V3 or >=0.1mV in 
other leads. 
In women: New ST elevation at the J-point in two contiguous 
leads with the cut-off points: >=0.15 mV in leads V2-V3 or 
>=0.1mV in other leads. 
OR New ST elevation at the J-point in two contiguous leads with 
the cut-off points: >=0.2 mV in leads V2-V3 or >=0.1mV in 
other leads. 
ST-
Depression  
ST-segment depression of at least 0.5 mm (0.05 mV) in 2 or more 
contiguous leads (includes reciprocal changes). 
T-Wave 
Inversion  
T-wave inversion of at least 1 mm (0.1 mV) including inverted T 
waves that are not indicative of acute MI. Indicate number of 
contiguous leads. (E.g. one, two or more). 
Q Wave 
Abnormality 
Q waves that are greater than or equal to 0.03 seconds in width, 
and greater than or equal to 1 mm (0.1 mV) in depth, in at least 2 
contiguous leads. 
LBBB Presence of a left bundle branch block should be noted. 
RBBB Presence of a right bundle branch block should be noted. 
 
Old Changes 
 
Identify all changes which are believed to have existed before the 
onset of presenting symptoms. Definitions are the same as above. 
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Core Laboratory Blood Test Results  
 
Haemoglobin 
 
First Haemoglobin level and units. 
 
Serum 
Creatinine  
 
First Creatinine level and units. 
 
Troponin  
 
First Troponin results and result >=6hrs later. Document time the 
sample was taken. 
State the manufacturer of the assay, the 10% coefficient of 
variation (CV), the limit of detection (LOD) and the units used in 
the measurement. Also state the 99th percentile for the normal 
population. State whether Troponin I or Troponin T are used. 
 
Classify biomarker investigations as (4): 
A. Adequate set of biomarkers: At least 2 measurements of the 
same marker taken at least 6 hours apart 
B. Diagnostic biomarkers: At least 1 positive biomarker in an 
adequate set (see A above) of biomarkers showing a rising or 
falling pattern in the setting of clinical cardiac ischemia and the 
absence of non-cardiac causes of biomarker elevation 
C. Equivocal biomarkers: Only 1 available measurement that is 
positive, or a rising or falling pattern not in the setting of clinical 
cardiac ischemia or in the presence of non-ischemic causes of 
biomarker elevation 
D. Missing biomarkers: Biomarkers not measured 
E. Normal biomarkers: Measured biomarkers do not meet the 
criteria for a positive biomarker (see F below) 
F. Positive biomarkers: At least 1 value exceeding the 99th 
percentile of the distribution in healthy populations or the lowest 
level at which a 10% coefficient of variation can be demonstrated 
for that laboratory 
 
Other 
Cardiac 
Biomarkers 
Other 
(Specify) 
 
Indicate the results of other local investigations that are used to 
determine if there is evidence of myocardial necrosis. Indicate 
reference range and units. E.g. Myoglobin, CK-MB, CK-MB 
mass, BNP. 
 
Investigation Endpoints 
Investigations performed in the 30 days following index presentation AND 
investigations performed prior to study enrolment may be recorded. 
 
 
Stress ECG  
(Exercise 
tolerance 
test/Exercise 
stress test) 
 
State whether stress is exercise or pharmacological.  
 
Maximal stress test (symptom limited) or submaximal test 
(e.g. modified Bruce protocol ending with stage 1 or stage 2) 
(2) 
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1. Positive: On a stress test, the patient developed either: 
 Both ischemic discomfort and ST segment shift greater 
than or equal to 1 mm (0.1 mV) (horizontal or down 
sloping) or  
 New ST shift greater than or equal to 2 mm (0.2 mV) 
(horizontal or down sloping) believed to represent 
ischemia even in the absence of ischemic discomfort.  
(2) 
 
2. Negative: No evidence of ischemia (i.e., no typical angina 
pain and no ST segment shifts).  (2) 
3.Equivocal: Either: 
 Typical ischemic pain/discomfort but no ST segment 
shift greater than or equal to 1 mm (0.1 mV) 
(horizontal or down sloping) or, 
 ST shift of 1 mm (0.1 mV) (horizontal or down 
sloping) but no ischemic discomfort. (5) 
 
Stress 
Radionuclide 
Imaging  
State whether stress is exercise or pharmacological  
All stress radionuclide imaging should be adjudicated by two 
independent cardiologists or nuclear physicians (double 
blinded). In cases where there is disagreement between the two 
adjudicators, a third adjudicator will be used as a tie-breaker. 
Some guidance is provided below: 
Positive Stress Scan 
Reversible perfusion defect. # 
#Needs a radiologist and/or cardiologist interpretation and 
clinical correlation, also report the size of the defect. 
Exercise portion of the test is defined as positive if >1.0 mm 
horizontal or down sloping ST segment depression of elevation 
80 msec after the J point. 
Negative Stress Scan 
Borderline or no reversible perfusion defects. 
Non-Diagnostic Scan 
Exercise ECG without ischemic changes at a peak HR less than 
85% of the age predicted maximum. 
 
Stress 
Echocardiogram  
State whether stress is exercise or pharmacological  
All stress echocardiograms will be adjudicated by two 
independent cardiologists (double blinded). In cases where 
there is disagreement between the two adjudicators, a third 
adjudicator will be used as a tie-breaker. Some guidance is 
provided below: 
Positive Scan 
Wall motion abnormality positive for ischemia when > 2 
contiguous segments exhibit resting or inducible wall motion 
abnormality. 
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Indeterminate Scan 
If the target heart rate is not achieved. 
 
Echocardiograp
hy (non-stress) 
 
Echocardiogram performed that assesses ejection fraction (EF) 
and regional wall motion abnormalities. 
 
Coronary CT  
Angiography 
(CCTA) 
 
Coronary CT Angiography performed during the index 
admission. Provide date in the DD/MM/YYYY format. 
Calcium Score: Report the score from radiologists or 
cardiologists review of CCTA. 
Percent Stenosis: Highest degree of stenosis noted by 
radiologists or cardiologists. 
 
Cardiac 
catheterization / 
Angiography 
 
Diagnostic cardiac catheterization/angiography performed 
during the hospital stay. Date should be noted. (2) 
Report if a stenosis of ≥70% is present OR a Culprit Lesion 
(ulcer or thrombus) in at least 1 vessel if present. 
Angiography – Additional information 
Additional information may be reported from diagnostic cardiac 
catheterization/angiography performed during the hospital stay.  
Provide date in the DD/MM/YYYY format. 
 
Maximum 
Stenosis by 
Vessel (2) 
 
Stenosis represents the percentage occlusion, from 0 to 100%, 
associated with the identified vessel systems. Percent stenosis 
at its maximal point is estimated to be the amount of reduction 
in the diameter of the "normal" vessel proximal to the lesion. 
For the denominator, take the maximum internal lumen 
diameter proximal and distal to the lesion. In instances where 
multiple lesions are present, enter the highest percentage 
stenosis noted. The systems of interest are as follows and 
should include major branch vessels of greater than 2 mm 
diameter: 
 
a) Greatest stenosis assessed in the LAD or any major 
branch vessel 
b) Greatest stenosis assessed in the LCx or any major 
branch vessel 
c) Greatest stenosis assessed in the RCA or any major 
branch vessel 
d) Greatest stenosis assessed in the L M 
       e)    Greatest stenosis assessed in bypass graft  
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Culprit Artery 
(2) 
 
Vessel considered to be responsible for the ACS. The 
investigator should use his/her judgment in choosing the 
primary vessel. In cases in which this is difficult to determine 
(despite correlation of ECG changes and angiographic data), 
the vessel supplying the largest territory of myocardium should 
be selected: • LAD • LCx • RCA •• LM • Graft • Unknown  
Note: "None" should be considered if there is no apparent 
coronary vessel lesion that could be responsible for evidence of 
ischemia. 
 
 
Culprit Artery 
TIMI Flow (2) 
TIMI grade flow in the culprit artery is defined as follows: 
Grade 0 (no perfusion): There is no antegrade flow beyond the 
point of occlusion. 
Grade 1 (penetration without perfusion): The contrast material 
passes beyond the area of obstruction but “hangs up” and fails 
to opacify the entire coronary bed distal to the obstruction for 
the duration of the cineangiographic filming sequence. 
Grade 2 (partial perfusion): The contrast material passes 
across the obstruction and opacifies the coronary bed distal to 
the obstruction. However, the rate of entry of contrast material 
into the vessel distal to the obstruction or its rate of clearance 
from the distal bed (or both) is perceptibly slower than its entry 
into or clearance from comparable areas not perfused by the 
previously occluded vessel (e.g., the opposite coronary artery 
or the coronary bed proximal to the obstruction).  
Grade 3 (complete perfusion): Antegrade flow into the bed 
distal to the obstruction occurs as promptly as antegrade flow 
into the bed from the involved bed and is as rapid as clearance 
from an uninvolved bed in the same vessel or the opposite 
artery. 
Percutaneous Intervention (PCI) 
PCI performed during admission. Provide date in the DD/MM/YYYY format. 
 
Time of First 
Balloon 
Inflation (2) 
 
Time of the first balloon inflation or stent placement. If the exact 
time of first balloon inflation or initial stent (if no balloon) 
placement is not known, the time of the start of the procedure 
should be indicated. 
 
Number of 
Lesions 
Attempted (2) 
 
Number of lesions into which an attempt was made to pass a 
guidewire, whether successful or not. 
 
Number of 
Stents Placed 
(2) 
 
Number of stents placed. 
Drug Eluting 
Stent (DES) 
Any stent which releases pharmacological agents after placement. 
 
Bare Metal 
 
Any stent which does not release pharmacological agents after 
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Stent (BMS) placement. 
 
Number of 
Lesions 
Successfully 
Dilated (2) 
 
Number of lesions in which residual postintervention stenosis is 
less than 50% of the arterial luminal diameter, TIMI flow is 3, 
and the minimum decrease in stenosis is 20%. 
Inpatient Coronary  Artery Bypass Grafting (CABG) 
CABG procedure performed during this admission. Provide date in the 
DD/MM/YYYY format. 
DISCHARGE INFORMATION 
 
ED Discharge 
Status 
 
Specify whether the patient was alive or dead at discharge from 
the ED. Choose one of the following: 
 Alive 
 Deceased 
 
 
ED Discharge 
Destination 
 
Identify which of the following locations the patient was 
discharged to: 
 Home – The patient is not placed in the care of any 
inpatient health care providers, or is referred to the care of 
the local medical practitioner 
 Inpatient admission – The patient is transferred to the care 
of a ward within the hospital 
 ED observation admission – The patient is transferred to a 
short -stay observation unit within the same ED 
 Self discharge – The patient removes themselves from the 
care of ED staff 
 Transferred to another facility – The patient is transferred 
to the care of health care providers that is not within the 
same hospital. The discharge summary and relevant 
treatment records must be obtained from the facility the 
patient was transferred to in order to complete the 
outcomes for the study.  
 
Note: Where a patient was admitted to inpatient service, ED 
observation unit or transferred to another facility for ongoing 
management then Hospital Discharge details MUST also be 
provided. 
 
Date and 
 
Date and time the patient left the ED. Provide date in the 
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Time of ED 
Discharge 
DD/MM/YYYY format and time in 24 hour format. 
 
Date and 
Time of 
Hospital 
Discharge 
 
The date the patient was discharged from hospital following 
inpatient admission (or transfer) for the index event.   Provide 
date in the DD/MM/YYYY format and time in 24 hour format. 
 
 
Hospital 
Discharge 
Status 
 
Specify whether the patient was alive or dead at discharge from 
the hospital following the index admission. Choose one of the 
following: 
 Alive 
 Deceased  
 
endpoints 
These elements are believed to be the most important outcomes to monitor in 
patients with ACS. Provide date in the DD/MM/YYYY format and time in 24 hour 
format for each endpoint that occurs.  
The definition for each endpoint is detailed below. 
 
 
DEATH 
 
Indicate date and time in DD/MM/YYYY and 24 hour clock 
time. 
 
 
Cause of death 
(2)* 
 
This category includes all deaths regardless of primary cause 
of death. 
Primary cause can be classified as follows: 
 Cardiovascular death 
a. Cardiac indicates cause of death was sudden 
cardiac death, MI, unstable angina, or other 
CAD; CHF; or cardiac arrhythmia. 
b. Non Cardiac (e.g., stroke, arterial embolism, 
pulmonary embolism, ruptured aortic 
aneurysm, or dissection).  
 Non-cardiovascular death indicates cause of death 
was respiratory failure, pneumonia, cancer, trauma, 
suicide, or any other already defined cause (e.g., liver 
disease or renal failure). 
 Death of uncertain cause: If a cardiac cause of death 
cannot be excluded after reasonable investigation, it is 
assumed that the death was cardiac related. 
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For patients whom die and for whom no cardiac markers 
were obtained, the presence of new ST-segment elevation and 
new chest pain would meet criteria for MI. 
 
Cardiac Arrest 
 
Cardiac Arrest 
Cardiac arrest is the cessation of cardiac mechanical activity 
as confirmed by the absence of signs of circulation. If an 
EMS provider or physician did not witness the cardiac arrest, 
then the professional may be uncertain as to whether a cardiac 
arrest actually occurred.  
Cause of Arrest (Etiology) 
An arrest is presumed to be of cardiac etiology unless it is 
known or likely to have been caused by trauma, submersion, 
drug overdose, asphyxia, exsanguination, or any other non-
cardiac cause as best determined by rescuers. 
 
Cardiogenic  
Shock (2) 
 
Experienced cardiogenic shock. Clinical criteria for 
cardiogenic shock are hypotension (a systolic blood pressure 
of less than 90 mmHg for at least 30 minutes or the need for 
supportive measures to maintain a systolic blood pressure of 
greater than or equal to 90 mmHg), end-organ hypoperfusion 
(cool extremities or a urine output of less than 30 ml/h, and a 
heart rate of greater than or equal to 60 beats per minute). The 
hemodynamic criteria are a cardiac index of no more than 2.2 
l/min per square meter of body-surface area and a pulmonary-
capillary wedge pressure of > 15 mmHg. 
 
Acute Myocardial 
Infarction (4) 
 
Detection of rise and/or fall of cardiac biomarkers (preferably 
troponin) with at least one value above the 99th percentile of 
the upper reference limit (URL) together with evidence of 
myocardial ischaemia with at least one of the following: 
 Symptoms of ischaemia; 
 ECG changes indicative of new ischaemia (new ST-T 
chamges or new left bundle branch block [LBBB]); 
 Development of pathological Q waves in the ECG; 
 Imaging evidence of new loss of viable myocardium 
or new regional wall motion abnormality. 
 
STEMI (2)* 
 
Defined as an ACS in which there is cardiac marker evidence 
of myocardial necrosis (e.g., positive Troponin) and new (or 
presumably new if no prior ECG is available) ST-segment 
elevation* on the admission ECG.  
*New ST elevation at the J-point in two contiguous leads 
with the cut-off points: >=0.2 mV in leads V2-V3 or 
>=0.1mV in other leads. 
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NSTEMI (2)* 
 
Defined as an ACS in which there is cardiac marker evidence 
of myocardial necrosis (e.g., positive CK-MB or troponin) 
without new ST-segment elevation.  
 
*For example, ST-segment depression of at least 0.5 mm 
(0.05 mV) in 2 or more contiguous leads (includes reciprocal 
changes) or T-wave inversion of at least 1 mm (0.1 mV) 
including inverted T waves that are not indicative of acute 
MI. 
 
Ventricular 
Arrhythmia (2) 
 
Ventricular tachycardia or fibrillation requiring cardioversion 
and/or intravenous anti-arrhythmics. 
 
High- degree 
Atrioventricular 
(AV) Block (2)* 
 
High-level AV block defined as third-degree AV block or 
second-degree AV block with bradycardia requiring pacing or 
pharmacological intervention. 
 
Emergency 
Revascularisation 
Procedure  (2)* 
 
Patient is symptomatic and requires emergency PCI or 
CABG. 
The patient’s clinical status includes any of the following:  
A. Ischemic dysfunction (any of the following)  
1. Ongoing ischemia including rest angina despite maximal 
medical therapy (medical and/or intra-aortic balloon pump 
[IABP]  
2. Acute evolving MI within 24 hours before intervention 3. 
Pulmonary oedema requiring intubation  
B. Mechanical dysfunction (either of the following):  
1. Shock with circulatory support  
2. Shock without circulatory support  
 
Urgent 
Revascularisation 
Procedure (2)* 
I.  
All of the following conditions are met: 
1. Not elective 
2. Not emergency 
3. Procedure required during the same hospitalization to 
minimize chance of further clinical deterioration 
  
 
Elective 
Revascularisation 
Procedure (2)* 
 
The procedure could be deferred without increased risk of 
compromised cardiac outcome.  
 
Unstable Angina 
 
Unstable angina pectoris (4)  
1. New cardiac symptoms and positive ECG findings with 
normal biomarkers 
2. Changing symptom pattern and positive ECG findings with 
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normal biomarkers 
 
 
Patients with clinical history consistent with the diagnosis of 
unstable angina as described above, in whom ischemia has 
been confirmed by the presence of ST-segment changes on 
the initial ECG or in association with recurrent rest pain, or 
by a positive objective test (e.g. stress test). 
 
 
Heart Failure 
Requiring 
Intervention 
 
When a physician has diagnosed congestive heart failure 
(CHF) by one of the following:    
a. Paroxysmal nocturnal dyspnoea (PND);  
b. Dyspnoea on exertion (DOE) due to heart failure;  
c. Chest X-ray (CXR) showing pulmonary congestion,  
AND 
 Patient has received treatment for this – e.g. ACE inhibition, 
diuretics, carvedilol or digoxin. 
 
Patient Refused 
to Comply with 
Medical 
Advice/Treatment 
 
Documented evidence in clinical notes or supplementary 
paperwork that patient has decided not to follow medical 
management recommended by the responsible clinical team. 
 
Stable CAD (2) 
 
The patient has a clinical diagnosis of prior history of CAD, 
but after evaluation in the hospital, the episode of discomfort 
was not thought to have represented unstable angina. 
 
Other Cardio-
vascular Problem 
 
Any other cardiovascular disease not stated above. Specify 
diagnosis. 
 
Non-cardio-
vascular Problem 
 
Any condition not better described as cardiovascular. Specify 
diagnosis. 
 
 
*Indicates a modification was made to an original data element 
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Chapter 4 
 
The ASia-Pacific Chest pain Trial (ASPECT) was the first major trial 
investigating the use of accelerated diagnosis protocols (ADP).  With the benefit of 
the dataset defined in Chapter 3, this large international multi-centre observational 
trial was designed and conducted to test an ADP that included risk stratification 
using the Thrombolysis In Myocardial Infarction (TIMI) score, electrocardiographs 
(ECGs) and a multi-marker approach. 
The ASPECT trial was designed as an observational trial rather than an 
intervention trial, as the clinical sentiment at the time that it would be able to rapidly 
identify patients at low risk of major adverse cardiac events in the ED, and safely 
discharge them was radical. A key factor in the design of this trial was to make this a 
multi-centre trial, and also to include patients from a wide range of ethnic 
backgrounds. With this design we hoped to define a strategy that would be 
generalizable to a wide range of EDs globally.   
The study was conducted in 14 centres in nine countries. Martin Than and the 
candidate led the trial, formally commencing with an Investigators Steering meeting 
in Singapore in 2008. Prior to this, meetings were held in Brisbane and Christchurch 
to develop the study protocol and tools required for conducting the trial. The 
candidate was the lead researcher for the Australian site and undertook the literature 
review, designed the research protocol, obtained the necessary approvals including 
ethics approval form the Royal Brisbane and Women’s Hospital Human Research 
Ethics Committee, developed the research team and led the conduct of the research.  
During the trial the candidate managed all research based in China, Indonesia, 
Korea, and Thailand in addition to the Australian site. This management included 
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site visits internationally, education sessions, ongoing involvement with local 
principle investigators and support for final documentation from local sites.  
In addition, numerous teleconferences and visits to Melbourne were required 
for the data analysis and interpretation. Finally Martin Than and the candidate wrote 
the paper conjointly, with the very final efforts completed by the candidate due to the 
devastating Christchurch earthquake that occurred just prior to the Lancets deadline. 
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Summary 
Background: Patients with chest pain contribute substantially to emergency 
department attendances, lengthy hospital stay, and inpatient admissions. A reliable, 
reproducible, and fast process to identify patients presenting with chest pain who 
have a low short-term risk of a major adverse cardiac event is needed to facilitate 
early discharge. We aimed to prospectively validate the safety of a predefined 2-h 
accelerated diagnostic protocol (ADP) to assess patients presenting to the 
emergency department with chest pain symptoms suggestive of acute coronary 
syndrome. 
Methods: This observational study was undertaken in 14 emergency departments 
in nine countries in the Asia-Pacific region, in patients aged 18 years and older 
with at least 5 min of chest pain. The ADP included use of a structured pre-test 
probability scoring method (Thrombolysis in Myocardial Infarction [TIMI] 
score), electrocardiograph, and point-of-care biomarker panel of troponin, 
creatine kinase MB, and myoglobin. The primary endpoint was major adverse 
cardiac events within 30 days after initial presentation (including initial hospital 
attendance). This trial is registered with the Australia-New Zealand Clinical 
Trials Registry, number ACTRN12609000283279. 
Findings: 3582 consecutive patients were recruited and completed 30-day follow-up. 
421 (11·8%) patients had a major adverse cardiac event. The ADP classified 352 
(9·8%) patients as low risk and potentially suitable for early discharge. A major 
adverse cardiac event occurred in three (0·9%) of these patients, giving the ADP a 
sensitivity of 99·3% (95% CI 97·9–99·8), a negative predictive value of 99·1% (97·3–
99·8), and a specificity of 11·0% (10·0–12·2). 
 113 
Interpretation: This novel ADP identifies patients at very low risk of a short-term 
major adverse cardiac event who might be suitable for early discharge. Such an 
approach could be used to decrease the overall observation periods and admissions 
for chest pain. The components needed for the implementation of this strategy are 
widely available. The ADP has the potential to affect health-service delivery 
worldwide. 
Funding: Alere Medical (all countries), Queensland Emergency Medicine Research 
Foundation and National Health and Medical Research Council (Australia), 
Christchurch Cardio-Endocrine Research Group (New Zealand), Medquest Jaya 
Global (Indonesia), Science International (Hong Kong), Bio Laboratories Pte 
(Singapore), National Heart Foundation of New Zealand, and Progressive Group 
(Taiwan). 
 
Introduction 
Every year, an estimated 5–10% of presentations to emergency departments, and up to 
a quarter of hospital admissions are attributable to symptoms suggestive of acute 
coronary syndromes.1 Patients with a missed diagnosis of acute myocardial infarction 
are at increased risk of a major adverse cardiac event. The need for safe discharge 
without a substantial risk of a major adverse cardiac event is a priority and a driver of 
clinician behaviour. Consequently, most patients with symptoms suggestive of acute 
coronary syndromes undergo lengthy assessment, either in the emergency department 
or as hospital inpatients, even though 75–85% of these patients ultimately do not have 
a final diagnosis of acute coronary syndromes.2–4 The assessment processes vary 
between institutions, with no one process being ideal. 
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Present recommendations are for serial sampling of cardiac troponin over at 
least 6 h from the onset of symptoms.5–7 Concerns about accuracy of patients’ recall 
of events has led many centres to time troponin sampling from the moment of 
presentation to the emergency department.8 Prolonged assessment contributes to 
overcrowding in the hospital or department, physician duplication of effort, and 
clinical risk as patients are treated by different clinical staff.1 Emergency department 
overcrowding is associated with increased costs and adverse patient outcomes, 
including increased mortality.9  
A reliable, reproducible, and more timely process for the identification of chest 
pain presentations that have a low short-term risk of a major adverse cardiac event is 
needed to facilitate earlier discharge.4 Accelerated diagnostic protocols (ADPs), clinical 
decision rules, and prediction rules are terms for processes or methods intended to help 
clinicians to make bedside diagnostic and therapeutic decisions. They involve variables 
from the patient’s history and examination, and often incorporate the results of diagnostic 
tests.6 ADPs for chest pain are well established but emphasise the need to assess the 
patient for at least 6 h after the onset of symptoms.6,10 Some studies have safely 
investigated patients with serial biomarkers during 1·5–3 h in a low-risk patient group, 
but have not defined a reproducible method to identify this low-risk group.11  
For an assessment of possible acute coronary syndromes, a maximum of 60 
min is recommended for the availability of troponin results.12 Many central 
laboratories have difficulty in meeting this standard. Point-of-care bio markers 
represent a possible solution to meeting this target. The Thrombolysis In Myocardial 
Infarction (TIMI) score for unstable angina or non-ST elevation myocardial infarction 
is an externally validated and widely used structured risk assessment method.3,13,14 
Its use in conjunction with serial 0–2 h biomarker testing (either via central laboratory 
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or point-of-care systems) and electrocardiograph (ECG) has not been prospectively 
tested. Importantly, there has been little validation of ADPs based in emergency 
departments outside North America, or in diverse population groups such as the Asia-
Pacific population, in whom a mix of ethnic backgrounds and variations in service 
delivery introduce important differences.15  
The ASia-Pacific Evaluation of Chest pain Trial (ASPECT) was a 
prospective observational validation study designed to assess whether a predefined 
ADP would identify patients presenting to the emergency department with chest 
pain, who would be at low risk of harm if they were to be discharged early. 
 
Methods 
Participants 
Enrolment occurred at 14 urban emergency departments in nine countries in the Asia-
Pacific region (Australia, China [including Hong Kong], India, Indonesia, New 
Zealand, Singapore, South Korea, Taiwan, and Thailand). Patients were included if 
they were at least 18 years old and had at least 5 min of chest pain (or discomfort) 
suggestive of acute coronary syndromes for whom the attending physician planned to 
investigate for these syndromes with serial biomarker tests. In accordance with 
American Heart Association case definitions,16 possible cardiac symptoms included 
acute chest; epigastric, neck, jaw, or arm pain; or discomfort or pressure without an 
apparent non-cardiac source. Generally, atypical symptoms (fatigue, nausea, vomiting, 
diaphoresis, faintness, and back pain) were not used as inclusion criteria in the absence 
of chest pain. 
Patients were excluded if they had an ST-segment elevation acute myocardial 
infarction, there was a clear cause other than acute coronary syndromes for the 
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symptoms (eg, clinical findings of pneumonia), they were unable or unwilling to 
provide informed consent, staff considered recruitment to be inappropriate (eg, 
terminal illness), they were transferred from another hospital, they were pregnant, 
they were recruited on previous presentation, or they were unable to be contacted 
after discharge. Perceived high risk was not regarded as an exclusion criterion. 
Recruitment included consecutive eligible cases at each site. Overall enrolment 
occurred between November, 2007, and July, 2010, but individual sites started and 
finished at different times according to local logistics. Patients were managed 
according to local protocols. 
All data collection occurred prospectively and the data dictionary has been 
published previously.17 Research nursing staff collected the demographic and risk data 
from each patient, supervised ECG testing, and drew blood samples for biomarker 
testing. If a patient was unsure of an answer (eg, family history) a response of no was 
recorded. Patients were tracked for adverse events at 30 days from initial attendance 
with hospital records and telephone follow-up. Data coordination, monitoring and 
analysis, and source verification was done through an independent university 
clinical research organisation at a non-recruitment location in Australia (Centre for 
Clinical Research Excellence, Monash University, Melbourne). Approval from local 
ethics committees was obtained, and all patients provided written informed consent. 
Procedures 
The primary endpoint was major adverse cardiac events within 30 days after initial 
presentation (including initial hospital attendance). The criteria for major adverse 
cardiac event included any of the following: death (not clearly non-cardiac), cardiac 
arrest, an emergency revascularisation procedure, cardiogenic shock, ventri cular 
arrhythmia needing intervention, high-degree atrio ventricular block needing 
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intervention, and prevalent (ie, being the cause for the patient’s initial presentation) 
and incident (ie, occurring during the 30-day follow-up) acute myocardial infarction. 
Outcomes and investigations were reported with minimum subjectivity with 
predefined standardised reporting guidelines (webappendix p 1).16–20 The presence of 
a major adverse cardiac event was adjudicated independently by local cardiologists 
with these reporting guidelines. Cardiologists were masked to results of the index test 
biomarkers under investigation and derived TIMI score, but had knowledge of the 
clinical record, ECG, and serial troponin results from usual care. 
In accordance with international guidelines, blood troponins at presentation, and 
then at least 6 h afterwards formed part of the reference standard to establish presence 
of acute myocardial infarction.7,16 These measurements were part of normal care and 
were analysed at the recruitment site central hospital laboratory. Webappendix p 2 
provides a summary of the characteristics of the laboratory troponins used at each 
hospital site. Treating clinicians were masked to the results of the index tests, with only 
central laboratory troponin results used in patient management. Classification of acute 
myocardial infarction was based on global taskforce recommendations requiring 
evidence of myocardial necrosis together with evidence of myocardial ischaemia 
(ischaemic symptoms, ECG changes, or imaging evidence).7 Necrosis was diagnosed 
on the basis of a rising or falling pattern of the laboratory cardiac troponin 
concentrations, with at least one value above the 99th percentile, at a level of assay 
imprecision near to 10%. If the troponin concentration was greater than the reference 
range, but no rise or fall was recorded, other causes of a raised troponin concentration 
were considered by the adjudicating cardiologist. If no clear alternative cause of the 
troponin rise was apparent, and if the clinical presentation was suggestive of acute 
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coronary syndromes, an adjudicated diagnosis of acute myocardial infarction was 
made. 
The predefined ADP under investigation was a combination of TIMI risk 
score of 0, no new ischaemic changes on the initial ECG, and normal point-of-care 
biomarker panel (at 0–2 h after arrival). All parameters had to be negative for the 
ADP to be considered negative (and thus for the patient to be identified as low risk). 
The TIMI score (panel 1) for unstable angina or non-ST-elevation myocardial 
infarction had to be zero for the sum of its seven parameters.14  
New ECG ischaemic changes, with evidence that these changes were not pre-
existing on previous ECGs, had to be absent. They were defined as ST-segment 
depression of at least 0·05 mV in two or more contiguous leads (including reciprocal 
changes), T-wave inversion of at least 0·1 mV, or Q-waves greater than 30 ms in 
width and 0·1 mV or greater in depth in at least two contiguous leads.17,18,20 Patients 
with abnormal ECG findings (eg, pacing, left ventricular hypertrophy, and left bundle 
branch block) that were proven to be pre-existing on previous ECGs were defined as 
low risk. 
Index test point-of-care biomarkers were measured with whole blood drawn 
at presentation and 2 h afterwards. Blood was immediately tested for troponin I, 
creatine kinase MB, and myoglobin. Results were available (to research staff only) 
within 15 min with the TRIAGE platform or CardioProfilER assay panels (both 
Alere, San Diego, CA, USA). The following assay results were predefined to be 
positive on either blood draw: troponin I 0·05 11g/L or greater, creatine kinase MB 
4·3 11g/L or greater, or an increase of 1·6 11g/L or more within 2 h; and myoglobin 
concentration of 108 11g/L or greater or an increase of 25% or more within 2 h. The 
point cutoffs were based on manufacturer recommendations, with an elevated 
 119 
troponin defined as any detectable concentration of troponin. The levels of change 
were based on a previous publication21 and peer-group consensus. 
Statistical analysis 
Data were collected with the web-based Open-Clinica data capture system. Baseline 
characteristics of the study population were analysed with conventional group 
descriptive statistics. χ2 analyses were used to generate two-by-two tables for the 
calculation of sensitivity, specificity, and positive and negative predictive values. All 
analyses were done with SPSS (version 18.0.0). 
 
Results 
3651 consenting eligible patients were enrolled, of whom 3582 completed 30-day 
follow-up (figure 1). Web-appendix p 3 shows the countries and hospitals that 
recruited patients. Study participants were mostly older men, either white or Chinese, 
and commonly had cardiovascular risk factors and background cardiovascular past 
medical history (table 1). A major adverse cardiac event occurred within 30 days in 
421 (11·8%) patients. Non-ST-segment acute myocardial infarction (NSTEMI) was 
the most frequently occurring major adverse cardiac event (table 2). 
The ADP identified 9·8% (352/3582) of patients as being at low risk of a major 
adverse cardiac event within 30 days (all ADP parameters were negative). Three (0·9%) 
of these patients had an event during initial hospital attendance and follow-up (figure 1). 
Webappendix p 4 outlines the clinical details of these false negatives. 
The combinations of parameters of the ADP were more effective at identifying 
patients who had a major adverse cardiac event than were the individual parameters 
themselves (table 3). The combination of the biomarkers and ECG without the TIMI 
score did not identify 47 patients with a major adverse cardiac event at day 30. With 
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use of the ADP including TIMI score, 44 additional patients were correctly identified, 
which reduced the number of false negatives to three (figure 2). 
Table 4 shows the statistical analysis of the ADP and its parameters for the 
prediction of a major adverse cardiac event by day 30. The ADP had a very high 
sensitivity and negative predictive value (table 4). 
Secondary analysis showed that patients identified as low risk by negative 
ADP were associated with a median initial hospital attendance of 26·0 h (IQR 9·9–
37·0) and a mean of 43·2 h (95% CI 36·2–51·2), representing 1–2 hospital bed-days. 
 
Discussion 
Findings from this large, multinational study have prospectively validated that a 2-h 
accelerated diagnostic protocol, with use of point-of-care biomarkers, ECG, and 
TIMI score, can safely identify patients at very low short-term risk of a major 
adverse cardiac event (panel 2). These patients could potentially be discharged 
several hours earlier to outpatient follow-up and further investigations than with 
present practices. 
The near 10% possible reduction in patients needing prolonged assessment 
in this large patient group could reduce overcrowding in hospitals and emergency 
departments and provide earlier reassurance and greater convenience for patients. 
The potential reduction in initial length of stay accords with the findings of a six 
centre study in the UK.22 These findings together with those from countries included 
in our study represent 42% of the world’s population. Extrapolation is difficult, but 
on the basis of incidence rates of chest pain in the USA of 2·21%, there might be 64 
million presentations of chest pain per year across these study nations. If the true 
incidence was half of this rate, then earlier discharge of 10% of patients could affect 
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3·2 million presentations. Patients in this study who were identified as low risk had 
an initial hospital attendance of about 1–2 days; these patients could potentially be 
discharged within 3–4 h of arrival if follow-up investigations could be arranged as 
an outpatient. Increasing demand for acute hospital beds is a key challenge for 
modern health services. 
The study shows that each of the components of the ADP is essential when 
used within such an early timeframe after presentation (figure 2, table 3). The use 
of the TIMI score within the ADP resulted in a lower and more acceptable false 
negative rate than when only biomarkers and ECG were used for the prediction of 
30-day major adverse cardiac event (0·7% vs 11·2%). 
Troponin assays with lower and more reliable levels of detection have been 
developed since this study started, but the assay we used was effective in this ADP. 
The focus of this study was the safety of the ADP when used as a whole; any 
contemporary troponin could be used either via the central laboratory or point of care 
as part of the ADP. Newer assays, which typically have lower detection limits and 
higher analytical precision, would probably improve the sensitivity of this ADP for 
the prediction of a major adverse cardiac event. These newer assays might be used 
with decision rules under development23 for use in a broad risk population. In this 
trial, combinations of biomarkers provided cumulative improvement in sensitivity, 
but a cardiac troponin as a sole biomarker was sufficient alone to produce a high 
sensitivity of 98·6% (415/421) once ECG and TIMI were added. Although not an a-
priori hypothesis, this finding suggests that the ADP might be optimised to include 
only the cardiac troponin results in conjunction with the ECG and TIMI risk score in 
the future. Other biomarkers (eg, copeptin and heart fatty acid binding protein) might 
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improve the diagnostic accuracy for acute myocardial infarction; however, their use 
as part of an ADP has not been reported.24,25 
The ADP might be expanded to a broader subset by development of a more 
specific risk score. The TIMI score was developed from a relatively high-risk population 
with acute coronary syndromes, but it has been externally validated in more general 
emergency department populations.2,3,26 A modified TIMI risk score has been derived 
and validated in an emergency department population previously with laboratory-based 
troponins,27,28 with a sensitivity of 96·6% reported in the validation study. There is no 
universally accepted definition of a low-risk patient for acute coronary syndromes. 
This lack of consensus is a serious concern, because according to Bayesian decision 
making, interpretation of post-test probability after a particular test result is dependent 
on knowledge of the pre-test probability. The use of a structured and reproducible 
method is important.29–33 Subjective pre-test probability estimation has much lower 
inter-rater agreement between clinicians than do structured methods.34 Furthermore, 
patients presenting to an emergency department are often initially assessed by junior 
staff, and evidence shows that traditionally taught clinical variables and risk factors 
are poor predictors of acute coronary syndromes in an undifferentiated population in 
these clinics.35–37 
Patients without chest pain but who presented with atypical symptoms 
(fatigue, nausea, vomiting, diaphoresis, faintness, and back pain) were not included 
in this trial, and we were unable to quantify the number of patients presenting with 
these symptoms. Thus the applicability of the ADP is limited to the selected cohort 
of patients with chest pain (or discomfort) suggestive of acute coronary syndromes 
for whom the attending physician planned to investigate for these syndromes. 
Another limitation of this study is that this was an observational, not an intervention 
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study. Ideally, a management study of the diagnostic protocol would now occur; 
however, in practice, such studies are rare. 
The low specificity (11%) of our approach might be regarded as a limitation, 
but the ADP was used as an exclusion method to predict safety of early discharge of 
patients and not to establish inpatient management. These patients would otherwise 
have had extended observation or admission. The low specificity accords with other 
diagnostic instruments to exclude acute coronary syndromes.10 The goal of a more 
specific test is to rule-in a diagnosis if positive with sufficient certainty to initiate a 
change in management. In the setting that we studied, a positive protocol result 
merely classified patients as requiring management as usual. The optimum balance 
between specificity and sensitivity is difficult to define. A process yielding a higher 
specificity is likely to discharge a larger number of patients; however, we believe 
that the main focus should be on safety and therefore sensitivity. Future research 
should focus on methods to identify a greater proportion of patients who can be 
discharged earlier without significant adverse events. 
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Panel 1: The TIMI score for unstable angina or non ST elevation myocardial 
infarction (56)  
 
TIMI Score 
1) age ≥65 years 
2) ≥3 risk factors for coronary artery disease  (family history of coronary artery 
disease, hypertension, hypercholesterolemia, diabetes, or being a current smoker) 
3) use of aspirin in the last 7 days 
4) significant coronary stenosis (e.g. prior coronary stenosis ≥50%) 
5) severe angina (e.g. ≥2 angina events in last 24 hours or persisting discomfort) 
6) ST-segment deviation of  0.05mV on first ECG 
7) elevated troponin and/or CK-MB on initial blood tests* 
*Point of Care values were used for TIMI score calculation 
 
TIMI = Thrombolysis In Myocardial Infarction. The TIMI score was required to be zero for the sum 
of its seven parameters to be categorised as TIMI=0. 
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Panel 2: Research in context 
Systematic review  
We searched Medline from March, 1995, to December, 2010, for full reports of 
original research and review articles with the terms “acute coronary syndrome”, “chest 
pain”, “emergency department”, “risk stratifi cation tools”, “point of care”, and 
“clinical decision rule”. We identified 114 articles. Abstracts were downloaded for all 
titles of potential relevance. Full papers were downloaded when the abstract was also 
deemed relevant. To be included in the final analysis, studies had to be prospective, 
have a large population, and have clearly described their methods and results. The 
methodology must have allowed the conclusions to be generalised to the emergency 
department population. 
Interpretation 
Together, the results of these studies show that the identification of patients at low risk for 
major adverse cardiac events is challenging. Increasing research is emerging into the use 
of accelerated diagnostic protocols (ADP). These protocols typically include the use of a 
risk stratification method, serial biomarkers, and electrocardiographs, and usually require 
an assessment period of 6–12 h. The results of our study indicate that a new ADP 
incorporating a risk stratification method (TIMI score), electrocardiograph, and point-of-
care biomarker testing can identify patients at low risk of 30-day major cardiac event at 2 
h. 
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Figure 1: Flow chart of participant recruitment and outcomes according to 
Accelerated Diagnostic Protocol (ADP) classification 
 
Index Test =ADP 
(n=3630 )
Consenting Eligible 
patients (n=3651 )
Inconclusive result
 (n=0 ) 
ADP Positive
‘not low-risk’ 
(n=3260 ) 
ADP negative
‘low-risk’
 (n=370 ) 
Excluded patients 
TIMI score incomplete 
(n=21 ) 
NO 30 day 
MACE
 (n=349 ) 
30 day 
MACE
 (n=3) 
30 day 
MACE 
(n=418 ) 
NO 30 day 
MACE
 (n=2812) 
Eligible patients
(n=3853)
Declined consent
(n=202)
Lost to 
follow-up
(n=30)
Lost to 
follow-up
(n=18)
Reference 
standard 
30 day follow-up
(n= 3230)
Reference 
standard 
30 day follow-up
(n= 352)
30 day follow-up includes initial hospital attendance.
Patients lost to follow-up did not have a MACE during 
the initial hospital attendance.
 
 
Legend: Thrombolysis In Myocardial Infarction (TIMI) score for unstable angina or non ST elevation 
myocardial infarction; Accelerated diagnostic protocol (ADP); Major adverse cardiac event (MACE) 
during initial hospital attendance or 30 day follow-up. 
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Figure 2: Occurrence of MACE during initial hospital attendance or 30 day follow-
up in patients with negative results for individual and combinations of diagnostic 
parameters (figures refer to numbers of patients). Legend: Thrombolysis In 
Myocardial Infarction (TIMI);  
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Table 1: Characteristics for low-risk (ADP negative) and high-risk (ADP positive) 
participants in the ASPECT study (n=3582) 
 
DEMOGRAPHICS Low Risk (n=352) High Risk 
(n=3230) 
Total 
Age (Years) 49.8 (9.2) 62.8 (14.0%) 61.5 (14.1) 
Men 220 (62.5%) 2014 (62.4%) 2234 (62.4%) 
Ethnic Origin    
White 190 (56.4%) 1281 (40.5%) 1471 (42.1%) 
Chinese 66 (19.6%) 1108 (35.1%) 1174 (33.6%) 
Korean 26 (7.7%) 194 (6.1%) 220 (6.3%) 
Indonesian 10 (3.0%) 200 (6.3%) 210 (5.9%) 
Indian 9 (2.7%) 122 (3.9%) 131 (3.7%) 
Thai 0 70 (2.2%) 70 (2.0%) 
Malay 2 (0.6%) 46 (1.5%) 48 (1.3%) 
Maori 3 (0.9%) 30 (0.9%) 33 (0.9%) 
Aboriginal 1 (0.3%) 8 (0.3%) 9 (0.3%) 
Other 30 (8.9%) 102 (3.2%) 132 (3.7%) 
Unknown 15 (4.2%) 69 (2.1%) 84 (2.3%) 
RISK FACTOR      
Hypertension 65 (19.9%) 1921 (60.4%) 1986 (56.5%) 
Dyslipidaemia 76 (24.0%) 1505 (48.3%) 1581 (46.0%) 
Family History of CAD 124 (39.9%) 1196 (37.6%) 1320 (38.1%) 
Smoking    
Previous 106 (32.3%) 1061 (33.2%) 1167 (33.1%) 
Current 69 (21.0%) 625 (19.5%) 694 (19.7%) 
PAST MEDICAL 
HISTORY  % (n) 
 
  
Angina 18 (8.6% 1120 (44%) 1138 (41.3%) 
Coronary Artery Disease 4 (1.9%) 735 (28.9%) 739 (26.8%) 
AMI 0 625 (24.5%) 625 (22.7%) 
Revascularisation 0 541 (21.3%) 541 (19.7%) 
Congestive Heart Failure 2 (1.0%) 281 (11%) 283 (10.3%) 
Stroke 3 (1.4%) 278 (10.9%) 281 (10.2%) 
CABG 0 200 (7.8%) 200 (7.3% 
Arrhythmia 5 (2.0%) 158 (6.2%) 163 (5.9%) 
LENGTH OF INITIAL 
HOSPITAL 
ATTENDANCE (h) 
 
  
 
26.0 (9.9-37.0) 
50.1 (12.6-123.3) 
46.0 (12.0-
120.8) 
 
Data are mean (SD), number (%), or median (IQR). Data were missing for each category as follows: 
ethnic origin (84), hypertension (75), dyslipidaemia (148), family history of CAD (118), smoking (54), 
previous medical history (824), and time in hospital (196). ADP=accelerated diagnostic protocol. 
CAD=coronary artery disease. CABG=coronary artery bypass graft. 
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Table 2: Frequency and type of MACE during initial hospital attendance or 30 day 
follow-up. 
 
Type of major adverse 
cardiac event (MACE) 
Number of 
events* 
Percentage of 
patients (out of 
421) that had 
event type  
Percentage 
frequency of 
event type out of 
total 3582 
patients in study 
NSTEMI 363 86.2 10.1 
STEMI 53 12.5 1.5 
Emergency 
Revascularisation 
32 7.6 0.9 
Cardiovascular death 19 4.5 0.5 
Ventricular arrhythmia 15 3.5 0.4 
Cardiac arrest 8 1.9 0.2 
Cardiogenic shock 7 1.7 0.2 
High atrio-ventricular 
block 
4 1.0 0.1 
* 421/3582 (11.8%) patients had total number of 501 events during initial hospital attendance or 30 
day follow-up. 
NSTEMI = Non ST segment elevation myocardial infarction 
STEMI = ST segment myocardial infarction occurring after initial recruitment 
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MACE No MACE Total 
  
ECG*             
Positive 148 (4·1%) 879 (24·5%) 1027 (28·7%) 
Negative 273 (7·6%)† 2282 (63·7%) 2555 (71·3%) 
Total 421 (11·8%) 3161 (88·2%) 3582 (100%) 
TIMI‡             
Positive 407 (11·4%) 2606 (72·8%) 3013 (84·1%) 
Negative 14 (0·4%)† 555 (15·4%) 569 (15·9%) 
Total 421 (11·8%) 3161 (88·2%) 3582 (100%) 
ECG and TIMI§             
Positive 413 (11·6%) 2701 (75·4%) 3114 (86·9%) 
Negative 8 (0·2%)† 460 (12·8%) 468 (13·1%) 
Total 421 (11·8%) 3161 (88·2%) 3582 (100%) 
POC biomarkers¶             
Positive 349 (9·7%) 1391 (38·8%) 1740 (48·6%) 
Negative 72 (2·0%)† 1770 (49·4%) 1842 (51·4%) 
Total 421(11·8%) 3161 (88·2%) 3582 (100%) 
ECG and POC biomarkers||         
Positive 374 (10·4%) 1803 (50·3%) 2177 (60·7%) 
Negative 47 (1·3%)† 1358 (37·9%) 1405 (39·2%) 
Total 421(11·8%) 3161 (88·2%) 3582 (100%) 
ADP**             
Positive 418 (11·7%) 2812 (78·5%) 3230 (90·2%) 
Negative 3 (0·08%)† 349 (9·7%) 352 (9·8%) 
Total 421 (11·8%) 3161 (88·2%) 3582 (100%) 
 
Table 3: Occurrence of MACE during initial hospital attendance or 30 day follow-up 
according to results of individual and combinations of the Accelerated Diagnostic 
Protocol (ADP) test parameters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MACE=major adverse cardiac event. ECG=electrocardiograph. TIMI=Thrombolysis In Myocardial 
Infarction score for unstable angina or non-ST-elevation myocardial infarction. POC=point of care. 
ADP=accelerated diagnostic protocol. *ECG alone; any new ischaemia was positive. †Numbers of 
patients who were identified as low risk by the diagnostic parameter(s) but had a MACE (ie, false-
negative cases). ‡TIMI score of ≥1 was positive and TIMI score of 0 was negative. §ECG and TIMI 
used. Result was positive if TIMI score was ≥1 or ECG was positive. ¶POC biomarkers: troponin I, 
creatine kinase MB and change, and myoglobin and change. Any positive parameter created a 
positive result. ||ECG and POC biomarkers used. Any positive parameter created a positive result. 
**ADP was negative if TIMI score was 0 and if ECG and POC biomarkers were all negative. If 
TIMI score was ≥1 or any other parameter was positive, then ADP was positive.  
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Table 4: Accuracy (95% CI) of POC Biomarkers, ECG and ADP for prediction of 
MACE 
 
 ECG POC 
Biomarkers† 
TIMI‡ POC 
Biomarkers and 
ECG § 
TIMI 
and ECG ¶ 
ADP || 
Sensitivity 35.2% 
(30.7-39.8) 
82.9% 
(79.0-86.2) 
96.7% 
(94.5-98.0) 
88.8% 
(85.5-91.5) 
98.1% 
(96.3-99.0) 
99.3% 
(97.9-
99.8) 
Negative  
predictive 
value 
89.3% 
(83-97) 
96.1% 
(95-97) 
97.5% 
(96-99) 
96.7% 
(96-97) 
98.3% 
(97-99) 
99.1% 
(98-
100) 
Specificity 72.2% 
(70.6-73.7) 
56.0% 
(54.3-57.7) 
17.6% 
(16.3-18.9) 
43.0% 
(41.2-44.7) 
14.6% 
(13.4-15.8) 
11.0% 
(10.0-
12.2) 
Positive  
predictive 
value 
14.4% 
(12-17) 
20.1% 
(18-22) 
13.5% 
(12-15) 
17.2% 
(16-19) 
13.3% 
(12-14) 
12.9% 
(12-
14) 
Negative 
Likelihood 
ratio 
0.90% 
(0.83-0.97) 
0.31% 
(0.25-0.38) 
0.189% 
(0.11-0.32) 
0.26% 
(0.20-0.34) 
0.13% 
(0.07-0.26) 
0.06% 
(0.02-
0.20) 
Positive 
Likelihood 
ratio 
1.26% 
(1.09–1.45) 
1.88% 
(1.77-1.99) 
1.17% 
(1.14-1.20) 
1.55% 
(1.48-1.62) 
1.14% 
(1.12-1.17) 
1.11% 
(1.09-
1.32) 
 
POC=point of care. ECG=electrocardiograph. ADP=accelerated diagnostic protocol. MACE=major 
adverse cardiac event. TIMI=Thrombolysis In Myocardial Infarction score for unstable angina or non-
ST-elevation myocardial infarction. *ECG alone; any new ischaemia was positive. †POC biomarkers: 
troponin I, creatine kinase MB and change, and myoglobin and change. Any positive parameter 
created a positive result. ‡TIMI score of ≥1 was positive and TIMI score of 0 was negative. §POC 
biomarkers and ECG used. Any positive parameter created a positive result. ¶TIMI and ECG used. 
Result was positive if TIMI score was ≥1 or ECG was positive. ||ADP was negative if TIMI score was 
0 and if ECG and POC biomarkers were all negative. If TIMI score was ≥1 or any other parameter 
was positive, then ADP was positive. 
 
 
 137 
Supplementary Webappendix  
Definitions for MACE 
 
DEATH 
 
 
 
 
Primary cause can be classified as follows: 
 Cardiovascular death 
a. Cardiac indicates cause of death was sudden cardiac death, MI, 
unstable angina, or other CAD; CHF; or cardiac arrhythmia 
b. Non Cardiac (e.g., stroke, arterial embolism, pulmonary 
embolism, ruptured aortic aneurysm, or dissection);  
 Non-cardiovascular death indicates cause of death was respiratory 
failure, pneumonia, cancer, trauma, suicide, or any other already defined 
cause (e.g., liver disease or renal failure) 
 Death of uncertain cause: If a cardiac cause of death cannot be excluded 
after reasonable investigation, it is assumed that the death was cardiac 
related. 
 
 
 
Cardiac Arrest 
Cardiac Arrest 
Cardiac arrest is the cessation of cardiac mechanical activity as confirmed by the 
absence of signs of circulation.  
 
 
Cardiogenic 
shock 
 
Clinical criteria for cardiogenic shock are hypotension (a systolic blood pressure of 
less than 90 mmHg for at least 30 minutes or the need for supportive measures to 
maintain a systolic blood pressure of greater than or equal to 90 mmHg), end-organ 
hypoperfusion (cool extremities or a urine output of less than 30 ml/h, and a heart 
rate of greater than or equal to 60 beats per minute). The hemodynamic criteria are 
a cardiac index of no more than 2.2 l/min per square meter of body-surface area 
and a pulmonary-capillary wedge pressure of at least 15 mmHg 
 
 
Ventricular 
arrhythmia 
 
Ventricular tachycardia or fibrillation requiring cardioversion and/or intravenous 
anti-arrhythmics 
 
High Level AV 
Block 
 
High-level AV block defined as third-degree AV block or second-degree AV block 
with bradycardia requiring pacing or pharmacological intervention. 
 
Acute 
Myocardial 
Infarction 
Detection of rise and/or fall of cardiac biomarkers (preferably troponin) with at 
least one value above the 99th percentile of the upper reference limit (URL) 
together with evidence of myocardial ischemia with at least one of the following: 
 
 Symptoms of ischemia; 
 ECG changes indicative of new ischemia (new ST-T changes or new left 
bundle branch block [LBBB]); 
 Development of pathological Q waves in the ECG; 
 Imaging evidence of new loss of viable myocardium or new regional wall 
motion abnormality. 
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Analytical characteristics of central laboratory assays 
 
Troponin assay LoD (mcg/L) 99th % (mcg/L) 10% CV (mcg/L) 
Abbott 
ARCHITECT 
<0.01 0.028 0.032 
Beckman Coulter 
Access Accu 
0.01 0.04 0.06 
bioMerieux Vidas 
Ultra 
0.01 0.01 0.11 
Ortho Vitros ECi 
ES 
0.012 0.034 0.034 
Roche E170 0.01 <0.01 0.03 
Riche Elecsys 
2010 
0.01 <0.01 0.03 
Siemens Centaur 
Ultra 
0.0006 0.04 0.03 
 
Limit of detection (LoD), Coefficient of variation (CV) 
Modified from: Analytical characteristics of commercial and research high 
sensitivity cardiac troponin I and T assays per manufacturer. IFCC website. Version 
updated September 12, 2009. 
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ASPECT Countries and hospitals 
Country Hospital 
Australia Royal Brisbane and Women’s Hospital 
China Peoples’ Hospital 
China Xuanwu Hospital 
China Queen Elizabeth Hospital 
India Medanta: The Medicity Hospital 
Indonesia National Cardiovascular Center Harapan Kita 
Korea Severance Hospital 
New Zealand Christchurch 
Singapore Singapore General Hospital  
Taiwan Chang Gung Memorial Hospital 
Taiwan Far Eastern Memorial Hospital 
Taiwan China Medical University Hospital 
Taiwan Mackay Memorial Hospital 
Thailand Ramathibodi Hospital 
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Clinical details of the three false negative cases (ADP-negative patients who had a 
major adverse event) 
 MACE Details of events Country 
41yo 
white 
male 
AMI Chest pain for 21.5h and normal ECG. 
Initial central laboratory troponin 
I<0.01mcg/L at 0 h, rising to 0.07mcg/L 
after 12 h (assay 99th percentile 
0.028mcg/L). Underwent angiogram and 
stenting for right coronary artery stenosis. 
No further problems at follow up. 
New Zealand 
48yo 
white 
male 
AMI Chest pain for 3h with undiagnosed 
dyslipidaemia, with a strong family 
history of ischemic heart disease; patient 
was a current smoker. ECG was normal. 
Initial central laboratory troponin I 
<0.01mcg/L at 0 h, rising to 0.33mcg/L 
after 12 hours (assay 99th percentile 
0.028mcg/L). Underwent angiography 
and stenting for right coronary and 
circumflex artery stenosis. No further 
problems at follow up. The POC CK-MB 
changed from 1.0mcg/L to 1.9mcg/L 
between 0 and 2 h samples (90% 
increase) but did not reach the cut off of 
New Zealand 
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4.3mcg/L or change by 1.6mcg/L. 
46yo 
Chinese 
male 
VT Presented with chest tightness. On the 
day of presentation he had a 30 min 
episode of self-terminating stable, broad 
complex tachycardia. Central laboratory 
troponin I was 0.024mcg/L at 0h and 
0.020mcg/L at 6 h (assay 99th percentile 
0.04mcg/L). On the second day he had 
EPS and radiofrequency ablation. 
Taiwan 
 
ADP= accelerated diagnostic protocol, MACE = major adverse cardiac event, AMI = 
acute myocardial infarction, ECG=electrocardiograph, POC = point of care, CK-MB 
= creatine kinase MB, VT = ventricular tachycardia, EPS = electrophysiology study. 
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Chapter 5  
 
By the time the paper in Chapter 4 was published, evidence was emerging that 
the use of biomarkers such as creatinine kinase MB (CK) and myoglobin in the 
assessment of patients with possible ACS was not ideal. Troponin alone as the 
biomarker for the detection of AMI was being supported by leading international 
organisations. This led to the evaluation of the ADP using troponin alone as 
measured by sensitive troponin assays (rather than the previous multi-marker 
approach in Chapter 4) in the ADAPT trial described in Chapter 5. 
The goal of this Chapter was to assess the safety of this approach, and identify 
if this supported the identification of a larger proportion of patients in whom lengthy 
assessment was not required in comparison to the ASPECT study. The theory was 
that the additional biomarker result utilised in the ADP described in ASPECT may 
have been associated with false positive findings, limiting the proportion of patients 
deemed low risk.  This study utilise only central lab-based sensitive assay results, 
and was restricted to the Brisbane and Christchurch cohorts (n=1975). 
It was hoped that if this approach was shown to be safe, it would gain extensive 
interest for practising clinicians, as access to sensitive troponin assays was 
widespread across the globe. 
Martin Than and the candidate conceived the project, undertook the literature 
review, designed the research protocol, obtained the necessary approvals including 
ethics approval form the Royal Brisbane and Women’s Hospital Human Research 
Ethics Committee needed to conduct of the research. She also was responsible for the 
analysis and interpretation of the data, drafting and critically reviewing the paper. All 
146  
of the authors have approved inclusion of this paper into the thesis. Copies of these 
authorisations are available on request. 
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Abstract 
Objectives: This paper sought to determine whether a new accelerated diagnostic 
protocol (ADP) for possible cardiac chest pain could identify low-risk patients 
suitable for early discharge (with follow-up shortly after discharge). 
Background: Patients presenting with possible acute coronary syndromes, who have 
a low short-term risk of adverse cardiac event may be suitable for early discharge 
and shorter hospital stays.  
Methods: This prospective observational study tested an ADP which included pre-
test probability scoring by the Thrombolysis in Myocardial Infarction (TIMI) score, 
electrocardiograph, and 0+2 hour values of laboratory troponin I as the sole 
biomarker. Patients presenting with chest pain due to suspected acute coronary 
syndromes were included. The primary endpoint was major adverse cardiac event 
(MACE) within 30 days. 
Results: Of 1975 patients, 302 (15.3%) had a MACE. The ADP classified 392 
patients (20%) as low risk. One (0.25%) of these patients had a MACE, giving the 
ADP a sensitivity of 99.7% (95% confidence interval [CI], 98.1-99.9), negative 
predictive value of 99.7% (95% CI, 98.6-100), specificity of 23.4% (95% CI, 21.4- 
25.4), and positive predictive value of 19.0% (95% CI, 17.2-21.0). Many ADP 
negative patients had further investigations (74.1%), and therapeutic (18.3%) or 
procedural (2.0%) interventions during the initial hospital attendance and/or 30 day 
follow-up.  
Conclusion: Using our ADP, a large group of patients was successfully identified as 
at low short-term risk of a MACE and therefore suitable for rapid discharge from the 
ED with early follow-up. This approach could decrease the observation period 
required for some patients with chest pain. 
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Abbreviations list 
ACS  Acute Coronary Syndrome 
ADP  Accelerated Diagnostic Protocol 
MACE  Major Adverse Cardiac Event 
AMI  Acute Myocardial Infarction 
cTn  Cardiac Troponin 
cTnI  Cardiac Troponin I 
HS-cTn Highly Sensitive Cardiac Troponin 
TIMI  Thrombolysis In Myocardial Infarction 
STEMI ST-Segment Elevation Myocardial Infarction 
ED  Emergency Department 
 
Introduction 
A missed diagnosis of acute coronary syndrome (ACS) may lead to further 
ischemic events and a potentially preventable death or disability. Therefore, patients 
with symptoms suggestive of ACS undergo an often lengthy assessment in the 
Emergency Department (ED) or as hospital inpatients. These patients account for 
approximately 10% of ED presentations and 25% of hospital admissions [1], yet up 
to 85% do not have a final diagnosis of acute coronary syndromes [2-4]. Prolonged 
assessment contributes to duplication of work, high costs, and ED overcrowding 
which leads to adverse patient outcomes including increased mortality [1,5]. The 
need for accurate identification of a low risk group that may be safely discharged 
without jeopardy of an adverse event from an acute coronary syndrome is therefore a 
priority [4].  
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International guidelines for the investigation of ACS recommend serial 
measurement of cardiac troponin (cTn) over from the onset of symptoms, and many 
hospitals use the presentation time at the ED as time zero for sampling [6-10]. A 
reproducible, reliable, and more timely process for identifying patients presenting 
with chest pain that have a low short-term risk of adverse cardiac events is needed to 
support their earlier discharge[4]. Only two studies have prospectively validated 
accelerated diagnostic protocols (ADPs) for the early discharge of low risk patients 
using serial biomarkers in the first 2 hours from arrival [11,12].  
The recent ASPECT study used 0-hour and 2-hour biomarker testing with a 
point-of-care multi-marker panel, electrocardiograph (ECG), and the Thrombolysis 
In Myocardial Infarction (TIMI) score[11]. In that study, the ADP identified 9.8% of 
patients with suspected ACS who could have been discharged early from the ED, 
with a sensitivity of 99.3% for 30-day major adverse cardiac events.  
Some studies have shown superiority of point of care multimarker strategies 
compared with troponin alone when used for early evaluation of such patients but 
studies have been criticized for using relatively insensitive cTn assays. Current 
laboratory troponins may now be equivalent or superior to point of care multimarker 
strategies even at these early time points [13]. This might increase the number of 
patients eligible for early discharge, whilst maintaining very high sensitivity (>99%).  
The purpose of this study was to determine if an ADP using a serial troponin 
as the only biomarker could identify ED patients suspected of ACS who are suitable 
for safe early discharge. These patients could then have early out-patient or 
accelerated in-patient follow-up. 
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Methods 
Study Design and Setting 
The ADAPT trial was a prospective observational validation study designed 
to assess a predefined ADP that consisted of TIMI score risk assessment, ECG, and 
0-hour and 2-hour central laboratory contemporary cardiac troponin I (cTnI) as the 
only biomarker. The study population was derived from the Brisbane and 
Christchurch; i.e. 2 out of the 14 sites participating in the ASPECT study. Most 
participants were recruited as part of the ASPECT trial but we have also included 
additional patients through ongoing post-ASPECT recruitment at both centres. The 
process for 2-hour blood sampling, and central laboratory analysis of cTnI was pre-
planned before the start of the ASPECT study and a priori local ethics committee 
approval was obtained for this. All participants provided written informed consent. 
The results of the 2-hour cTnI samples were not used as part of routine clinical care 
(or for reference standard adjudication). This study was subsequently separately 
registered with the Australia-New Zealand Clinical Trials Registry, number 
ACTRN12611001069943.  
 
Participants 
Patients were enrolled consecutively between November 2007 and February 
2011, at two urban Emergency Departments in Brisbane, Australia and in 
Christchurch, New Zealand. Due to local recruitment logistics enrolment did not start 
and finish at the same time in each centre. Criteria for enrolment included age of 18 
years or over, with at least 5 minutes of symptoms consistent with ACS, where the 
attending physician planned to perform serial cTn tests. The American Heart 
Association case definitions for possible cardiac symptoms were used (i.e. acute 
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chest, epigastric, neck, jaw, or arm pain; or discomfort or pressure without an 
apparent non-cardiac source)[14]. Patients were excluded for any of the following: 
ST-segment elevation myocardial infarction (STEMI), a clear cause other than ACS 
for the symptoms (e.g. examination findings of varicella zoster), inability to provide 
informed consent, staff considered recruitment to be inappropriate (e.g. receiving 
palliative treatment), transfer from another hospital, pregnancy, previous enrolment, 
or inability to be contacted after discharge. Perceived high risk was not used as an 
exclusion criterion. Patients were managed according to local hospital protocols 
including blood draws for cTnI measurement at presentation, and then 6 to 12 hours 
afterwards in compliance with international guidelines.[6,14]. Christchurch Hospital 
used Abbott ARCHITECT cTnI assay (Abbott, Inc, Chicago, IL, USA), detection 
limit of <0.01μg μg/L, 99th percentile of 0.028μg/L, 10% coefficient of variation 
0.032μg/L, decision cut-off as per manufacturer >0.030μg/L. Royal Brisbane and 
Women’s Hospital used the DxI Access Accu cTnI assay (Beckman Coulter, Chaska, 
MN, USA), detection limit of 0.01 μg/L, 99th percentile 0.04 μg/L, 10% coefficient 
of variation 0.06 μg/L, decision cut-off as per manufacturer >0.04μg/L. Following 
Federal Drug Authority concerns about results consistency between DxI analysers 
for measurement of the Beckman assay a local reassessment was performed in 
Brisbane which showed only a 5% bias between the two local DxI analysers. Long 
term imprecision at the 99th percentile has been 13-14%. After assessment of local 
data there has been no market withdrawal in Australasia. In both centres, results for 
clinical use and outcomes adjudication were rounded to two decimal places. 
Data were collected prospectively using a published data dictionary[15]. 
Nursing staff collected the demographic and clinical data from patients, supervised 
ECG testing, and drew blood samples for cTnI testing. If a patient was unsure of an 
154  
answer to a question (e.g. history of hypertension) a response of “No” was recorded. 
Patients were followed up to determine the occurrence of major adverse cardiac 
events within 30 days of presentation, at 45 days, and after one year using all of: (i) 
telephone contact by research staff, (ii) review of patients’ hospital notes, and (iii) a 
national health events search (which identifies any death). Data was also recorded 
regarding the use of further testing for acute coronary syndromes (e.g. stress testing 
or imaging) and interventions (therapeutic or procedural) within 30 days. The Centre 
for Clinical Research Excellence, Monash University, Melbourne, Australia, 
independently undertook data coordination, monitoring, analysis, and source 
verification.  
 
Index Test 
The predefined ADP under investigation consisted of TIMI risk score of 0 at 
presentation [16], no ischemic changes on the initial ECG (i.e. not known to be pre-
existing), and central laboratory cTnI concentrations (at 0 and 2 hours after arrival) 
below the institutional cut-off used to indicate troponin elevation (Table 1). For a 
patient to be identified as low risk, all parameters in the ADP had to be negative. 
Patients with ischemic ECG changes and no evidence that they were pre-
existing were defined as high risk.  ECG changes were defined as ST-segment 
depression of at least 0.05 mV in two or more contiguous leads (including reciprocal 
changes), T-wave inversion of at least 0.1 mV, or Q-waves greater than 30 ms in 
width and 0.1 mV or greater in depth in at least two contiguous leads[15,18,19].), 
and Patients with other abnormal ECG findings (e.g. pacing artifact, and left bundle 
branch block) that were present on pre-existing ECGs were not defined as high risk. 
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Central laboratory cTnI concentrations (at 0h and 2h after arrival) above the 
institutional cut-off were used to indicate cTnI elevation. The same troponin assays 
and cut-offs were used to indicate cTnI elevation as for standard care at each 
institution (as described above). 
 
Reference Standard 
The primary end-point was a composite of major adverse cardiac events 
(MACE) that occurred within 30 days after first presentation (including the initial 
hospital attendance). An adverse event included: death (unless clearly non-cardiac), 
cardiac arrest, emergency revascularization procedure, cardiogenic shock, ventricular 
arrhythmia needing intervention, high-degree atrioventricular block needing 
intervention, and acute myocardial infarction (See Table S1 in the Supplementary 
Appendix). Acute myocardial infarction (AMI) was classified using the global 
taskforce recommendations requiring evidence of myocardial necrosis together with 
clinical evidence of myocardial ischemia (ischemic symptoms, ECG changes, or 
imaging evidence)[8]. Necrosis was diagnosed on the basis of a rising or falling 
pattern (a delta of ≥20% was used) of the laboratory troponin concentrations, with at 
least one value above the decision cut-point (99th percentile, at a level of assay 
imprecision near 10%). The cTnI results from blood draws at presentation, and after 
6 to 12 hours (i.e. from routine care) were used for determination of necrosis. If the 
cTnI concentration was elevated, but a <20% rise or fall was recorded, then other 
causes of a raised troponin concentration were actively pursued by the adjudicators. 
If no clear alternative cause of the troponin rise was evident, and if the clinical 
presentation was suggestive of an acute coronary syndrome, an adjudicated diagnosis 
of acute myocardial infarction was decided. 
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Statistical analysis 
Baseline characteristics of the participants were analyzed with conventional group 
descriptive statistics. For continuous variables, means (± standard deviation) were 
calculated, whilst for categorical data, the proportions in each of the ADP positive 
and negative groups are reported. The sensitivity, specificity, and positive and 
negative predictive values for hierarchical primary and secondary events were 
generated using chi-square analyses for the ADP as a whole and its constituents 
individually or in combination. Sensitivities were compared using the McNemar test. 
 
Results 
Patient characteristics 
There were 1975 consenting, eligible patients suitable for analysis (Fig. 1). No 
patients were lost to 30-day follow up. Participants were predominantly Caucasian, 
older men commonly with risk factors for coronary artery disease, and the cohort had 
a significant rate of known coronary artery disease (Table 2).  
A total of 302 patients (15.3%) had a primary outcome event within 30 days, with 
most occurring within the first 10 days. The majority of these events (15.1%) were 
myocardial infarctions (Table 3). The ADP identified 392 patients (20%) as low risk 
of a major adverse cardiac event within 30 days (Table 4).  
 
Diagnostic Accuracy 
Table 5 presents the statistical analysis of the ADP and its parameters for predicting 
major adverse cardiac events within 30 days. Only one (0.25%) of patient classified 
as low risk by the ADP had a major adverse cardiac event during initial hospital 
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attendance and follow-up. This patient was a 52-year-old Caucasian male who 
presented after 3.5 hours of chest pain. He was previously fit with no risk factors for 
ischemic heart disease. He had a normal ECG and his Abbott troponin I was 
<0.01μg/L at 0h, 0.03μg/L 2h and 16.8μg/L after 12h. He underwent angiography 
and stenting for right coronary and circumflex artery stenosis. The patient had no 
further cardiac problems during one year follow-up.  
A secondary analysis using a TIMI score of 0 or 1 (as opposed to TIMI=0) in 
the ADP resulted in 38.4% of patients being categorized as low risk, but with nine 
false negative results for the primary outcome giving a sensitivity of 97.0%, negative 
predictive value of 98.8%, specificity of 44.8%, and positive predictive value of 
24.1%.  
Individual diagnostic parameters were not as effective at identifying patients 
who had a major adverse cardiac event compared to when these parameters were 
used together (Tables 4 and 5). The combination of TIMI score and ECG without 0-
hour and 2-hour troponin failed to identify five patients with a major adverse cardiac 
event at 30 days. Using the ADP four of these five patients were correctly identified 
with a reduction in the number of false negatives to one (Fig.2). The ADP identified 
a larger proportion of patients as low risk in participants presenting early after the 
onset of symptoms (0-3 hours) than amongst those presenting later (Web appendix 
table 1). 
The majority of ADP negative patients 316/392 (74.1%) had further 
investigations within 30 days, and most of these investigations were stress tests 
(81.1%) and occurred during the initial hospital attendance (88.0%). Investigations 
generally occurred within a median timeframe of approximately 7 days (Web 
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Appendix Table-2a). Therapeutic and procedural interventions occurred in 18.3% 
and 2.0% of ADP negative patients respectively (Web Appendix Table-2b). 
 
Discussion 
This large two-center Australasian study prospectively validated a 2-hour ADP 
incorporating ECG, TIMI score, and cTnI. With use of this ADP, a large group 
(20%) of patients presenting with possible acute coronary syndromes was identified 
as low risk and suitable for outpatient care at a risk of 0.25% for short term MACE. 
These patients could have been safely discharged to outpatient follow-up many hours 
earlier than occurs in current practice. The reduction in time required for observation 
for some patients through application of this ADP could have significant benefits for 
health services, even in those centres with chest pain observation units. In the USA 
alone, more than 6 million Emergency Department visits a year involve patients 
presenting with chest pain [20]. In centres with lower disease prevalence such as in 
the USA, it is likely that even more patients will be suitable for discharge to out-
patient care with this ADP and could potentially reduce extended observation in 
millions of patients annually. In patients unsuitable for out-patient follow-up a 
negative ADP result could allow earlier in-patient investigation and still reduce 
length of stay in hospital. 
The new ADP has a very high sensitivity and negative predictive value and 
using a contemporary cTnI as the single biomarker in the ADP doubled the 
proportion of patients classified as low risk in comparison to the ASPECT study 
(20% vs. 9.8%)[11]. If the cut-off used to define an elevated troponin had been the 
internationally recommended value of greater than the 99th percentile (rather than 
using the local institution‘s cut-off rounded to 2 decimal places), the sensitivity of 
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this ADP would have been unchanged at (99.7%). Using such a cut-off would have 
identified three less patients (n=389, 19.7%) as low-risk (Web Appendix-Table 3)  
This study confirms that each of the components of the ADP, including 
troponin, is needed to achieve sufficient sensitivity to be used at an early timeframe 
after presentation (Table 3). A TIMI score equaling 0 within the ADP resulted in a 
lower and more acceptable false negative rate than when only troponins and ECG 
were used for the prediction of 30-day major adverse cardiac event (0.25% vs. 3.2%).  
This study also demonstrates that central laboratory troponin assays currently 
in use have sufficient sensitivity at an early time point to negate the need for 
additional biomarkers (such as myoglobin and CK-MB) as components of the ADP. 
These other biomarkers do not improve the sensitivity, and reduce the proportion of 
patients defined as low risk (due to a greater number of patients with a positive 
biomarker result), as was shown in ASPECT [11]. 
The results show that the ADP is sensitive for both early and late presenters, 
identifying a greater proportion of patients as low risk in early presenters. Thus the 
ADP could have the greatest impact in patients presenting within 3 hours of 
symptom onset; the group in which the 2nd troponin sampling time-point is usually 
most delayed. 
Body et al. [21] described how a highly sensitive cardiac troponin T assay 
may allow early “rule-out” of AMI using an arrival blood test only. Their study 
utilized the assay level of detection rather than the 99th percentile. Highly sensitive 
assays are not yet widely available, but if prospectively validated, then this approach 
may be important. However, when early results are used in conjunction with the 
TIMI risk score and ECG, sensitivity may not be significantly improved and 
specificity may be reduced. It is not yet clear how early after presentation we can 
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rely on negative highly sensitivity troponin results alone without requiring other 
clinical data such as the TIMI score. Further work is also needed to guide the 
interpretation and management of the increased number of patients with a positive 
troponin result that occur using highly sensitive troponin assays. Other biomarkers, 
such as copeptin and heart fatty acid binding protein, may improve the baseline 
sensitivity for acute myocardial infarction; however their use as part of an ADP has 
not been reported[22,23]. The early identification of patients with acute myocardial 
infarction is important, but identifying a true low risk cohort must involve the 
detection of those at risk of a broader group of adverse events, in addition to acute 
myocardial infarction. 
 
Study Limitations 
The applicability of the ADP is restricted to the selected cohort of patients with chest 
discomfort suggestive of acute coronary syndromes that the attending physician 
planned to investigate. In particular the inclusion of predominantly Caucasian 
patients may restrict the international generalizability of these findings. Patients who 
presented with atypical symptoms without chest pain were not included in this trial, 
and deciding when to investigate these for an acute coronary syndrome remains a 
challenge. 
  The study was an observational study and not an intervention study. Ideally, a 
randomized controlled trial of the diagnostic protocol would now occur. However, in 
practice, such studies are rare. As a result of the observational design, most ADP 
negative patients had further investigations and some treatments as in-patients (Web 
Appendix-Tables 2a and 2b). Hospital admission, investigation and subsequent 
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treatment (e.g. revascularisation, anti-platelet or anti-thrombotic therapy) were 
common and possibly secured better outcomes.  
Thus, patients that are ADP negative require further non-urgent follow-up 
investigations and possibly treatment. In some health systems it will be possible for 
these investigations to occur rapidly on an out-patient basis, and where this is not 
possible a negative ADP result could allow earlier progression to in-patient 
investigation and still reduce length of stay in hospital. 
  The sensitivity of the ADP appears to be high. Highly sensitive cardiac 
troponin (HS-cTn) assays appear to detect and predict additional adverse outcomes 
compared with conventional assays. It is possible that if an HS-cTn assay was used 
as the reference standard troponin at arrival and after 6+ hours then this would lead 
to a greater number of patients being classified as having a NSTEMI and therefore 
maybe a lower sensitivity. This potential limitation is always a possibility when 
changing technology creates a more sensitive reference standard. It is also possible 
that by using HS-cTn assays, some patients with negative results may be able to 
avoid, or have less extensive follow-up investigations after ED assessment than 
occurred in this cohort of patients. This requires further evaluation. The purpose of 
this study was to show that that an ADP could use the same two troponin assays as 
currently used at our hospitals to identify a group of patients as very low risk at an 
earlier time-point than usual. The specificity (23.5%) of our method might be 
regarded as a limitation, but as a “rule-out” rather than a “rule-in” tool, this 
specificity is a significant improvement compared to other pathways [13]. Patients 
who are not low-risk according to the ADP should continue to be managed with 
existing clinical care that involves extended observation or admission. A process 
yielding a higher specificity could discharge a larger number of patients, but at the 
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cost of an unacceptable drop in sensitivity. This is demonstrated by the improved low 
risk eligibility, but increase in false negative cases that would occur by using a TIMI 
score of 0 or 1 within this ADP. The TIMI score was derived from a high-risk in-
patient population to predict the likelihood of a major adverse cardiac event and to 
guide therapy, and not for this “rule-out” purpose in a low-risk Emergency 
Department population. Yet to date, it is one of the most validated ACS risk tool 
available.  
In conclusion, a 2-hour ADP using a central laboratory troponin as the sole 
biomarker in conjunction with ECG and the TIMI risk score identified a large group 
of patients suitable for safe early discharge. These patients are at low risk of short-
term major adverse cardiac event. They could therefore have rapid discharge with 
early out-patient follow-up or proceed more quickly to further in-patients tests 
potentially shortening hospital length of stay. The components required for this 
strategy are already widely available; therefore rapid uptake of the ADP is possible 
by most hospitals with the potential for immediate health service benefit.  
 
Acknowledgments 
The authors thank Dr Joanne Deely for expert medical writing services, (who is 
employed directly by our local research group) the dedicated staff of our research 
groups in Brisbane and Christchurch, and those from the Centre for Clinical 
Research Excellence in Melbourne. We also thank the staff of the respective 
Emergency Departments for their assistance and support.  
 
 163 
References for Chapter Five 
 
1. Goodacre S, Cross E, Arnold J, Angelini K, Capewell S, Nicholl J. The health care 
burden of acute chest pain. Heart 2005;91:229-30. 
2. Pollack CV, Jr., Sites FD, Shofer FS, Sease KL, Hollander JE. Application of the 
TIMI risk score for unstable angina and non-ST elevation acute coronary syndrome 
to an unselected emergency department chest pain population. Acad Emerg Med 
2006;13:13-8. 
3. Chase M, Robey JL, Zogby KE, Sease KL, Shofer FS, Hollander JE. Prospective 
validation of the Thrombolysis in Myocardial Infarction Risk Score in the emergency 
department chest pain population. Ann Emerg Med 2006;48:252-9. 
4. Hollander JE. The continuing search to identify the very-low-risk chest pain 
patient. Acad Emerg Med 1999;6:979-81. 
5. Bernstein SL, Aronsky D, Duseja R et al. The effect of emergency department 
crowding on clinically oriented outcomes. Acad Emerg Med 2009;16:1-10. 
6. Pollack CV, Jr., Antman EM, Hollander JE. 2007 focused update to the 
ACC/AHA guidelines for the management of patients with ST-segment elevation 
myocardial infarction: implications for emergency department practice. Ann Emerg 
Med 2008;52:344-55 e1. 
7. Amsterdam EA, Kirk JD, Bluemke DA, et al. Testing of low-risk patients 
presenting to the emergency department with chest pain: a scientific statement from 
the American Heart Association. Circulation 2010;122:1756-76. 
8. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial 
infarction. Circulation 2007;116:2634-53. 
164  
9. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the 
management of patients with unstable angina/non–ST-elevation myocardial 
infarction—. J Am Coll Cardiol 2007;50:652–726. 
10. Aroney CN, Dunlevie HL, Bett JH. Use of an accelerated chest pain assessment 
protocol in patients at intermediate risk of adverse cardiac events. Med J Aust 
2003;178:370-4. 
11. Than M, Cullen L, Reid CM, et al. A 2-h diagnostic protocol to assess patients 
with chest pain symptoms in the Asia-Pacific region (ASPECT): a prospective 
observational validation study. Lancet 2011;377:1077-84.  
12. Goodacre SW, Bradburn M, Cross E, Collinson P, Gray A, Hall AS. The 
Randomised Assessment of Treatment using Panel Assay of Cardiac Markers 
(RATPAC) trial: a randomised controlled trial of point-of-care cardiac markers in the 
emergency department. Heart 2011;97:190-6. 
13. Lee-Lewandrowski E, Januzzi JL, Jr., Grisson R, Mohammed AA, 
Lewandrowski G, Lewandrowski K. Evaluation of first-draw whole blood, point-of-
care cardiac markers in the context of the universal definition of myocardial 
infarction: a comparison of a multimarker panel to troponin alone and to testing in 
the central laboratory. Arch Pathol Lab Med 2011;135:459–463. 
14. Luepker RV, Apple FS, Christenson RH, et al. Case definitions for acute 
coronary heart disease in epidemiology and clinical research studies: Circulation 
2003;108:2543-9. 
15. Cullen L, Than M, Brown AF, et al. Comprehensive standardized data definitions 
for acute coronary syndrome research in emergency departments in Australasia. 
Emerg Med Australas 2010;22:35-55.  
 165 
16. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable 
angina/non-ST elevation MI: A method for prognostication and therapeutic decision 
making. JAMA 2000;284:835-42. 
17. Hollander JE, Blomkalns AL, Brogan GX, et al. Standardized reporting 
guidelines for studies evaluating risk stratification of ED patients with potential acute 
coronary 
syndromes. Acad Emerg Med 2004;11:1331-40.  
18. Cannon CP, Battler A, Brindis RG, et al. American College of Cardiology key 
data elements and definitions for measuring the clinical management and outcomes 
of patients with acute coronary syndromes. J Am Coll Cardiol 2001;38:2114-30.  
19. Forest RS, Shofer FS, Sease KL, Hollander JE. Assessment of the standardized 
reporting guidelines ECG classification system: the presenting ECG predicts 30-day 
outcomes. Ann Emerg Med 2004;44:206-12. 
20. Pitts SR, Niska RW, Xu J. National Hospital Ambulatory Medical Care Survey: 
2006 Emergency Department Summary: Division of Health Care Statistics 2008. 
(Accessed November 12, 2010, at http://www.cdc.gov/nchs/data/nhsr/nhsr007.pdf) 
21. Body R, Carley S, McDowell G, et al. Rapid exclusion of acute myocardial 
infarction in patients with undetectable troponin using a high-sensitivity assay. J Am 
Coll Cardiol 2011;58:1332-9. 
22. Reichlin T, Hochholzer W, Stelzig C, et al. Incremental value of copeptin for 
rapid rule out of acute myocardial infarction. J Am Coll Cardiol 2009;54:60-8. 
23. Valle HA, Riesgo LG, Bel MS, Gonzalo FE, Sanchez MS, Oliva LI. Clinical 
assessment of heart-type fatty acid binding protein in early diagnosis of acute 
coronary syndrome. Eur J Emerg Med 2008;15:140-4. 
166  
Figures 
Figure 1: Participant Recruitment Flowchart 
The 193 patients eligible but not recruited were similar in age, gender and risk 
factors (p>0.05 for all). 30 day follow-up includes initial hospital attendance and no 
patients were lost to follow-up. 
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Figure 2: ADP Component False Negatives 
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Table 1: ADAPT Accelerated Diagnostic Protocol (ADP) 
 
All parameters had to be negative for the ADP to be considered negative and for the 
patient to be identified as low-risk 
1. cTnI level at 0 and 2 hours below institutional cut-off for an elevated troponin 
concentration. 
2. No new ischemic changes on the initial ECG 
3. TIMI score = 0[16] 
a. Age 65 years or older 
b. Three or more risk factors for coronary artery disease:  
(family history of coronary artery disease, hypertension, 
hypercholesterolaemia, diabetes, or being a current smoker) 
c. Use of aspirin in the past 7 days 
d. Significant coronary stenosis (e.g., previous coronary stenosis 
≥50%) 
e. Severe angina (e.g., two or more angina events in past 24 h or 
persisting discomfort) 
f. ST-segment deviation of 0.05 mV or more on first ECG 
g. Increased troponin and/or creatine kinase MB blood tests (during 
assessment*) 
* The results of the 0 hour cTnI were used for calculation of the TIMI score in this 
study which is a modification from the original published score. This score parameter 
and that of ST-segment deviation are effectively redundant in the ADP because of 
the broader cTnI and ECG criteria - numbers 1. and 2. above.  
 
 169 
Table 2: Demographics – Participant characteristics 
 Total 
(N=1975) 
ADP positive 
ADP  
negative 
DEMOGRAPHICS % n % n % n 
Age (Years±SD) 60.4±14.9 63.2±14.8 49.4±9.2 
Gender (% Male) 60.0 1185 60.1 951 59.7 234 
Ethnicity %(n)*        
Caucasian 89.8 1748 90.3 1411 87.5 337 
Maori 1.7 34 1.9 30 1.0 4 
Aboriginal 0.8 16 0.8 13 0.8 3 
Indian 0.9 17 0.8 13 1.0 4 
Chinese 0.2 3 0.2 3 0 0 
Other 6.8 129 6.0 92 9.6 37 
RISK FACTORS       
Hypertension 52.1 1029 59.0 934 24.2 95 
Diabetes 14.4 285 17.4 276 2.3 9 
Dyslipidemia 51.1 1009 57.5 907 26.1 102 
Smoking       
     Previous smoker 41.7 823 43.5 688 34.5 135 
     Current smoker 18.9 374 18.3 289 21.7 85 
Family History of 
Coronary Artery Disease 
53.5 1056 55.4 874 46.4 182 
PAST MEDICAL 
HISTORY 
      
Angina 33.8 668 41.5 657 2.8 11 
Coronary artery disease 21.0 415 26.2 414 0.3 1 
Acute myocardial 
infarction 
23.3 461 29.1 461 0 0 
Revascularization  17.3 341 21.7 341 0 0 
Congestive Heart Failure 7.9 157 9.8 155 0.5 2 
Stroke 9.6 190 11.6 183 1.8 7 
Coronary Artery Bypass 
Graft  
8.7 172 10.9 172 0 0 
170  
Arrhythmia  6.1 121 7.4 116 1.3 5 
LENGTH OF INITIAL HOSP ATTENDANCE (in hours) 
Medi
an 
 31.3 (IQR: 24-96) 48.0 (IQR: 24 -
120) 
24.1 (IQR:11.3-
28.1) 
Mea
n 
 81.8  ± 245.2 93.1  ± 270.8 34.8 ± 48.2 
Data are mean (SD), number (%), or median (IQR).  
* Data missing in 28 patients. Values >100% due to multiple factors reported by 
patients. 
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Table 3: Occurrence of MACE–Frequency and type of major adverse cardiac event 
during initial hospital attendance or 30- day follow-up 
 
Major adverse cardiac 
event  
Number of 
events 
         (n=350) 
Percentage of 
patients that had 
event type – 
(n=302) 
Percentage 
frequency of 
event type out of 
total 1975 
patients  
Non-STEMI 273 90.40 13.82 
STEMI 25 8.28 1.27 
Emergency 
Revascularization 
26 8.61 1.32 
Cardiovascular death 8 2.65 0.41 
Ventricular arrhythmia 6 1.99 0.30 
Cardiac arrest 3 0.99 0.15 
Cardiogenic shock 4 1.32 0.20 
High atrio-ventricular 
block 
5 1.66 0.25 
    
 
STEMI occurred after initial recruitment. *350 events occurred in 302 patients during 
initial hospital attendance or 30-day follow-up. 
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Table 4:  Test Parameter Performance – Occurrence of major adverse cardiac events 
during initial hospital attendance or 30- day follow-up according to the 
results of individual and combination of the accelerated diagnostic protocol 
test parameters 
Test Outcome Test Outcome 
ECG* MACE No 
MACE 
Total TROPONIN§ MACE No 
MACE 
Total 
Positive 74 193 267 Positive 264 124 388 
Negative 228# 1480 1708 Negative 38# 1549 1587 
Total 302 1673 1975 Total 302 1673 1975 
TIMI†    
ECG + 
Troponin║ 
   
Positive 293 1238 1531 Positive 269 291 560 
Negative 9# 435 444 Negative 33# 1382 1415 
Total 302 1673 1975 Total 302 1673 1975 
ECG + 
TIMI‡ 
   
ADP (ECG + 
TIMI* + 
Troponin)¶ 
   
Positive 297 1280 1577 Positive 301 1282 1583 
Negative 5# 393 398 Negative 1# 391 392 
Total 302 1673 1975 Total 302 1673 1975 
 
*ECG alone; any new ischaemia was positive.  
†TIMI score of ≥1 was positive. TIMI used contemporary cardiac troponin I and ECG result at 0-hour.  
‡Any new ischaemia on ECG or TIMI score ≥1 was positive.   
§Any cTnI > cut-off was positive.  
║cTnI > cut-off or any new ischaemia on ECG was positive.  
¶ADP was negative if TIMI score was 0 and ECG and cTnI were all negative. If TIMI score was ≥1 or 
any other parameter was positive, then ADP was positive.  
#ADP false-negative cases. 
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Table 5: Diagnostic Accuracy – Accuracy of cTnI, ECG, TIMI and ADP for 
prediction of MACE 
ECG ECG* Troponin† Troponin 
and 
ECG‡ 
TIMI 
and 
ECG§ 
ADP 
(ECG+ 
TIMI + 
Troponin)║ 
Sensitivity 
24.5 
(20.0-
29.7) 
87.4  
(83.2-90.7) 
89.1 
 (85.1-
92.1) 
98.3  
(96.2-
99.3) 
99.7  
(98.1-99.9) 
Negative predictive 
value 
86.7 
(85.0-
88.2) 
97.6 
 (96.7-
98.3) 
97.7  
(96.7-
98.3) 
98.7 
 (97.1-
99.5) 
99.7  
(98.6-100.0) 
Specificity 
88.5 
(86.8-
89.9) 
92.6  
(91.2-93.7) 
82.6  
(80.7-
84.3) 
23.5  
(21.5-
25.6) 
23.4 
 (21.4-25.5) 
      
Positive predictive 
value 
27.7 
(22.7-
33.4) 
68.0 
 (63.2-
72.5) 
48.0 
 (43.9-
52.2) 
18.8 
 (17.0-
20.8) 
19.0  
(17.2-21.0) 
Negative likelihood 
ratio 
0.85 
(0.80-
0.91) 
0.14 
 (0.10-
0.18) 
0.13  
(0.10-
0.18) 
0.07  
(0.03-
0.17) 
0.01  
(0.002-0.10) 
Positive likelihood 
ratio 
2.12 
(1.67-
2.70) 
11.79 
(9.90-
14.05) 
5.12  
(4.58-
5.72) 
1.29  
(1.25-
1.33) 
1.30  
(1.27-1.34) 
*ECG alone; any new ischaemia was positive. †cTnI > cut-off for an elevated troponin was positive. 
‡Troponin and ECG; cTnI> cut off value cut-off for an elevated troponin and/or any new ischaemia 
on ECG was positive. §TIMI and ECG; TIMI score of ≥1 was positive and/or any new ischaemia on 
ECG was positive. ║ADP was negative if TIMI score was 0 and ECG and troponin were all negative. 
If TIMI score was ≥1 or any other parameter was positive, then ADP was positive. 
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Web Appendix Table 1: ADP performance in early and later presenting patients 
Occurrence of MACE during initial hospital attendance or 30-day follow-up in 
patients within 3 hours after symptom onset and later than 3 hours. 
 
PATIENTS PRESENTING 0-3 HOURS 
AFTER SYMPTOM ONSET 
PATIENTS PRESENTING >3 HOURS AFTER 
SYMPTOM ONSET 
Test Outcome Test Outcome 
ADP  MACE No 
MACE 
Total ADP MACE No MACE Total 
Positive 99 483 582 Positive 202 799 1001 
Negative 0 200 200 Negative 1 191 192 
Total 99 683 782 Total 203 990 1193 
 
 % 95% CI  % 95% CI 
Sensitivity 100 95.3 - 100 Sensitivity 99.5 96.8 – 99.9 
Specificity 29.2 25.9 – 32.8 Specificity 19.2 16.9 – 21.9 
Negative 
Predictive Value 
100 97.6 - 100 
Negative Predictive 
Value 
99.4 96.6 – 99.9 
Positive Predictive 
Value 
17.0 14.0 - 20.3 
Positive Predictive 
Value 
20.1 17.7 – 22.8 
 
MACE = Major Adverse Cardiac Event 
ADP was negative if TIMI score was 0 and ECG and cTnI were all negative. If TIMI score was ≥1 
or any other parameter was positive, then ADP was positive 
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Web Appendix Table 2a: Use of further investigations in ADP negative patients 
within 30 days 
 
  
Median # of 
days post 
presentation 
Inpatient Outpatient 
CT Coronary 
Angiogram 
2.0 17 2 
Stress Radionuclide 5.5 11 14 
Stress Echo 11.5 5 7 
Stress ECG 0.5 265 18 
Angiography 2.6 26 3 
 
Web Appendix Table 2b  Acute treatments on ADP negative patients within 30 days 
 
In-patient Therapy Number 
Heparin 8 
LMW Heparin 20 
G2b3a inhibitor 9 
Heparin + G2b3a inhibitor 0 
LMW Heparin + G2b3a inhibitor 27 
Non-emergency Revascularization 7 
 
ADP – Accelerated Diagnostic Protocol 
LMW – Low Molecular Weight 
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Web Appendix Table 3: Analysis of performance of ADP using >99th Centile 
Troponin Cut-off for a positive result (and reporting results to 3 decimal places). 
 
ADP (ECG + TIMI + 
Troponin)¶ 
MACE NO MACE TOTAL 
Positive 301 1285 1586 
Negative 1 388 389 
Total 302 1673 1975 
 
 % 95% CI 
Sensitivity 99.7 98.2-100.0 
Specificity 23.3 21.2-25.3 
Negative Predictive Value 99.7 98.6-100.0 
Positive Predictive Value 19.0 17.1-21.0 
   
MACE = Major Adverse Cardiac Event 
Christchurch Hospital used the Abbott ARCHITECT cTnI assay (Abbott, Inc, Chicago, IL, USA), 
detection limit of <0.01μg μg/L, 99th percentile of 0.028μg/L, 10% coefficient of variation 
0.032μg/L, decision cut-off as per manufacturer >0.030μg/L. For the purpose of this analysis the 
cut-off for a positive result in Christchurch patients was changed from >0.03 μg/L (results reported 
to two decimal places with rounding) to >0.028 μg/L 
ADP was negative if TIMI score was 0 and ECG and cTnI were all negative. If TIMI score was ≥1 
or any other parameter was positive, then ADP was positive 
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Chapter 6 
 
The findings from Chapter 5, embracing results using sensitive troponin assays, 
were significant. The ability to define 20% of the ED chest pain population safe for 
early discharge strategies could lead to improvements for patients and the healthcare 
system. 
The troponin assays though continued to evolve, and with each new generation 
of assay, associated with improvement in the precision of assay detection at low 
levels, ADPs such as the ADAPT ADP needed to be reassessed. Importantly with the 
precise detection of low concentrations of troponin near the clinical cut-point for 
abnormality (the 99th percentile) with newer assays, the theory that even larger 
proportions of low risk patients may be identified for safe, early discharge needed to 
be tested.  We postulated that due to the accuracy of the new assays at low levels of 
troponin concentration patients with higher pre-test probability (TIMI score 0 and 1) 
may be able to be safely defined as low risk. 
Of equal importance to the safety of such strategies, was the need to assess the 
ADP in independent, geographically distinct, well-described cohorts from the 
original work. The candidate was fortunate to have worked with Prof. Christian 
Mueller on another project, and approached him to assess the Modified-ADAPT 
ADP in the Advantageous Predictors of Acute Coronary Syndrome Evaluation 
(APACE) cohort.  
This study found that the Modified ADAPT ADP could allow patients at higher 
pre-test risk than the original ADAPT study (TIMI score 0 and 1 in comparison to 
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TIMI 0 only) to be safely deemed as low risk. In addition we showed that this 
Modified ADP performed well in an independent cohort. Rarely is it found that the 
validation of a study performs equally well (or better) than in the cohort it was 
derived. This however was our finding.  
The candidate was the lead researcher for this element of the research program. 
She conceived the project with the support of the broader research team, undertook 
the literature review, designed the research protocol, obtained the necessary 
approvals including ethics approval form the Royal Brisbane and Women’s Hospital 
Human Research Ethics Committee, developed the research team and lead the 
conduct of the research. She also led the analysis and interpretation of the data and as 
principal author was responsible for drafting and critically reviewing the paper. All 
of the authors have approved inclusion of this paper into the thesis. Copies of these 
authorisations are available on request. 
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Abstract 
Objectives: To validate a new high-sensitivity troponin I assay in a clinical protocol 
for assessing patients who present to the emergency department with chest pain. 
Background: Protocols using sensitive troponin assays can accelerate the rule-out of 
acute myocardial infarction in low-risk (suspected) acute coronary syndrome (ACS) 
patients.  
Methods: This study evaluated two prospective cohorts of emergency-department 
patients with ACS in an accelerated diagnostic pathway integrating 0- and 2-h high-
sensitivity troponin I results, Thrombolysis In Myocardial Infarction (TIMI) risk 
scores, and electrocardiographs. Strategies to identify low-risk patients incorporated 
either TIMI-risk scores =0 or ≤1. The primary endpoint was adverse cardiac events 
(MACE) within 30 days. 
Findings: In the primary cohort, 1635 patients were recruited and had 30-day follow-
up. 247 (15.1%) patients had a MACE. The TIMI=0 and TIMI≤1 pathways, 
respectively, classified 19.6% (320) and 41.5% (678) of these patients as low-risk; 
0% (0) and 0.8% (2) had a MACE respectively. In the secondary cohort, 909 patients 
were recruited. 156 (17.2%) had a MACE. The TIMI=0 and TIMI≤1 pathways, 
respectively, classified 25.3% (230) and 38.6% (351) of these patients as low risk 
with 0% (0) and 0.8% (1) having a MACE respectively. Sensitivity, specificity, and 
negative predictive value for TIMI=0 in the primary cohort were 100% (95% CI 
98.5-100%), 23.1% (20.9-25.3%), and 100% (98.8-100%), respectively. Sensitivity, 
specificity, and negative predictive value for TIMI≤1in the primary cohort were 99.2 
(97.1-99.8%), 48.7 (46.1-51.3%), and 99.7 (98.9-99.9%), respectively. Sensitivity, 
specificity, and negative value for TIMI≤1 in the secondary cohort were 99.4% 
(96.5-100%), 46.5% (42.9-50.1%), and 99.7% (98.4-100%), respectively. 
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Conclusion: An early-discharge strategy utilizing a high-sensitivity troponin assay 
and TIMI score ≤1 had similar safety as previously reported, with  the potential to 
decrease the observation periods and admissions for approximately 40% of patients 
with suspected ACS.  
Abbreviations 
ACS: Acute coronary syndrome 
ADAPT: Accelerated Diagnostic protocol to Assess Patients with chest Pain 
symptoms using contemporary troponin as the only biomarker 
ADP: Accelerated diagnostic protocol 
AMI: Acute myocardial infarction 
APACE: Advantageous Predictors of Acute Coronary Syndromes Evaluation 
(APACE) Study 
ECG: Electrocardiograph 
hs TnI: high-sensitivity troponin I 
MACE: Major adverse cardiac event 
TIMI: Thrombolysis in Myocardial Infarction  
 
Introduction   
High-sensitivity troponin (hs Tn) assays have shown excellent diagnostic 
performance in the evaluation of patients with possible acute myocardial infarction.1-
3    However, clinicians worry that because of lower specificity for the diagnosis of 
AMI4,5  that many patients may require unnecessary investigations because of  
elevated troponin values.  Approximately 75-85% of patients who present to 
emergency departments with chest pain are not finally diagnosed with acute coronary 
syndromes.6 Prolonged assessment of these patients contributes to overcrowding, 
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increased costs and adverse patient outcomes including increased mortality.  Early-
discharge strategies combining electrocardiographs (ECGs), Thrombolysis in 
Myocardial Infarction (TIMI) score of zero, with multi-markers or some of the 
contemporary, sensitive troponin assays have classified 10-20% of chest-pain 
presentations as low-risk.7,8  Potentially, more patients could be safely classified as 
low-risk by incorporating the new high-sensitivity cardiac troponin I (hs TnI) assays 
into similar strategies that assess patients with possible acute coronary syndrome.9 
Troponin testing alone cannot identify all patients at risk for AMI or other 
serious cardiac conditions and it appears that biomarker-negative unstable angina 
pectoris can still be present.  Therefore, troponin testing alone is unable to identify 
the patient-group that is safe for early discharge.  Previous research on high-
sensitivity troponin assays has focused on their use in the early exclusion (rule-out) 
of acute myocardial infarction,1-3 but has not focused on the low risk group or 
defined the optimal methods of integrating assays into emergency-department 
clinical practice pathways in the diverse group of patients with chest pain; data which 
is critically needed.10  
Evidence of how to integrate new high-sensitivity assays into clinical practice 
protocols is required to guide clinicians on their optimum use.10  The TIMI score was 
established for the risk stratification of patients with ACS and divides patients into 
prognostic categories that enable targeted management according to the level of 
risk.11  Serial contemporary troponin assay results used in association with a TIMI 
score =0 enables identification of low-risk cohorts of roughly 20% of patients who 
suitable for early discharge from the emergency department with few false-negative 
results.7,12 High-sensitivity assays may make it possible to increase the proportion of 
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patients identified as low-risk by including patients with a higher pre-test probability 
of ACS, i.e. both TIMI=0 and 1. 
This study aimed to internally and externally validate the first commercially 
available high-sensitivity troponin I (hsTnI) assay within an accelerated diagnostic 
pathway (ADP) for patients with possible acute coronary syndrome. Two multicenter 
emergency-department cohorts were investigated. The aim was to optimize the 
proportion of patients identified as low-risk for serious 30-day major adverse events 
 
Methods 
Participants 
The ADP was investigated as two sub-studies; the primary, internal cohort was 
ADAPT8 and the secondary external cohort APACE.3,13 In the ADAPT cohort, 
patients were consecutively recruited at two urban emergency departments in 
Brisbane, Australia and Christchurch, New Zealand.  ADAPT patients were 
prospectively-recruited adult patients with at least five minutes of possible cardiac 
symptoms in accordance with the American Heart Association case definitions (acute 
chest, epigastric, neck, jaw, or arm pain; or discomfort or pressure without a clear 
non-cardiac source).14   Recruitment occurred between November 2007 and February 
2011, but local logistics resulted in different enrolment periods in each centre.8 
Exclusion criteria included pregnancy, patients under the age of 18 years, those 
unable or unwilling to consent, recruitment inappropriate (e.g. terminal illness), 
transfer from another hospital and patients in whom follow-up was considered 
impossible (e.g. homeless).8 Data were prospectively collected on standardized 
collection forms using a published data dictionary.8,15 Research staff collected the 
demographic and clinical data from patients, supervised ECG testing, and drew blood 
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samples for troponin testing.8 If a patient was unsure of an answer to a question (e.g. 
history of diabetes) a response of ‘no’ was recorded.8 In the APACE cohort, 
consecutive adult patients were prospectively recruited who presented to the 
emergency departments in a multinational, multicenter study with symptoms 
suggestive of acute myocardial infarction (AMI) with onset or peak symptoms within 
the previous 12h.3 Patients were excluded who had end-stage renal failure treated 
with dialysis.3,13 The ADAPT substudy was performed in accordance with details 
registered with the ACTRN126110010699438 and APACE ClinicalTrials gov 
registry No. NCT00470587.3,13 
In both cohorts, patients received usual care according to local-hospital 
protocols including blood draws for troponin measurement at presentation, and then 
6 to 9h later in compliance with international guidelines16 or as long as clinically 
appropriate in the APACE cohort with timing left to the discretion of the attending 
physician. Additional blood samples from consenting patients were stored for pre-
planned analysis with high-sensitivity troponin assays. In both cohorts, usual care 
included further assessment by exercise tolerance testing, nuclear myocardial 
perfusion scanning, coronary computed tomography angiography, stress 
echocardiography and/or invasive coronary angiography for all patients with elevated 
troponin results and/or ECG findings of ischemia. Occasionally the clinical context 
of the presentation precluded further investigation.3,8  
Patients in both studies were followed up for major adverse cardiac events within 30 
days using telephone follow-up, and a national health-events search (which identifies 
any death) at least six months after the follow-up period. Where patients reported 
further medical contact in the 30-day period, their hospital notes and documentation 
from subsequent medical contact and cardiac investigations were reviewed.8 The 
 189 
Centre for Clinical Research Excellence, Monash University, Melbourne, Australia,  
independently undertook data coordination, monitoring, and source data verification 
for the ADAPT study.8 The University Hospital, Basel, Switzerland undertook data 
coordination, monitoring, and source data verification for the APACE study. 
Approval from local ethics committees was obtained, and all patients had 
provided written informed consent. 
 
Procedures 
The primary endpoint was major adverse cardiac events within 30 days after initial 
presentation (including initial hospital attendance). The criteria for a major adverse 
cardiac event included any of the following: death (excluding clearly non-cardiac), 
cardiac arrest, acute myocardial infarction, an emergency revascularization 
procedure, cardiogenic shock, ventricular arrhythmia needing intervention, and high-
degree atrio-ventricular block needing intervention. 
Outcomes and investigations were reported with predefined, structured 
reporting guidelines.15 The presence of a 30-day major adverse cardiac event was 
adjudicated independently using these reporting guidelines. Adjudication of all 
cardiac endpoints was performed by two cardiologists with a third cardiologist in 
cases of disagreement. Cardiologists were masked to results of the index-test 
biomarkers under investigation, but had knowledge of the clinical record, ECG, and 
serial troponin results from routine care.  
In accordance with international guidelines, blood was drawn on presentation 
and at least 6 h later or as long as clinically indicated for troponin results that were 
used to determine the presence of myocardial necrosis.14, 17 These samples were 
analyzed at the recruitment site laboratories (Online Appendix 1) and were the only 
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troponin values used in patient management. The diagnosis of acute myocardial 
infarction was based on evidence of myocardial necrosis together with clinical 
evidence of myocardial ischemia (ischemic symptoms, ECG changes or imaging 
evidence) in accordance with current guidelines.17 Additional details of the criteria 
for adjudication are provided in Online Appendix 2.  
In addition to sampling for routine clinical care, blood was drawn on 
presentation and two hours later for both the ADAPT and APACE cohorts. Samples 
were immediately centrifuged. Serum and EDTA plasma were separated and stored 
frozen at -70°C, within two hours, for later analysis using high-sensitivity cTn 
assays. During March and April, 2012, in Australia and New Zealand, and June and 
September, 2012 in the Switzerland, previously unthawed samples were tested with 
the final pre-commercial release version of the ARCHITECT High Sensitive STAT 
Troponin-I assay (Abbott Laboratories, Abbott Park, IL). Laboratory technicians 
were blinded to patient data. Samples were thawed, mixed, and centrifuged (for 30 
minutes at 3,000 RCF and 4°C for serum samples or 10 minutes, twice, at 3,000 RCF 
for plasma samples) prior to analysis and according to manufacturer’s instructions.  
The hsTnI assay has a 99th percentile concentration of 26.2ng/L with a corresponding 
co-efficient of variation (CV) of <5% and a limit of detection of 1.2ng/L.18,19 Long-
term stability of TnI has been demonstrated previously.20 Good correlation between 
plasma and serum has been demonstrated previously.21 Total imprecision (CV) for 
the manufacturer’s quality controls measured over 11 days of specimen analysis 
ranged from 3.53% at 19.90ng/L to 2.20% at 14604ng/L cTnI (n=31-33) at the 
Australian site. 
The predefined diagnostic protocols under investigation included a 
combination of i) Thrombolysis in Myocardial Infarction risk score, ii) ECG, and iii) 
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hs TnI sampling at 0 and 2 h. The first ADP defined low-risk as patients with a TIMI 
score of zero, plus no new ischemic changes on ECG, and 0- and 2-h hs TnI 
concentrations ≤26.2ng/L (Online Appendix 3). The second ADP defined low risk as 
those with a TIMI score of ≤1 (i.e. zero or 1), plus no new ischemic changes on 
ECG, and 0- and 2-h hs TnI concentrations ≤26.2ng/L (Online Appendix 3). 
The TIMI risk score for unstable angina or non-ST elevation myocardial 
infarction uses seven predictors with a value of one point assigned for each positive 
finding.11 When the TIMI score was used within the ADP (Online Appendix 3), the 
original criteria on ECG and biomarkers were unnecessary due to the broader criteria 
required. These two original TIMI parameters were incorporated within i) 
electrocardiograph findings of new ischemic changes and ii) increased hs-troponin I 
results on 0- or 2- h blood tests. Abnormal ECG criteria are outlined in Online 
Appendix 4. The cut-off value for an elevated hsTnI was the 99th percentile 
(26.2ng/L).  
 
Statistical analysis 
Baseline characteristics of the participants were analyzed with conventional 
group descriptive statistics. For continuous variables, mean ± SD and median ± 
interquartile range, were calculated. For categorical data, the proportions in each of 
the ADP positive and negative groups were reported. The sensitivity, specificity, and 
positive, and negative predictive values for hierarchical primary and secondary 
events were generated using chi-square analyses for the ADP as a whole and its 
constituents individually or in combination. Correlated proportions and sensitivities 
were compared using the McNemar test. Analyses were done with SPSS (Version 
19).  
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Role of funding source 
The sponsors of this study had no role in the study design, data collection, data 
analysis, data interpretation, or writing of the report. The corresponding author had 
full access to all the data in the study and had final responsibility for the decision to 
submit for publication. 
 
Results  
Integrating hs TnI with a TIMI score ≤1 within the protocol classified 41.5% 
(678/1635; p <0.01) and 38.6% (351/909) of patients as low risk (ADAPT and 
APACE, respectively; table 1), while maintaining excellent diagnostics statistics 
(table 2). Only 0.8% and 0.6% of the patients that had a 30-day adverse event in 
ADAPT and APACE, respectively, were classified in this group.  Fewer patients 
were classified as low risk (19.6% [320/1635] and 25.3% [230/909], ADAPT and 
APACE, respectively) with the use of a TIMI risk score of zero within the ADP. 
There were 1976 consenting patients recruited in the ADAPT cohort, of 
which 1635 participants had stored samples available for the primary analysis (figure 
1). No patients were lost to 30-day follow-up. The APACE cohort included 909 
patients with stored samples for analysis (figure 1). Baseline characteristics of the 
two cohorts are shown in Table 3. In the ADAPT cohort, 247 of 1635 (15.1%) 
patients had a total of 280 adverse cardiac events within 30 days of presentation; 242 
events were myocardial infarction (table 4). In the APACE cohort, 156 of 909 
(17.2%) patients had a total of 261 adverse cardiac events within 30 days of 
presentation; 153 events were myocardial infarction. 
 193 
In the ADAPT and APACE cohorts, respectively, 94.9% and 96.0% of 
patients had a hs TnI value on presentation above the limit of detection (1.2ng/L) for 
the high-sensitivity troponin I assay (table 5). 
Further objective investigations within the 30-day period, including exercise 
stress testing, echocardiography, computed tomography coronary angiography and 
angiography occurred in 246 (76.9 %) and 519 (76.5%) patients in the ADAPT low-
risk cohorts analyzed using TIMI=0 and TIMI≤1 respectively, and 51 (22.2 %) and 
94 (26.8%) patients in the APACE low-risk cohort analyzed using TIMI=0 and 
TIMI≤1 (table 3).  
Two  patients in the ADAPT cohort and one patient in the APACE cohort 
were determined as low-risk and had a 30-day event (Online Appendix 5). The 
adjudicated diagnosis for all three of these patients was NSTEMI.  
 
Discussion  
Two large, international, multi-centered, emergency-department cohorts have 
validated the integration of high-sensitivity troponin I results in a 2-h investigative 
pathway for the assessment of patients with possible acute coronary syndromes. The 
strategy using TIMI=0 classified similar numbers of patients as low risk as 
previously reported using currently available troponin assays8,22  while maintaining a 
sensitivity of >99% in both cohorts. The strategy incorporating a TIMI risk score ≤1 
doubled the proportion of emergency department patients classified as low-risk while 
maintaining >99% sensitivity and negative predictive value for adverse events in 
both cohorts. This finding suggests that approximately 40% of patients presenting to 
emergency departments with possible cardiac chest pain could rapidly and safely 
progress to early discharge for outpatient management.23 The rise in the proportion of 
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patients identified as low-risk incorporating TIMI ≤1 in the strategy has the potential 
to have a considerable impact on reducing hospital admission rates and emergency-
department overcrowding.  
Incorporating hsTnI results in clinical practice pathways will improve the 
management of patients presenting with chest pain to emergency departments. The 
strategy integrating hsTnI with TIMI ≤1 resulted in an improved specificity of >45% 
for risk of 30-day cardiac events. This finding is in contrast to previous studies that 
have found that the improvements in analytical performance of high-sensitivity 
troponin assays have led to increased rates of elevated troponin and decreased 
specificity for acute myocardial infarction.4   
This is the first paper to validate the clinical integration of hs TnI into a 
pragmatic and useful algorithm for medical decision-making in real-life practice. 
Until now there has been no literature to provide guidance on how to use hs TnI in 
clinical care. Guideline bodies have recommended that the 99th percentile (and not 
other cut-off levels) be used in clinical practice irrespective of the troponin assay.24,25 
This study demonstrates the effectiveness of this cut-off value in combination with 
the TIMI risk score and ECG findings in clinically useful algorithms for emergency-
department patients with possible ACS.  
Some techniques optimize the utilization of high-sensitivity troponin assays 
using alternative cut-off values (other than the 99th percentile) and change metrics 
(deltas).1,2 The details of these techniques need to be individualized for each new 
assay.10  The value of serial changes (deltas) was not assessed in this study.  
Previously the limit of detection for high-sensitivity troponin T was suggested to be 
clinically useful as a cut-off value. An un-recordable hs TnT value was found in up 
to 30% of patients on initial presentation, supporting this cut-off value for the early 
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rule-out of acute myocardial infarction when using this assay.1 We cannot 
recommend the use of the limit of detection as a cut-off value for this assay due to 
the improved ability of hs TnI assays to detect troponin concentrations in the normal 
range supported by our finding that the majority of patients (>95%) had defined 
troponin values on presentation. 
Three patients in the low-risk group were diagnosed with 30-day events. It is 
possible that these were cases of false negative results with hsTnI (25). However it is 
also  possible, that the apparent troponin elevation identified with the troponin assay 
in clinical use at the time of recruitment may have been false positive results, and the 
adjudicated outcomes were incorrect 26 as the finding of an elevated troponin value is 
critical for the diagnosis of AMI.(Online Appendix 6) 
The applicability of this risk stratification process is limited to patients with 
chest pain or discomfort. Patients with acute coronary syndrome and other serious 
conditions may present with atypical symptoms such as fatigue or nausea without 
associated chest discomfort. Most patients recruited were Caucasian limiting the 
generalizability of the results to other populations; however the studies were 
conducted in two geographically distinct regions. During these observational studies, 
at least 77% of patients in the ADAPT and at least 27% in the APACE low-risk 
cohorts received further treatment and/or investigations during the index 
presentation. In low risk patients, we would argue such studies can be safely 
accomplished as outpatients,27,28  but further studies (ideally in a randomized 
controlled trial) are required to determine if further investigation (including 
outpatient testing) is required in the low risk cohort to prevent longer-term, adverse 
outcomes.   
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Conclusion 
An early-discharge strategy using an hs-TnI assay and TIMI score ≤1 had similar 
safety as previously reported, with the potential to decrease the observation periods 
and admissions for approximately 40% of patients with suspected ACS. 
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Figure 1: ADAPT (top) and APACE (bottom) cohort-participant flow diagrams for 
the accelerated diagnostic protocol incorporating high-sensitivity troponin I and 
TIMI ≤1.  
 
 
Eligible patients with 
informed consent
(n=1976)
Index test = ADP
(n=1635)
ADP positive 
“not low risk” 
(n=957)
ADP negative 
“low risk” 
(n=678)
No 30 day MACE
(n=676)
Excluded
(n=341)
-   TIMI score incomplete 
-   No serial stored bloods 
30 day MACE
(n=2)
No 30 day MACE
(n=712)
30 day MACE
(n=245)
      
Eligible patients with 
informed consent
(n=1616)
Index test = ADP
(n=909)
ADP positive 
“not low risk” 
(n=558)
ADP negative 
“low risk” 
(n=351)
No 30 day MACE
(n=350)
Excluded
 Chest pain of unknown origin          
and hs-TnT above cutoff (n=46)
 No serial blood samples (n=655)
 No ECG available (n=6)
30 day MACE
(n=1)
No 30 day MACE
(n=403)
30 day MACE
(n=155)
 
 
MACE=major adverse cardiac event. 
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Table 1: Occurrence of major adverse cardiac events during initial hospital 
attendance or 30-day follow-up according to individual and combinations of the ADP 
test parameters in the ADAPT and APACE cohorts. 
ADAPT MACE [n=247] 
ADAPT(%) 
No MACE [n=1388] 
ADAPT(%) 
Total [n=1635] 
ADAPT(%) 
ECG*    
Positive 46 (18.6) 58 (4.2) 104 (6.4) 
Negative 201 (81.4)† 1330 (95.8) 1531 (93.6) 
TIMI=0ǂ    
Positive 243 (98.4) 1065 (76.7) 1308 (80) 
Negative 4 (1.6) † 323 (23.3) 327 (20) 
TIMI≤1§    
Positive 210 (85.0) 693 (49.9) 903 (55.2) 
Negative 37 (15.0) † 695 (50.1) 732 (44.8) 
hsTnI ¶    
Positive 227 (91.9) 96 (6.9) 323 (19.8) 
Negative 20 (8.1) † 1292 (93.1) 1312 (80.2) 
TIMI=0 or hsTnI or 
ECG** 
   
Positive 247 (100) 1068 (76.9) 1315 (80.4) 
Negative 0 (0) † 320 (23.1) 320 (19.6) 
TIMI≤1 or hsTnI or 
ECG†† 
   
Positive 245 (99.2) 712 (51.3) 957 (58.5) 
Negative 2 (0.8) † 676 (48.7) 678 (41.5) 
APACE MACE [n=156] 
APACE(%) 
No MACE [n=753] 
APACE(%) 
Total [n=909] 
APACE(%) 
ECG*    
Positive 81 (51.9) 165 (21.9) 246 (27.1) 
Negative 75 (48.1) † 588 (78.1) 663 (72.9) 
TIMI=0ǂ    
Positive 155 (99.4) 504 (66.9) 659 (72.5) 
Negative 1 (0.6) † 249 (33.1) 250 (27.5) 
TIMI≤1§    
Positive 144 (92.3) 344 (45.7) 488 (53.7) 
Negative 12 (7.7) † 409 (54.3) 421(46.3) 
hsTnI ¶    
Positive 129 (82.7) 62 (8.2) 191 (21.0) 
Negative 27 (17.3) † 691 (91.8) 718 (79.0) 
TIMI=0 or hsTnI or 
ECG** 
   
Positive 156 (100) 523 (69.5) 679 (74.7) 
Negative 0 (0) † 230 (30.5) 230 (25.3) 
TIMI≤1 or hsTnI or 
ECG†† 
   
Positive 155 (99.4) 403 (53.5) 558 (61.4) 
Negative 1 (0.6) † 350 (46.5) 351 (38.6) 
 
MACE=major adverse cardiac event. ECG=electrocardiograph. TIMI=Thrombolysis In Myocardial 
Infarction score. hsTnI=high sensitivity troponin I. *ECG alone; any new ischemia at 0 or 2 h is 
positive. † Numbers of patients who were identified as low-risk by the diagnostic parameter(s) but had 
a MACE (i.e. false-negative cases). ǂ TIMI score ≥1 is positive. The 0-h hsTnI result was part of the 
TIMI score. § TIMI score ≥ 2 is positive. ¶ 0- or 2-h hsTnI >26.2ng/L is positive. **Any new 
ischemia at 0 or 2 h or 0- or 2-h hsTnI >26.2ng/L or TIMI ≥1 is positive. ††Any new ischemia at 0 or 
2 h or 0- or 2-h hsTnI >26.2ng/L or TIMI ≥2 is positive.
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Table 2: Accuracy (95% CI) of ECG, hsTnI, TIMI and ADP for exclusion of MACE. 
  ECG* hsTnI† TIMI = 0 TIMI ≤ 1 TIMI = 0 
and ECG* 
and 
hsTnI† 
TIMI ≤1  
and 
ECG* 
and 
hsTnI† 
Sensitivity ADAPT 
cohort 
18.6 
(14.3-
23.9) 
91.9 
(87.8-
94.6) 
98.4 
(95.9-
99.4) 
85  
(80-88.9) 
100 
(98.5-100) 
99.2 
(97.1-
99.8) 
APACE 
cohort 
51.9  
(43.8-
60.0) 
82.7  
(75.8-
88.3) 
99.4 
(96.5-100) 
92.3 
(87.0-
96.0) 
100 
(97.7-100) 
99.4 
(96.5-
100) 
Negative 
predictive 
value 
ADAPT 
cohort 
86.9 
(85.1-
88.5) 
98.5 
(97.7-
99.0) 
98.8 
(96.9-
99.5) 
94.9 
(93.1-
96.3) 
100 
(98.8-100) 
99.7 
(98.9-
99.9) 
APACE 
cohort 
87.7 
(86.0-
91.0) 
96.3 
(94.6-
97.5) 
99.6 
(97.8-100) 
97.2  
(95.1-
98.5) 
100 
(98.4-100) 
99.7  
(98.4-
100) 
Specificity ADAPT 
cohort 
95.8 
(94.6-
96.8) 
93.1 
(91.6-
94.3) 
23.3 
(21.1-
25.6) 
50.1 
(47.4-
52.7) 
23.1 
(20.9-
25.3) 
48.7 
(46.1-
51.3) 
APACE 
cohort 
78.1  
(75.0-
81.0) 
91.8 
(89.6-
93.6) 
33.1  
(29.7-
36.6) 
54.3 
(50.7-
57.9) 
30.5 
(27.3-
34.0) 
46.5 
(42.9-
50.1) 
Positive 
predictive 
value 
ADAPT 
cohort 
44.2 
(35.1-
53.8) 
70.3 
(65.1-
75.0) 
18.6 
(16.6-
20.8) 
23.3 
(20.6-
26.1) 
18.8 
(16.8-
21.0) 
25.6  
(22.9-
28.5) 
APACE 
cohort 
32.9 
(27.1-
39.2) 
67.5 
(60.4-
74.1) 
23.5 
(20.3-
27.0) 
29.5 
(25.5-
33.8) 
23.0 
(19.9-
26.3) 
27.8 
(24.1-
31.7) 
 
ECG=electrocardiograph. TIMI=Thrombolysis In Myocardial Infarction score (Appendix 3). 
hsTnI=high sensitivity troponin I. ADP=accelerated diagnostic protocol. *ECG alone; any new 
ischemia at 0 or 2 h is positive. †hsTnI at 0 and 2 h ≤ 26.2ng/L.   
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Table 3: Characteristics for low-risk and high-risk participants in the ADAPT and 
APACE cohorts. 
Characteristics ADAPT cohort (n=1635) APACE cohort (n=909) 
Low Risk  
(TIMI≤1, N 
ECG and N 
hsTnI) 
(n=678) 
High  Risk 
(TIMI>1 or 
abnormal 
ECG or 
raised hsTnI) 
(n=957) 
Low Risk  
(TIMI≤1, N 
ECG and N 
hsTnI) 
(n=351) 
High  Risk 
(TIMI>1 or 
abnormal 
ECG or 
raised hsTnI) 
(n=558) 
Age, yrs 51.3 (11.9) 67.0 (13.5) 53.5 (14.6) 66.4 (13.8) 
Gender (% Male) 399 (58.8) 577 (60.3) 238 (67.8) 397 (71.1) 
Risk Factors     
Hypertension 197 (29.1) 655 (68.4) 139 (39.6) 437 (78.3) 
Dyslipidaemia 236 (34.8) 689 (72) 72 (20.5) 345 (61.8) 
Diabetes  40 (5.9) 203 (21.2) 26 (7.4) 131 (23.5) 
Family history of coronary 
artery disease 
312 (46) 617 (64.5) 58 (16.5) 142 (25.4) 
Smoking (Current) 156 (23) 143 (14.9) 124 (35.3) 111 (19.9) 
Past Medical History     
Angina 46 (6.8) 543 (56.7) Not recorded Not recorded 
Acute myocardial infarction 6 (0.9) 380 (39.7) 3 (0.9) 215 (38.5) 
Angiography 2 (0.3) 282 (29.5) 3 (0.9) 230 (41.2) 
Congestive heart failure 6 (0.9) 120 (12.5) 17 (4.8) 96 (17.2) 
Cerebrovascular event 29 (4.3) 154 (16.1) 8 (2.3) 37 (6.6) 
CABG 1 (0.1) 138 (14.4) 1 (0.3) 83 (14.9) 
Time of symptom onset to 
presentation (h) 
    
Mean (SD) 21.1 (58.5) 23.4 (62.5) 13.5 (21.9) 14.1 (21.4) 
Median (IQR) 4.6  
(1.7-14.9) 
6.2  
(2.4-16.6) 
4 (2-11) 5 (3-12) 
Length of initial hospital 
attendance (h) 
    
Mean (SD) 39.7  
(59.6) 
104.4 (151.5) 29.7 (65.9) 115.8 (200.0) 
Median (IQR) 26.3  
(10.4-31.4) 
65.9  
(28.5-124.8) 
7.2  
(5-21.8) 
47.9  
(8.2-169.2) 
Investigations within 30 
days 
    
Stress ECG 446 (65.8) 206 (21.5) 64 (18.2) 76 (13.6) 
Stress Radionuclide Imaging 42 (6.2) 50 (5.2) 22 (6.3) 80 (14.3) 
Stress Echocardiogram 8 (1.2) 20 (2.1) Not recorded Not recorded 
Non Stress Echocardiogram 48 (7.1) 130 (13.6) Not recorded Not recorded 
Angiography 57 (8.4) 317 (33.1) 12 (3.4) 194 (34.8) 
 
Data are mean (SD), number (%), or median (IQR). ADP = accelerated diagnostic protocol. N = 
normal. Data were missing for time of symptom onset to presentation (7 (ADAPT) and 12 (APACE)), 
Length of hospital attendance was 59 and 29  in the ADAPT and APACE studies, respectively. 
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Table 4: Frequency of major adverse cardiac events during initial hospital attendance 
or 30-day follow-up period in the ADAPT and APACE cohorts. 
 
 ADAPT cohort* 
(n=1635) 
 
APACE cohort^ 
(n=909) 
 
Number 
of events 
Frequency 
of event 
type  
(%) 
Number of 
events 
Frequency 
of event 
type  
(%) 
NSTEMI 225 13.8 142 15.6 
Emergency 
Revascularisation 
19 1.2 83# 9.1# 
STEMI 17 1.0 11 1.2 
Cardiovascular death 5 0.3 11 1.2 
Ventricular 
Arrhythmia 
5 0.3 3 0.3 
High atrioventricular 
block 
5 0.3 7 0.8 
Cardiogenic Shock 3 0.2 2 0.2 
Cardiac Arrest 1 0.1 2 0.2 
 
STEMI= ST-segment elevation myocardial infarction occurring of after initial recruitment. 
NSTEMI=Non-ST-segment myocardial infarction. *247 of 1635 (15.1%) patients in ADAPT cohort 
had a total of 280 events. ^156 of 909 (17.2%) patients in APACE cohort had a total of 261 events. # 
Revascularization within 24 hours 
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Table 5: Participants with detectable troponin values (>1.2ng/L) on presentation. 
 
 Number % 
ADAPT cohort 1551 94.9 
APACE cohort 873 96.0 
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Online Appendix 1: Analytical characteristics of central laboratory reference 
troponin assays and the highly sensitive troponin I assay 
 
Assay LOD (µg/L) 99th % (µg/L) 10% CV (µg/L) 
Abbott 
ARCHITECT 
<0.01 0.028  0.032 
Abbott 
ARCHITECT High 
Sensitive STAT 
Troponin I 
0.0012 
 
(1.2ng/L) 
0.0262 
 
(26.2ng/L) 
0.01 
 
(10ng/L) 
Abbott Axsym 
cTnI ADV 
0.02 0.04 0.16 
Beckman Coulter 
Access Accu 
0.01  0.04  
 
0.06 
Roche cTnT 4th 
generation 
 
 
0.01 
 
0.01 
 
0.035 
Roche High 
Sensitive Troponin 
T 
0.005 
 
0.014 
 
 
0.013 
 
 
 
Limit of detection (LOD), Coefficient of variation (CV). Modified from: Analytical 
characteristics of commercial and research high sensitivity cardiac troponin I and T 
assays per manufacturer. IFCC website. Version updated September 12, 2009 1 
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Online Appendix 2: Additional details for the adjudication of final diagnosis  
 
AMI was defined as recommended in current guidelines.2,3 Necrosis was diagnosed 
on the basis of a rising or falling pattern of the laboratory cardiac troponin 
concentrations, with at least one value above the 99th percentile, at a level of assay 
imprecision near to 10%. 
In the ADAPT cohort, if the troponin concentration was greater than the cut-
off value, but no rise or fall was determined, other causes of troponin elevation were 
considered. If no clear alternative cause of the troponin rise was apparent, and if the 
clinical presentation was suggestive of acute coronary syndromes, an adjudicated 
diagnosis of acute myocardial infarction was made. 
In the APACHE cohort, adjudication of final diagnoses was performed twice 
using different assays for the central laboratory results (University Hospital Basel) 
for all patients. Initially the assays used were the conventional cTn levels used 
locally (Online Appendix 1) and secondly using the Roche hs-cTnT. The second 
adjudication was performed to utilize the higher sensitivity and higher diagnostic 
accuracy offered by hs-cTn assays.4   
To identify potential patients with small AMIs that were missed by the 
adjudication using conventional cTn assays, the second adjudication using hs-cTnT 
was performed in all non-AMI patients according to the first adjudication. For hs-
cTnT, the 99th percentile (14ng/l) was used as cut-off for myocardial necrosis.5,6 
Absolute changes in hs-cTnT were used to determine significant changes.7,8  A 
significant absolute change was defined as a rise or fall of at least 10ng/l within 6 
hours. 9-11 In patients, in whom a 6 h hs-cTnT level was not available, changes were 
assessed at earlier time points. In an assumption of linearity, an absolute change of 
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6ng/l within 3 hours, 4ng/l within 2 h or 2ng/l within 1 h was considered. However if 
discordant findings occurred, the longest time interval available was required to 
fulfill the change criteria. Measurements performed with lots that required the 
revision of the calibration curve were corrected using non-linear regression 
correction (Fred Apple, personal communication July 30th, 2012). 
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Online Appendix 3: Accelerated Diagnostic Protocol (ADP) 
 
4. hs-TnI level at 0 and 2 h below or equal to the 99th percentile (26.2ng/L). 
5. No new ischemic changes on the initial ECG 
6. TIMI score ≤1 (1 point given for each positive parameter a.-g. below) 
h. Age 65 years or older 
i. Three or more risk factors for coronary artery disease (family history 
of coronary artery disease, hypertension, hypercholesterolemia, 
diabetes, or being a current smoker) 
j. Use of aspirin in the past 7 days 
k. Significant coronary stenosis (e.g. previous coronary stenosis ≥50%) 
l. Severe angina (e.g. two or more angina events in past 24 h or 
persisting discomfort) 
m. ST-segment deviation of 0.05 mV or more on first ECG 
n. Increased troponin and/or creatine kinase MB blood tests (during 
assessment*) 
 
hs-TnI = high-sensitivity troponin I. ADP = accelerated diagnostic protocol. TIMI = Thrombolysis In 
Myocardial Infarction. ECG = electrocardiograph. Parameters  1 and 2 had to be negative and the 
TIMI score =0 or ≤1 for the ADP to be considered negative  and for the patient to be identified as low-
risk *The results of the 0 h hs TnI were used for calculation of the TIMI score in this study which is a 
modification from the original published score. This score parameter (g. above) and that of ST-
segment deviation (f. above) are unnecessary in the ADP because of the broader hs-TnI and ECG 
criteria (in 1 and 2).  
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Online Appendix 4: Abnormal ECG changes 
 
In both cohorts, new ischemic changes were defined as ST-segment depression of at 
least 0.05mV in two or more contiguous leads (including reciprocal changes); T-
wave inversion of at least 0.1mV, or Q-waves greater than 30ms in width and 0.1mV 
or greater in depth in at least two contiguous leads; new or presumed new ST-
segment elevation at the J point in two or more contiguous leads with the cut-off 
points greater than or equal to 0.2mV in leads V1, V2, or V3, or greater than or equal 
to 0.1mV in other leads or new left bundle branch block ST-elevation or left bundle 
branch block. All other ECG findings including findings of ischemic changes known 
to have been pre-existing were considered negative in the ADP.  
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Online Appendix 5: Occurrence of MACE within 30 days according to the results of 
individual and combination of the test parameters in combined ADAPT and APACE 
cohorts 
Test Outcome Test Outcome 
ECG MACE No 
MACE 
Total Troponin MACE No 
MACE 
Total 
Positive 127 223 350 Positive 356 158 514 
Negative 276 1918 2194 Negative 47 1983 2030 
Total 403 2141 2544 Total 403 2141 2544 
TIMI ≤1*    
ECG + 
Troponin 
   
Positive 354 1037 1391 Positive 371 334 705 
Negative 49 1104 1153 Negative 32 1807 1839 
Total 403 2141 2544 Total 403 2141 2544 
ECG + 
TIMI ≤1* 
   
TIMI* ≤1 +  
0 & 2h 
Troponin 
   
Positive 358 1093 1451 Positive 397 1063 1460 
Negative 45 1048 1093 Negative 6 1078 1084 
Total 403 2141 2544 Total 403 2141 2544 
    
ECG + 
TIMI ≤1* +  
0 & 2h 
Troponin 
   
    Positive 400 1115 1515 
    Negative 3 1026 1029 
    Total 403 2141 2544 
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Online Appendix 6: Characteristics of the three low risk patients with 30 day 
outcomes. 
PATIENT 1   
Details of 
presentation 
A 67 year old male presented with single 7-h episode of 
chest pain. He had known hypercholesterolemia but no 
history of cardiac disease.  
Reference troponin 
values 
Reference cTnI concentrations were 120ng/L, 120ng/L and 
160ng/L (99th % 28ng/L, Abbott ARCHITECT) at 0h, 2h 
and beyond 6 h respectively. 
hs-TnI values hs-TnI results were 5.2ng/L and 5.7ng/L (99th % 26.2ng/L, 
ARCHITECT High Sensitive STAT Troponin-I assay) at 0 
and 2h respectively. 
Subsequent 
management and 
outcome 
He had an angiogram five days after presentation showing 
normal coronary arteries. He was diagnosed with a 
NSTEMI because no alternate cause could be found for the 
troponin elevation. There were no other follow-up events. 
PATIENT 2  
Details of 
presentation 
A 72 year-old male presented after half an hour of chest 
pain. He had a history of congestive heart failure, 
hypertension, and dyslipidemia. 
Reference troponin 
values 
His reference cTnI concentrations were 0.0ng/L, 3.0ng/L 
and 280ng/L (99th % 28ng/L, Abbott ARCHITECT) at 0 h, 
2h and greater than 6 h respectively. 
hs-TnI values His hs-TnI results were 6.5ng/L and 16.5ng/L (99th % 
26.2ng/L, ARCHITECT High Sensitive STAT Troponin-I 
assay) at 0 and 2 h respectively. 
Subsequent 
management and 
outcome 
He had an angiogram five days after presentation showing 
maximum stenosis of 30% in the left anterior descending 
artery, and was diagnosed with a NSTEMI. There were no 
other follow-up events. 
PATIENT 3  
Details of 
presentation 
A 64 year-old male with a known history of coronary 
artery disease, and a previous AMI presented with a five-
hour history of chest pain. He had a history of hypertension 
and dyslipidemia. 
Reference troponin 
values 
His reference hs-TnT concentrations were 77.3ng/L at 
admission and 70.8ng/L (99th % 14ng/L Roche High 
Sensitive Troponin T) after 2 hours. 
hs-TnI values The respective hs TnI concentrations were 6.1ng/L and 
6.2ng/L (99th % 26.2ng/L, ARCHITECT High Sensitive 
STAT Troponin-I assay) at 0 and 2 hours. 
Subsequent 
management and 
outcome 
The following day the patient performed an exercise stress 
test that was clinically and electrically negative at a 
submaximal workload (<85%). His adjudicated final 
diagnosis was a NSTEMI due to his pain characteristics 
and dynamic troponin changes.  
  
214  
  
 215 
 
 
7 
George, T., S. Ashover, L. Cullen, P. Larsen, J. Gibson, J. Bilesky, S. 
Coverdale and W. Parsonage (2013). "Introduction of an accelerated diagnostic 
protocol in the assessment of emergency department patients with possible acute 
coronary syndrome: the Nambour Short Low-Intermediate Chest pain project." 
Emerg Med Australas 25(4): 340-344. 
* Reproduced with permission of Wiley 
 
216  
  
 217 
Chapter 7 
 
In the previous chapters (5 and 6) we described the opportunity to safely 
identify and assess low risk patients who present to the Emergency Department with 
symptoms of possible ACS. We believed that this ADP was safe for the 
identification of patients suitable for early discharge with further outpatient 
assessment and in this manner it was ready for implementation into clinical practice. 
As these were observational trials, they were unable to define if cessation of all 
further investigation in this low risk group was appropriate.  
The ultimate proof of benefit of this concept was to put the ADP into clinical 
practice and assess the outcomes. In 2012, Prof Will Parsonage and the candidate 
approached the then Director General for Queensland Health (Prof Tony O’Connell), 
informing him of our findings and requesting support to trial this ADP in a pilot site. 
Nambour Hospital was chosen due to the tremendous support of the clinical leads, Dr 
Terry George, Dr Peter Larsen and Mr Jason Gibson in addition to all staff at the 
Nambour Hospital. The pilot study was supported by a dedicated Project Officer role 
filled by Ms Jennifer Bilesky and Sarah Ashover.  
The ADAPT ADP was implemented following introduction, identification of 
local clinical leads, analysis of local practices, amendment of clinical support tools, 
and education for all staff involved in the care if these patients. The troponin assay 
used was the current Queensland Pathology central laboratory troponin assay 
available in July 2012, a sensitive troponin assay. We rigorously assessed and 
reported the change in practice in terms of clinical outcomes, uptake and utilisation 
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by staff, patient satisfaction and process indicators such as National Emergency 
Access Target achievements and length of stay.  
The candidate with Will Parsonage led the research. She undertook literature 
review, assisted in the designed the research protocol and obtaining the necessary 
approvals including ethics approvals and supported the conduct of the research. She 
also was involved in the analysis and interpretation of the data and was responsible 
for drafting and critically reviewing the paper. All of the authors have approved 
inclusion of this paper into the thesis. Copies of these authorisations are available on 
request. 
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Background 
One of the few constants in emergency medicine over the last 30 years is 
acknowledged inaccuracy of clinical assessment alone for identifying the cause of 
undifferentiated chest pain.1 With a high risk of avoidable adverse outcomes, 
combined with a high volume of such ED presentations (5–10%),2 it is not surprising 
that another constant is the propensity for aggrieved patients and their families to 
successfully seek compensation following related adverse outcomes.3  
These two factors provide strong rationale for emergency physicians to 
follow widely accepted guidelines when managing patients with undifferentiated 
chest pain and possible acute coronary syndrome (ACS). The National Heart 
Foundation of Australia (NHFA) and the Cardiac Society of Australia and New 
Zealand (CSANZ) published such guidelines in 2006,4 which have provided a de 
facto local standard of care. Although up to 85% are eventually diagnosed with a 
non-cardiac cause, it is recommended that patients presenting with pain within the 
past 48 h that occurred at rest or was repetitive or prolonged but not accompanied by 
high-risk features should undergo repeat cardiac troponin testing at least 8 h after the 
last episode of pain. If the delayed, second cardiac troponin result is also normal, 
they should undergo provocative testing, for example, exercise stress test (EST), 
preferably prior to discharge. Only 2% of ED patients presenting with undifferenti-
ated chest pain with possible ACS can be risk stratified as sufficiently low risk to not 
require this delayed cardiac troponin testing and further provocative test-ing.5 An 
addendum to the guidelines was subsequently published,6 recommending the use of 
high-sensitivity cardiac troponin with delayed testing 3 h after arrival or 6 h from 
symptom onset, whichever was later. Of note, high-sensitivity cardiac troponin 
testing is not available in all hospitals. 
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One of the more recent developments in Australia is the National Emergency 
Access Targets (NEAT). The National Health Reform Agreement mandates that 
public hospital EDs achieve the target of 90% of all presenting patients physically 
leaving the ED for admission to hospital, referral to another hospital or discharge 
within 4 h, with interim targets in Queensland of 70% in 2012 and 77% in 2013.  To 
comply with NEAT, all but 2% of patients with undifferentiated chest pain with 
possible ACS managed according to current NHFA and CSANZ guidelines require 
admission to hospital with an obvious self-defeating negative impact on access 
block.  Recent evidence has emerged that the risk stratification process can be 
shortened using accelerated diagnostic protocols (ADPs). Using a Thrombolysis in 
Myocardial Infarction (TIMI) risk score of zero and ECGs in combination with 
sensitive troponin testing 2 h after presentation (the ADAPT ADP) can accurately 
identify a low-risk cohort for major adverse cardiac events (MACE) at 30 days with 
a sensitivity of 99.7% (95% CI: 98.1–99.9%).7 ADAPT was a prospective 
observational study. Many ADAPT ADP negative patients received further 
investigation and interventions during their initial hospital attendance. Management 
was not directed by the ADAPT ADP but rather by existing local protocols including 
6–12 h troponin and pre-discharge EST. 
 
Strategies implemented 
We report the Nambour Short Low-Intermediate Chest pain (SLIC) project, which 
trialled ADAPT ADP directed management and outpatient EST. The aims were to 
safely introduce an ADP for a significant proportion of ED patients with 
undifferentiated chest pain and possible ACS to allow compliance with NEAT. In 
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addition, we aimed to trial a process of care that was acceptable to patients and staff 
while reducing system costs and being readily applicable across Queensland EDs. 
The local Nambour chest pain pathway was modified so that a subgroup, risk 
stratified as intermediate risk by NHFA and CSANZ guidelines, would be identified 
as ADAPT ADP negative (low risk) and suitable for a SLIC risk evaluation. The 
TIMI score was determined by the treating clinician (at any level of experience). 
Following the second negative (normal) sensitive cardiac troponin (Beckman TnI, 
Beckman Coulter, Chaska, MN, USA) taken 2 h after presentation, patients were 
discharged from the ED and arranged to return for outpatient investigation within 14 
days, most commonly EST (computed tomography coronary angiography if EST was 
contraindicated). For convenience, SLIC patients were admitted to the ED short stay 
unit (SSU). On discharge they received a pre-formatted patient information advice 
sheet and general practitioner (GP) discharge letter explaining the management 
rationale and emphasising the importance of returning for follow-up EST. Data 
collection was via the current Queensland version of the Emergency Department 
Information System database (EDIS Version 9.34.1029PR1, HAS Solutions), 
medical records and telephone follow up at 30 days after presentation. 
Outcomes 
ED patients (1762) with undifferentiated chest pain (6.5% of a total 27 208 ED 
attendances) were identified between 1 July 2012 and 31 January 2013. Two hundred 
and fourteen (12.2%) were risk stratified to the SLIC evaluation. Thirty day follow up 
was achieved in 91%. After excluding cases diagnosable in the ED as either ACS (17% 
of all chest pain presentations) or non-cardiac (12% of all chest pain presentations), 19% 
of the remaining cases of possible cardiac chest pain were risk stratified to SLIC (Fig. 1). 
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In the SLIC group, there were no MACE (cardiac death, acute myocardial infarction or 
urgent revascularisation) reported by 30 days. Seventy-nine per cent returned for planned 
investigation, with 12% abnormal (positive or equivocal findings) and investigated 
further. Ultimately, only two patients were diagnosed with ischaemic heart disease and 
managed non-invasively. Twenty-one per cent did not return by 30 days; 14% through 
personal choice; 3.5% owing to external circumstances preventing their attendance; and 
3.5% as advised by their GP. There were 6.2% who represented to an ED with chest pain 
within 30 days of initial evaluation. 
Prior to the trial, NEAT performance for chest pain presentations consistently 
failed to exceed 25%. For both SLIC and non-SLIC cases, this improved significantly 
through the trial, with SLIC cases achieving NEAT after the first month (Fig. 2). This 
compared favourably against improved NEAT performance for all ED patients from 
47% to 63% through the same period. Average ED length of stay (LOS) for 
undifferentiated chest pain patients in the 6 months prior to the trial was 425 min. During 
the trial, this reduced to 344 min (SLIC cases 163 min, non-SLIC cases 370 min). Total 
ED LOS saving was 121 743 min over 6 months, translating to a gain equivalent to 0.46 
of a staffed and equipped treatment space. This time saving was not at the expense of an 
increased demand on other hospital departments as all investigations performed on the 
SLIC group had occurred previously as an inpatient. The total hospital LOS saving was 
not calculated. 
Patient satisfaction was estimated at 30 day follow up by a rating from 1 to 
10, with 10 indicating ‘very satisfied’ and 1 indicating ‘very dissatisfied’. Ninety-five 
per cent of patients rated the process as 7 or above, with 56% rating it 10. 
 
Limitations 
224  
This trial set out to implement existing published research findings into 
clinical practice and assess outcomes, rather than investigating a research hypothesis. 
This should be taken into consideration when interpreting the results. Follow up was not 
able to be completed in all patients on the SLIC pathway. Although EDIS was monitored 
and patient charts reviewed, it is possible that a MACE in this group of patients could 
have been missed. 
ED LOS and NEAT data were affected by an inbuilt and locally unmodifiable 
EDIS auto-completion of the ‘actual departure time’ field from ED into the SSU as the 
same as the ‘departure ready time’ to the SSU regardless of whether a SSU bed was 
immediately available. This would lead to an underestimation of the ED LOS and an 
overestimation of the NEAT performance for SLIC patients during the trial. 
Comparisons of the effect of the project with the pre-project period are not possible as, 
prior to the project, patients with undifferentiated chest pain and possible ACS were not 
admitted to the SSU. This did not affect non-SLIC patients who were not admitted to the 
SSU. 
 
Future directions 
Planned extension of this clinical redesign project to other Queensland hospitals is 
occurring and, ultimately, modification of the Queensland Health Chest Pain Pathway 
guidelines to improve efficiency and the patient journey for a large number of patients 
should occur. It is hoped that the findings presented will have even broader application 
both nationally and internationally.  Further gains could be sought by increasing the pro-
portion of cases suitable for early discharge, possibly using high-sensitivity cardiac 
troponin, as well as accelerating definitive investigation for the remainder.  Re-
evaluation of ED LOS and NEAT performance as targets reach 90% would be 
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worthwhile following adjustment of EDIS auto-completion of ‘actual departure time’ for 
SSU admissions. 
 
Conclusion 
This trial safely and effectively introduced the ADAPT ADP into local clinical practice 
using widely available assessment methodology. This facilitated early discharge, and 
return for outpatient follow-up investigation, in approximately 20% of ED patients with 
undifferentiated chest pain and possible ACS. A reduction in ED LOS, a significant 
improvement in NEAT performance in a manner acceptable to patients and staff, and a 
reduction in system costs were found. Although emergency physicians might at times 
feel pressured by powerful opposing forces of clinical reality and the need to publish 
successful key performance indicators in an environment of increasing demands and 
increasing cost containment, this trial provides reassuring evidence supporting a practice 
compatible with all of these forces in relation to ED management of patients with 
undifferentiated chest pain with possible ACS. 
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Figure 1.         Figure 2. 
 
Figure 1. Distribution of chest pain presentations to Nambour General Hospital 
( July 2012–January 2013). (a) All patients presenting with chest pain; (b) patients 
presenting with chest pain considered to be possibly due to acute coronary syndrome 
(ACS). (  ), ACS; (  ), non-cardiac; (  ), possible ACS; (  ), SLIC; (  ), non-
SLIC. SLIC, Short Low-Intermediate Chest pain risk.   
 
Figure 2. Monthly percentage of chest pain presentations to Nambour General 
Hospital ( July 2012–January 2013) discharged from the ED <_ 4 h. (  ), All chest 
pain; (  ), possible cardiac chest pain; (  ), Short Low-Intermediate Chest pain risk. 
NEAT, National Emergency Access Targets. 
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Chapter 8 
 
The main findings and novel additions to the existing literature of this PhD by 
publication in relationship to the assessment of ED patients with symptoms of 
possible acute coronary syndrome are;  
1) the description of the current Guideline-based assessment process of care in 
relation to patient outcomes and health economics;  
2) the development of a comprehensive standardised data set for ED-based 
research providing the basis for this and future research;  
3) the proof that accelerated diagnostic pathways utilising multi-marker, 
sensitive troponin and highly sensitive troponin assays were able to safely identify 
patients at low risk of a major adverse cardiac event and;  
4) the translational of this research into clinical practice and reporting the 
pragmatic evidence of the safety and benefits of utilisation of the ADP. 
Several knowledge gaps existed prior to this work. Despite the NHF/CSANZ 
Guidelines influencing clinical care for over a decade, no pragmatic assessment had 
been made of their use in practice. At the time of the Guideline development, a key 
focus was on the rule-in ACS process to minimise poor outcomes related to missed 
ACS events (6, 7). Without knowledge of the true implications of these Guidelines in 
clinical care, there has been no baseline for comparison for future improvements in 
the process of assessment of this cohort. Importantly a true economic analysis had 
never been performed. Chapter 2 now provides a contemporary baseline from which 
future comparison can be made.  
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Another key gap in literature prior to this research was an existing 
comprehensive dataset that supported ED- based research into patients presenting 
with possible ACS. Whilst an Australian dataset had been described, the utility of 
this was for research about patients with a known ACS diagnosis rather than for 
those being investigated with possible ACS (57). It was essential to develop this to 
allow the research described in this thesis to be conducted and to support future 
investigation of ED-derived decision rules for the risk stratification of this cohort.  
Since its publication in 2011, this paper has been cited 26 times (as of July 2014), 
indicating some acceptance of its content.  
The testing of the predefined ADP in a large international ED cohort in the 
ASPECT trail was progressive. Prior to this, clinical concerns about missed events 
and the associated morbidity and mortality, drove conservative approaches that 
encouraged lengthy assessment often including admission for all patients with 
possible ACS. The finding that one in ten patients may be safely discharged at an 
early time point in the ASPECT trial was a means to decompress EDs and hospitals 
of low risk patients whist maintaining excellent health outcomes. This paper has been 
widely discussed and cited 137 times (as of July 2014). 
With the rapid evolution of knowledge about cardiac biomarkers, and the de-
emphasis on multi-marker approaches by international bodies, the significant inroads 
into improving patient care would have been lost without the re-evaluation of the 
ADP using both sensitive and highly sensitive troponin assay in the ADAPT 
(Chapter 5) and Modified ADAPT (Chapter 6) studies respectively. With the use of 
troponin alone in the original ADP, double the numbers (~20%) of patients were 
found to be eligible for early discharge. By manipulation of the pre-test probability 
tool (the TIMI score) and utilisation of the latest generation high sensitivity troponin 
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I assay, around 40% of patients were deemed low risk. Since its publication, the 
ADAPT study has been a landmark trial, with the findings being utilised in centres 
around Australia and internationally to streamline the process of assessment of ED 
patients with chest pain. With increasing approval and utilisation of the high 
sensitivity troponin I assays, it is hoped the Modified ADAPT rule will be embraced 
in institutions utilising this assay. Preliminary signs are encouraging, with the Royal 
Perth Hospital utilising the Modified ADAPT ADP as the cornerstone of their 
assessment strategy (Appendix 1).   
The greatest achievement of this PhD has been achieving the translation of this 
research into clinical practice (Chapter 7). Reports of the difficulty in achieving true 
change in medicine based on research findings are numerous (58-60). The successes 
in meeting needs of the patient, ED and hospital were significant. The findings 
outlined in Chapter 7 formed the basis of a successful application, led by the 
candidate and Prof. Will Parsonage, to the Health Innovation Grant for funding to 
support future redesign work across Queensland Health. The Accelerated Chest pain 
Risk Evaluation project (ACRE) began in April 2014 and has led to changed practice 
in seven Queensland Health hospitals as of July 2014, with the roll-out continuing 
state wide over the next 2 years. The Australian Institute of Health and Welfare 
(AIHW) reported over 1.2 million (1,238,522) presentations to 26 Queensland public 
hospital EDs between July 2011 and June 2012. (15) International literature shows 
that patients investigated for suspected ACS account for 6-10% of ED presentations. 
(1, 61) Using these figures, we estimate that there are between 74,311 and 123,852 
chest pain presentations to Queensland public hospital EDs per annum. 
The clinical redesign project is designed to assist meeting the National 
Emergency Access Target (NEAT) and reduce length of stay for patients presenting 
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to EDs with chest pain. The redesign project introduces the ADAPT ADP to quickly 
and safely identify around 20 % of such patients (between 14,862 and 24,770 
patients per annum) at low risk of heart attack who can be discharged home after 
blood tests at 2 hours from presentation for outpatient follow-up. 
In addition, other sites nationally and internationally have investigated the 
ADAPT and Modified ADAPT ADPs, with the Royal Perth hospital (Western 
Australia) and the Southampton General Hospital (UK) adopting a modified ADAPT 
ADP approach due to their utilisation of high sensitivity assays.  Much interest in the 
ADPs has also been from Victoria Health and sites in New Zealand.  
Work beyond the scope of this PhD has subsequently been performed 
developing the first ED-derived risk stratification tool, the Emergency Department 
Assessment of Chest pain Score (EDACS)  based on the robust data collated in the 
process of these studies (62). Until the EDACS score was derived no existing risk 
stratification tool had been derived on a population with possible ACS. Prior tools 
had been derived on patient cohorts with known ACS (29, 63).   
 
Strengths and Weaknesses 
There are several weaknesses to this thesis. No randomised controlled trial 
(RCT) has been performed comparing the ADP to current processes of care to 
determine comparative safety outcomes. A RCT utilising the ADAPT ADP was 
performed and published however the focus was the process outcomes (64). Despite 
the lack of an RCT, the robustness of the research on review by practicing clinicians 
has supported the change in clinical care at many sites. In addition a detailed analysis 
of the ACRE project will be published at conclusion of the State-wide project.  
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The understanding of the clinical implications of differences in precision of 
troponin assays is not complete. There are significant differences in the analytical 
characteristics of both sensitive and highly sensitivity assays (65, 66), however the 
effects these differences may have on the safely of patient assessment processes 
requires more investigation. Although not part of this thesis, the candidate has 
continued to investigate these issues in other research (49). More work is needed 
before clinicians will have a full understanding about troponin assays.   
 
Implications for clinicians, researchers or policymakers 
The main findings of this thesis have already influenced clinicians locally, 
nationally and internationally and are impacting the care of many patients currently. 
It is hoped that the strategies described will continue to challenge the traditional 
approaches of assessment for this cohort of ED patients.  
A key focus of the research projects has been in developing strong national and 
international collaborations. The network of researchers that the candidate has been 
involved with has strengthened, leading to more opportunities to be involved in 
multi-centred research and additional publications as outline in List of publications 
by Candidate.   
The achievement the candidate has described in this thesis and other work over 
the last six years has resulted in her being invited to participate in the revision of the 
National Heart Foundation and Cardiac Society of Australia and New Zealand 
Guidelines. This is currently underway, and is like to be completed in 2016.  
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A major implication for policy makers is that the investment in high quality 
local research, including the support of translational research, can achieve significant 
successes in improved patient care. 
 
Unanswered questions and future research 
Key areas of investigation that still require research have been uncovered 
during this study. The true implication of the analytical differences in troponin assays 
on actual patient care and outcomes requires additional examination. Recently there 
has been much interest in point-of-care analysers, which have the benefit over lab-
based assays in that the time that results are available to clinicians is more rapid. In 
addition they do not require the infrastructure of a laboratory to run the tests, making 
them most useful in rural and regional areas. The analytical characteristics of theses 
assays though are significantly different to most lab assays and the true implications 
of their use, including safety and patient flow issues in the setting of an ADP are 
currently unknown.   
Conclusion  
 
Accelerated diagnostic protocols for the assessment of patients presenting to 
the Emergency Department with symptoms of possible ACS are safe and effective at 
identifying low risk patients who can be managed in an outpatient setting. This 
important finding will inform clinicians and health services about improvements that 
can be made at this current time in the process of care of ED patients.  
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